Compositions and methods for genome editing

Through the DNMT3A, DNMT3L, dCas9 and KRAB polynucleotide sequences and polypeptide sequences in the construct, combining antibodies or nucleic acid structural elements, the challenge of delivering synthetic repressors in vivo is solved, and the targeted modification and expression regulation of gene products is achieved. Improves the safety and efficiency of gene therapy.

CN119095972AActive Publication Date: 2024-12-06EPIGENIC THERAPEUTICS PTE LTD

Patent Information

Application Number
CN202380023772.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-04
Filing Date
2023-03-03
Publication Date
2024-12-06
Estimated Expiration
2043-03-03

AI Technical Summary

Technical Problem

In the prior art, the use of synthetic dCas9-KRAB fusion protein in in vivo therapy faces challenges such as packaging size limitation, safety, toxicity, immunogenicity and off-target effects, and it is difficult to deliver and use effectively.

Method used

Construct 5'-(Am1-Bm2)n1-CasN-(Am3-Bm4)n2-CasC-Tp-E-3' is provided, which contains a polynucleotide sequence encoding DNMT3A, DNMT3L, dCas9 and KRAB, and is capable of being connected with The polypeptide sequence bound by an antibody or nucleic acid structural element is modified by gene expression regulators to achieve the expression regulation of targeted gene products.

Benefits of technology

Targeted modification of gene product expression in vivo is achieved, reducing gene product expression by 50-100%, and the ratio of gene regulatory element modification to off-target modification is about 10:1, improving the safety and efficiency of gene therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present disclosure provides CRISPR / Cas9-based fusion molecules and guide RNAs for targeted reduction or elimination of VEGFA gene products in vivo. The disclosure also relates to formulations, methods of production and methods of use thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure generally relates to the fields of molecular biology, immunology and medicine. More specifically, it relates to CRISPR / Cas9-based fusion molecules and methods of using the same for targeted reduction or elimination of gene products in vivo. Background Art

[0002] Engineered DNA-binding proteins that can be customized to target any gene in mammalian cells have enabled rapid advances in biomedical research and are a promising platform for gene therapy. The RNA-guided CRISPR-Cas9 system has emerged as a promising platform for programmable targeted gene regulation. Fusion of catalytically inactive "dead" Cas9 (dCas9) to the Kruppel-associated box (KRAB) domain generates synthetic repressors that are able to regulate or silence target genes with high specificity and efficiency in cell culture experiments.

[0003] However, the use of synthetic dCas9-KRAB fusion proteins to continuously regulate and silence endogenous genes poses a challenge for use in in vivo therapies. Synthetic repressors exceed the packaging size limitations of viral vector delivery methods. Safety, toxicity, immunogenicity, and off-target effects are other challenges that limit the use of synthetic repressors in vivo. The art needs alternative methods for producing genetically engineered synthetic gene repressors, as well as in vivo delivery of synthetic gene repressors used as therapeutic agents. The present disclosure addresses unmet needs in the prior art. Summary of the invention

[0004] The present disclosure provides constructs of Formula I: 5'-(A m1 -B m2 ) n1 -CasN-(A m3 -B m4 ) n2 -CasC-T p -E-3' (I), wherein: one of A and B is a polynucleotide encoding DNMT3A or a portion thereof; the other of A and B is a polynucleotide encoding DNMT3L or a portion thereof; CasN is a polynucleotide encoding the N-terminal portion of dCas9; CasC is a polynucleotide encoding the C-terminal portion of dCas9; E is 5'-(A m5 -B m6 ) n3 -K r -D q -3' or 5'-K r -D q -(A m5 -B m6 ) n3-3'; K is a polynucleotide encoding KRAB or a portion thereof; D is a polynucleotide encoding a gene expression regulator; T comprises a polynucleotide encoding (i) an epitope capable of binding to an antibody or an antigen-binding fragment thereof or (ii) a polypeptide sequence capable of binding to a nucleic acid structural element; m1, m2, m3, m4, m5 and m6 are each independently an integer selected from 0 to 3; n1, n2 and n3 are each independently an integer selected from 0 to 2; p is an integer selected from 0 to 20; q is an integer selected from 0 to 5; r is an integer selected from 0 to 5; and wherein when p is 0, at least one of m1, m2, m3 and m4 is not 0, at least one of n1 and n2 is not 0, and at least one of q and r is not 0.

[0005] In some embodiments, the construct comprises Formula II: 5'-CasN-(A m3 -B m4 ) n2 -CasC-K r -D q -3'(II), wherein: n2 is an integer selected from 1 and 2; r is an integer selected from 1 to 5; q is an integer selected from 0 to 5; and at least one of m3 and m4 is not 0. In some embodiments, the construct comprises Formula IIa: 5'-CasN-(AB)-CasC-K r -D q -3' (IIa).

[0006] In some embodiments, the construct comprises Formula III: 5'-(A m1 -B m2 ) n1 -CasN-(A m3 -B m4 ) n2 -CasC-T p -E-3'(III), wherein p is an integer selected from 1 to 20. In some embodiments, the construct comprises Formula IIIa: 5'-CasN-CasC-T p -3' (IIIa).

[0007] In some embodiments, the construct comprises Formula IIIb: 5'-(A m1 -B m2 )-CasN-CasC-T p -E-3'(IIIb), wherein at least one of m1 and m2 is not 0. In some embodiments, the construct comprises Formula IIIb-1: 5'-(AB)-CasN-CasC-T p -K r -D q-3' (IIIb-1), wherein: r is an integer selected from 1 to 5; and q is an integer selected from 0 to 5.

[0008] In some embodiments, the construct comprises Formula IIIc: 5'-CasN-CasC-T p -E-3'(IIIc), wherein: n3 is an integer selected from 1 and 2; r is an integer selected from 1 to 5; and q is an integer selected from 0 to 5; and at least one of m5 and m6 is not 0. In some embodiments, the construct comprises formula IIIc-1: 5'-CasN-CasC-Tp-(A m5 -B m6 )n3-K r -D q -3'(IIIc-1). In some embodiments, the construct comprises formula IIIc-2: 5'-CasN-CasC-T p -K r -D q -(A m5 -B m6 ) n3 -3' (IIIc-2).

[0009] In some embodiments, T comprises (a) a polynucleotide encoding an epitope capable of binding to an antibody or an antigen-binding fragment thereof, and further comprises (b) a polynucleotide encoding a self-cleaving peptide at the 3' end of the polynucleotide in (a). In some embodiments, the 3' end of the nucleotide encoding the self-cleaving peptide further comprises (c) a polynucleotide encoding an antibody or an antigen-binding fragment thereof capable of binding to the epitope.

[0010] In some embodiments, T comprises (a) a polynucleotide encoding a polypeptide sequence capable of binding to a nucleotide sequence element, and further comprises a polynucleotide encoding a self-cleaving peptide at the 3' end of the polynucleotide in (a).

[0011] In some embodiments, the self-cleaving peptide is selected from the group consisting of T2A, P2A, E2A and F2A self-cleaving peptides. In some embodiments, the self-cleaving peptide is T2A. In some embodiments, T2A comprises the amino acid sequence of SEQ ID NO: 99.

[0012] In some embodiments, DNMT3A comprises the amino acid sequence of SEQ ID NO: 69. In some embodiments, the polynucleotide encoding DNMT3A comprises the nucleic acid sequence of SEQ ID NO: 83.

[0013] In some embodiments, DNMT3L includes Homo sapiens DNMT3L, Mus musculus DNMT3L, Mouse castellani ( Mus caroli) DNMT3L, Sikkim mice ( Mus Pahari ) DNMT3L, Rattus norvegicus ( Rattus norvegicus ) DNMT3L, Rattus houseus ( Rattus Rattus ) DNMT3L, Nile grass rat ( Arvicanthis niloticus ) DNMT3L, Jungle Mouse ( Grammomys surdaster ) DNMT3L or white-nosed rat ( Mastomys coucha ) DNTM3L. In some embodiments, DNMT3L comprises the amino acid sequence of any one of SEQ ID NOs: 74-82. In some embodiments, the polynucleotide encoding DNMT3L comprises the nucleic acid sequence of any one of SEQ ID NOs: 84-92.

[0014] In some embodiments, KRAB comprises an amino acid sequence of SEQ ID NO: 51, 53, or 230-241. In some embodiments, the polynucleotide encoding KRAB comprises a nucleic acid sequence of SEQ ID NO: 52, 54, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, or 228.

[0015] In some embodiments, the gene expression regulator comprises Kruppel-associated repression box (KRAB), enhancer of zete homolog 2 (EZH2), G9A, lysine-specific histone demethylase 1A (LSD1), heterochromatin protein 1 (HP1), Friend of GATA protein 1 (FOG1), histone deacetylase (HDAC3) and / or DOT1L. In some embodiments, the gene expression regulator comprises the amino acid sequence of SEQ ID NO: 51, 53, 55, 57, 59, 61, 63, 65 or 67. In some embodiments, the polynucleotide encoding the gene expression regulator comprises the nucleic acid sequence of SEQ ID NO: 52, 54, 56, 58, 60, 62, 64, 66 or 68.

[0016] In some embodiments, dCas9 comprises Staphylococcus aureus ( Staphylococcus aureus )dCas9, Streptococcus pyogenes ( Streptococcus pyogenes )dCas9, Campylobacter jejuni ( Campylobacter jejuni ) dCas9, Corynebacterium diphtheriae ( Corynebacterium diphtheria ) dCas9, Eubacterium convexum ( Eubacterium ventriosum ) dCas9, Streptococcus pasteurianus ( Streptococcus pasteurianus ) dCas9, Lactobacillus farnesii ( Lactobacillus farciminis) dCas9, Chaetomium sphaeroides ( Sphaerochaeta globus )dCas9, Azospirillum ( Azospirillum ) (e.g., strain B510) dCas9, Gluconobacter diazoacetobacter ( Gluconacetobacter diazotrophicus ) dCas9, Neisseria cinerea ( Neisseria cinerea )dCas9, enteric Roseburia ( Roseburia intestinalis ) dCas9, Bacillus subtilis ( Parvibaculum lavamentivorans ) dCas9, brine nitrate lysing bacteria ( Nitratifractor salsuginis ) (e.g. strain DSM 16511) dCas9, Campylobacter gullus ( Campylobacter lari ) (e.g. strain CF89-12) dCas9, Streptococcus thermophilus ( Streptococcus thermophilus ) (e.g., strain LMD-9) dCas9. In some embodiments, dCas9 comprises the amino acid sequence of any one of SEQ ID NOs: 106-122. In some embodiments, the polynucleotide encoding dCas9 comprises the nucleic acid sequence of SEQ ID NO: 26.

[0017] In some embodiments, the dCas9 comprises the amino acid sequence of SEQ ID NO: 1. In some embodiments, the N-terminal portion of dCas9 comprises the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 24. In some embodiments, the C-terminal portion of dCas9 comprises the amino acid sequence of SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, or 25.

[0018] In some embodiments, the polynucleotide encoding dCas9 comprises the nucleic acid sequence of SEQ ID NO: 26. In some embodiments, the polynucleotide encoding the N-terminal portion of dCas9 comprises the amino acid sequence of SEQ ID NO: 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, or 49. In some embodiments, the polynucleotide encoding the C-terminal portion of dCas9 comprises the nucleic acid sequence of SEQ ID NO: 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, or 50.

[0019] In some embodiments, the polypeptide capable of binding to an antibody or antigen-binding fragment thereof is selected from the group consisting of GCN4, T2A, 10xGCN4, and 10xGFP-11. In some embodiments, GCN4 comprises the amino acid sequence of SEQ ID NO: 97. In some embodiments, the polynucleotide encoding GCN4 comprises the nucleic acid sequence of SEQ ID NO: 101.

[0020] In some embodiments, the antibody or antigen-binding fragment is a single domain antibody, scFv, Fab, VH, VHH or an antibody mimetic. In some embodiments, the antigen-binding fragment is a scFv.

[0021] In some embodiments, the polypeptide sequence capable of binding to a nucleic acid structural element is selected from the group consisting of MS2 bacteriophage coat protein (MCP), PP7 and PCP. In some embodiments, the polypeptide sequence capable of binding to a nucleic acid structural element is MCP. In some embodiments, MCP comprises the amino acid sequence of SEQ ID NO: 100. In some embodiments, the polynucleotide encoding MCP comprises the nucleic acid sequence of SEQ ID NO: 105.

[0022] In some embodiments, the nucleic acid structural element is an RNA hairpin motif. In some embodiments, the RNA hairpin motif is selected from the group consisting of MS2 and PP7. In some embodiments, the RNA hairpin motif is an MS2 RNA hairpin motif. In some embodiments, the MS2 RNA hairpin motif comprises the nucleic acid sequence of SEQ ID NO: 104.

[0023] In some embodiments, the construct comprises the nucleic acid sequence of SEQ ID NOs: 134-162.

[0024] The present disclosure provides polypeptides expressed by any of the constructs described herein.The present disclosure provides vectors comprising any of the constructs described herein.

[0025] In some embodiments, the vector further comprises a polynucleotide encoding a single guide RNA (sgRNA). In some embodiments, the polynucleotide encoding the sgRNA further comprises 2-20 copies of a nucleic acid structural element.

[0026] The present disclosure provides cells comprising any of the constructs described herein. The present disclosure provides cells comprising any of the polypeptides described herein. The present disclosure provides cells comprising any of the vectors described herein.

[0027] In some embodiments, the cell further comprises at least one sgRNA. In some embodiments, the at least one sgRNA further comprises 2-20 copies of a nucleic acid structural element.

[0028] The present disclosure provides compositions comprising any of the constructs described herein. The present disclosure provides compositions comprising any of the polypeptides described herein. The present disclosure provides compositions comprising any of the vectors described herein.

[0029] In some embodiments, the composition further comprises at least one sgRNA. In some embodiments, the sgRNA further comprises 2-20 copies of a nucleic acid structural element. In some embodiments, the composition further comprises a pharmaceutically acceptable carrier.

[0030] The present disclosure provides a method for altering the expression of a gene product in a cell population and minimizing off-target modifications, comprising the steps of introducing into the cell population: i) any one of the constructs described herein or one or more polypeptides expressed by the construct; and ii) at least one sgRNA, wherein KRAB and / or a gene expression regulator provides modification of at least one nucleotide near a gene and / or within a gene regulatory element, thereby altering the expression of the gene product.

[0031] In some embodiments, (a) comprises a 5'-(A m1 -B m2 ) n1 -CasN-(A m3 -B m4 ) n2 -CasC-T p -3' part, 5'-(A m1 -B m2 ) n1 -CasN-(A m3 -B m4 ) n2 -CasC-T p -3' part, 5'-(A m1 -B m2 )-CasN-CasC-T p -3' part, 5'-(AB)-CasN-CasC-T of formula IIIb-1 p -3' part, 5'-CasN-CasC-T of formula IIIc p -3' part, 5'-CasN-CasC-T of formula IIIc-1 p -3' part, 5'-CasN-CasC-T of formula IIIc-2 p-3' portion i) of the polypeptide and ii) of the sgRNA are recruited to the genomic locus, and (b) multiple copies of the 5'-E-3' portion of Formula I, the 5'-E-3' portion of Formula III, the 5'-E-3' portion of Formula IIIb, the 5'-Kr-Dq-3' portion of Formula IIIb-1, the 5'-E-3' portion of Formula IIIc, the 5'-(A-3' portion of Formula IIIc-1 m5 -B m6 ) n3 -K r -D q -3' part or 5'-K of formula IIIc-2 r -D q -(A m5 -B m6 ) n3 -3' portion i) is recruited to the genomic locus by binding of the antibody or antigen-binding fragment thereof to the epitope, thereby recruiting the polypeptide expressed by the construct to the genomic locus and altering the expression of the gene product in the cell population.

[0032] In some embodiments, the method further comprises introducing into the cell: iii) a 5'-(A m5 -B m6 ) n3 -K r -D q -3' or 5'-K r -D q -(A m5 -B m6 ) n3 -3' of the second construct or the polypeptide expressed by the second construct, which comprises 5'-CasN-CasC-T of Formula IIIa p -3' portion of the polypeptide of i) and sgRNA are recruited to the genomic locus, wherein multiple copies of the polypeptide of iii) are recruited to the genomic locus through the binding of the antibody or its antigen-binding fragment to the epitope, thereby recruiting the polypeptides expressed by the construct of i) and the construct of iii) to the genomic locus and changing the expression of the gene product in the cell population.

[0033] In some embodiments, (a) comprises a 5'-(A m1 -B m2 ) n1 -CasN-(A m3 -B m4 ) n2 -CasC-T p -3' part, 5'-(A m1 -B m2 ) n1-CasN-(A m3 -B m4 ) n2 -CasC-T p -3' portion, the 5'-(A m1 -B m2 )-CasN-CasC-T p -3' part, 5'-(AB)-CasN-CasC-T of formula IIIb-1 p -3' part, 5'-CasN-CasC-T of formula IIIc p -3' part, 5'-CasN-CasC-T of formula IIIc-1 p -3' portion or 5'-CasN-CasC-T of formula IIIc-2 p -3' portion i) of the polypeptide and ii) of the sgRNA are recruited to the genomic locus, and (b) multiple copies of the 5'-E-3' portion of Formula I, the 5'-E-3' portion of Formula III, the 5'-E-3' portion of Formula IIIb, the 5'-Kr-Dq-3' portion of Formula IIIb-1, the 5'-E-3' portion of Formula IIIc, the 5'-(A-3' portion of Formula IIIc-1 m5 -B m6 ) n3 -K r -D q -3' part or 5'-K of formula IIIc-2 r -D q -(A m5 -B m6 ) n3 -3' portion i) is recruited to the genomic locus by binding of the polypeptide sequence capable of binding to the nucleic acid structural element to the nucleic acid structural element, thereby recruiting the polypeptide expressed by the construct to the genomic locus and changing the expression of the gene product in the cell population.

[0034] In some embodiments, the method further comprises introducing into the cell: iii) a 5'-(A m5 -B m6 ) n3 -K r -D q -3' or 5'-K r -D q -(A m5 -B m6 ) n3 -3' portion of the second construct or the polypeptide expressed by the second construct, wherein the 5'-CasN-CasC-T of formula IIIa p-3' portion i) and sgRNA are recruited to the genomic locus, wherein multiple copies of the polypeptide of iii) are recruited to the genomic locus through the binding of the polypeptide sequence capable of binding to the nucleic acid structural element to the nucleic acid structural element, thereby recruiting the polypeptide expressed by the construct to the genomic locus and changing the expression of the gene product in the cell population.

[0035] The present disclosure provides an in vivo method for reducing or eliminating the expression of a gene product in a subject, comprising the steps of introducing into a cell of the subject: i) any one of the constructs described herein or one or more polypeptides expressed by the construct; and ii) at least one sgRNA, wherein the KRAB and / or gene expression modulator provides modification of at least one nucleotide near the gene and / or within the gene regulatory element, thereby altering the expression of the gene product in the subject.

[0036] The present disclosure provides a method for treating or alleviating the symptoms of a gene product-related disorder in a subject, comprising the steps of introducing into a cell of the subject: i) any one of the constructs described herein or one or more polypeptides expressed by the construct; and ii) at least one sgRNA, wherein KRAB and / or a gene expression regulator provides modification of at least one nucleotide near a gene and / or within a gene regulatory element, thereby altering the expression of the gene product and treating or alleviating the symptoms of a gene product-related disorder in the subject.

[0037] In some embodiments, the expression of a gene product in a plurality of modified cells is reduced by 50-100% compared to a population of wild-type cells. In some embodiments, the ratio of on-site modification of a gene product to off-site modification of a gene product is about 10:1.

[0038] In some embodiments, the modification of at least one nucleotide is DNA methylation or histone modification. In some embodiments, the modification of at least one nucleotide is DNA methylation.

[0039] In some embodiments, the gene regulatory element is a core promoter, a proximal promoter, a distal enhancer, a silencer, an insulator element, a boundary element, or a locus control region.

[0040] In some embodiments, the modification of at least one nucleotide near a gene and / or within a gene regulatory element is located within about 100 bp, about 200 bp, about 300 bp, about 400 bp, about 500 bp, about 600 bp, about 700 bp, about 800 bp, about 900 bp, about 1000 bp, about 1100 bp, about 1200 bp, about 1300 bp, about 1400 bp, or about 1500 bp upstream of the transcription start site of the gene.

[0041] In some embodiments, the modification of at least one nucleotide near a gene and / or within a gene regulatory element is located within about 100 bp, about 200 bp, about 300 bp, about 400 bp, about 500 bp, about 600 bp, about 700 bp, about 800 bp, about 900 bp, about 1000 bp, about 1100 bp, about 1200 bp, about 1300 bp, about 1400 bp, or about 1500 bp downstream of the transcription start site of the gene.

[0042] In some embodiments, the construct is deoxyribonucleic acid (DNA). In some embodiments, the construct is messenger ribonucleic acid (mRNA). In some embodiments, the construct is formulated in liposomes or lipid nanoparticles. In some embodiments, the construct and sgRNA are formulated in liposomes or lipid nanoparticles. In some embodiments, the construct and sgRNA are formulated in the same liposome or lipid nanoparticle. In some embodiments, the construct and sgRNA are formulated in different liposomes or lipid nanoparticles.

[0043] In some embodiments, the liposome or lipid nanoparticle comprises an ionizable lipid (20%-70%, molar ratio), a pegylated lipid (0%-30%, molar ratio), a supporting lipid (30%-50%, molar ratio) and cholesterol (10%-50%, molar ratio). In some embodiments, the ionizable lipid is selected from a pH-responsive ionizable lipid, a thermally responsive ionizable lipid and a light-responsive ionizable lipid.

[0044] In some embodiments, the construct is formulated in an AAV vector. In some embodiments, the construct and sgRNA are formulated in an AAV vector. In some embodiments, the construct and sgRNA are formulated in the same AAV vector. In some embodiments, the construct and sgRNA are formulated in different AAV vectors.

[0045] In some embodiments, the construct or one or more polypeptides expressed by the construct is delivered to the cell by local injection, systemic infusion, or a combination thereof.

[0046] In some embodiments, the gene product is selected from the group consisting of a VEGFA gene product, a PCSK9 gene product, an ANGPTL3 gene product, a PTBP1 gene product, a TTR gene product, an Ube3a-ATS gene product, a Ptp1b gene product, an APOC3 gene product, an hsd17b13 gene product, a bcl11a gene product, and a TGF-β gene product.

[0047] In some embodiments, the subject is a human. In some embodiments, the disease or condition is selected from the group consisting of familial hypercholesterolemia (FH), non-alcoholic steatohepatitis (NASH), Parkinson's disease, liver fibrosis (HF), age-related maculopathy (AMD), Angelman syndrome (AS), type II diabetes, β-thalassemia, and hepatocellular carcinoma. BRIEF DESCRIPTION OF THE DRAWINGS

[0048] Figure 1A is a schematic diagram showing the interaction of a construct comprising DNMT3A, DNMT3L, KRAB and intact or cleaved dCas9 with DNA. Figure 1B shows a schematic diagram of the construct. Figure 1C shows the editing efficiency of the constructs shown in Figures 1A-1B using gRNAs targeting CD81 or CD151, respectively, to repress the expression of two target genes, wherein: Dnmt-dCas9-Krab represents Dnmt3A-Dnmt3L-dCas9-Krab; 768 INS represents dCas9N-2-Dnmt3A-Dnmt3L-dCas9C-2-Krab; 776 INS represents dCas9N-3-Dnmt3A-Dnmt3L-dCas9C-3-Krab; 1009 INS represents dCas9N-4-Dnmt3A-Dnmt3L-dCas9C-4-Krab; 1048-1063 INS represents dCas9N-5-Dnmt3A-Dnmt3L-dCas9C-5-Krab; 1072 INS indicates dCas9N-6-Dnmt3A-Dnmt3L-dCas9C-6-Krab; 1246 INS indicates dCas9N-7-Dnmt3A-Dnmt3L-dCas9C-7-Krab; 1248 INS indicates dCas9N-8-Dnmt3A-Dnmt3L-dCas9C-8-Krab; 1260 INS indicates dCas9N-10-Dnmt3A-Dnmt3L-dCas9C-10-Krab; control indicates Dnmt3A-Dnmt3L-dCas9-Krab with Nt gRNA.

[0049] Figure 2A is a schematic diagram showing that DNMT3A, DNMT3L and KRAB are recruited to dCas9 by scFv bound to 10×GCN4. Figure 2B shows a schematic diagram of the construct. Figures 2C-2E show the editing efficiency of the constructs shown in Figures 2A-2B using gRNAs targeting CD81 or CD151, respectively, to suppress the expression of two target genes, where: Suntag means Dnmt3A-Dnmt3L-dCas9-10×GCN4-T2A-scFv-KRAB; Dnmt-dCas9+scFv-Krab also means Dnmt3A-Dnmt3L-dCas9-10×GCN4 -T2A-scFv-KRAB; dCas9+scFv-Dnmt-Krab means dCas9-10×GCN4-T2A-scFv-Dnmt3A-Dnmt3L-KRAB; dCas9+scFv-Dnmt+scFv-Krab means dCas9-10×GCN4-T2A-scFv-Dnmt3A-Dnmt3L-scFv-KRAB; control means Dnmt3A-Dnmt3L-dCas9-Krab in Figure 1 with Nt gRNA.

[0050] Fig. 3A is a schematic diagram showing a construct comprising dCas9 and a guide RNA containing MS2, which is combined with DNMT3A, DNMT3L and KRAB by MCP. Fig. 3B shows a schematic diagram of a construct comprising DNMT3A, DNMT3L, MCP, dCas9 and KRAB.

[0051] Fig. 4A is a schematic diagram showing the interaction between a complex comprising dCas9, DNMT3A and DNMT3L and a gene expression regulator (selected from Kruppel-associated repression box (KRAB), enhancer 2 of zete homolog (EZH2), G9A, lysine-specific histone demethylase 1A (LSD1), heterochromatin protein 1 (HP1), friend of GATA protein 1 (FOG1), histone deacetylase (HDAC3) and / or DOT1L) and their DNA target sites. Fig. 4B shows a schematic diagram of a construct comprising dCas9, DNMT3A and DNMT3L and a gene expression regulator (selected from Kruppel-associated repression box (KRAB), enhancer 2 of zete homolog (EZH2), G9A, lysine-specific histone demethylase 1A (LSD1), heterochromatin protein 1 (HP1), friend of GATA protein 1 (FOG1), histone deacetylase (HDAC3) and / or DOT1L). Figures 4C-4D show the editing efficiency of the constructs shown in Figures 4A-4B to inhibit target gene expression, wherein the gene expression regulator is selected from the types listed on the right side of the figure. Figures 4E-4F show the editing efficiency of the constructs shown in Figures 4A-4B to inhibit target gene expression, wherein the KRAB regulator is selected from the sources listed on the right side of the figure. The control refers to Dnmt3A-Dnmt3L-dCas9-Krab in Figure 1 with Nt gRNA.

[0052] Figure 5A is a schematic diagram showing the interaction between complexes containing dCas9, DNMT3A and DNMT3L from different species. Figure 5B shows a schematic diagram of the construct. Figures 5C-5D show the editing efficiency of the constructs shown in Figures 5A-5B to inhibit target gene expression, wherein DNMT3A and DNMT 3L are selected from the sources listed on the right side of the figure. The control refers to Dnmt3A-Dnmt3L-dCas9-Krab in Figure 1 with NtgRNA.

[0053] Figure 6A shows three examples of constructs of the present application. Figure 6B shows the editing efficiency of three constructs in inhibiting target gene expression. DETAILED DESCRIPTION

[0054] The present disclosure overcomes the problems associated with current technologies by providing constructs comprising DNMT3A, DNMT3L, dCas9 and KRAB for targeted modification of gene product expression, for example, for targeted modification of gene products in cells for in vivo gene therapy.

[0055] Definition of terms As used herein, the term "coding sequence" or "coding nucleic acid" means a nucleic acid (RNA or DNA molecule) comprising a nucleotide sequence encoding a protein. The coding sequence may also include start and stop signals operably linked to regulatory elements, including a promoter and polyadenylation signal capable of directing expression in cells of an individual or mammal to which the nucleic acid is administered. The coding sequence may be codon optimized.

[0056] The terms "complement" or "complementary" used herein with respect to nucleic acids may refer to the Watson-Crick (e.g., AT / U and CG) or Hoogsteen base pairing between nucleotides or nucleotide analogs of a nucleic acid molecule. "Complementarity" refers to a property shared by two nucleic acid sequences such that when they are arranged antiparallel to each other, the nucleotide bases at each position will be complementary.

[0057] The terms "correction", "genome editing" and "restoration" refer to changing a mutant gene that encodes a mutant protein, a truncated protein, or no protein at all, so as to obtain full-length functional or partially full-length functional protein expression. Correcting or restoring a mutant gene may include replacing a gene region with a mutation or replacing the entire mutant gene with a gene copy that does not have a mutation using a repair mechanism such as homology-directed repair (HDR). Correcting or restoring a mutant gene may also include repairing a frameshift mutation that causes a premature stop codon, an abnormal splice acceptor site, or an abnormal splice donor site by creating a double-strand break in the gene and then repairing it using non-homologous end joining (NHEJ). NHEJ may add or delete at least one base pair during the repair process, which may restore the correct reading frame and eliminate premature stop codons. Correcting or restoring a mutant gene may also include destroying an abnormal splice acceptor site or a splice donor sequence. Correcting or restoring a mutant gene may also include deleting a non-essential gene segment by the simultaneous action of two nucleases on the same DNA chain, so as to restore the correct reading frame by removing the DNA between the two nuclease target sites and repairing the DNA break by NHEJ.

[0058] As used herein, the terms "donor DNA", "donor template" and "repair template" refer to a double-stranded DNA fragment or molecule comprising at least a portion of a gene of interest. The donor DNA may encode a fully functional protein or a partially functional protein.

[0059] As used herein, the term "frameshift" or "frameshift mutation" is used interchangeably and refers to a type of genetic mutation in which the addition or deletion of one or more nucleotides results in a shift in the codon reading frame in the mRNA. The shift in the reading frame can result in changes in the amino acid sequence when the protein is translated, such as missense mutations or premature stop codons.

[0060] As used herein, the terms "functional" and "fully functional" describe a protein that has biological activity. A "functional gene" refers to a gene that is transcribed into mRNA, which is translated into a functional protein.

[0061] As used herein, the term "fusion protein" refers to a chimeric protein produced by directly or indirectly covalently or non-covalently linking two or more genes that originally encoded separate proteins. In some embodiments, translation of the fusion gene produces a single polypeptide having functional properties derived from each original protein.

[0062] As used herein, the term "genetic construct" refers to a DNA or RNA molecule comprising a nucleotide sequence encoding a protein. The coding sequence includes start and stop signals operably linked to regulatory elements, including a promoter and polyadenylation signal capable of directing expression in a cell.

[0063] The term "homologous directed repair" or "HDR", used interchangeably herein, refers to a mechanism for repairing double-stranded DNA damage in cells when homologous DNA fragments are present in the nucleus (mainly in the G2 and S phases of the cell cycle). HDR uses a donor DNA template to guide repair and can be used to produce specific sequence changes to the genome, including targeted additions of entire genes. If the donor template is provided with a site-specific nuclease, such as with a CRISPR / Cas9-based system, the cellular machinery will repair the break by homologous recombination, which is enhanced by several orders of magnitude in the presence of DNA cutting. When homologous DNA fragments are not present, non-homologous end joining can occur instead.

[0064] As used herein, the term "genome editing" refers to changing a gene. Genome editing may include correcting or restoring a mutant gene. Genome editing may include knocking out a gene, such as a mutant gene or a normal gene. Genome editing may treat a disease by changing a target gene.

[0065] The term "identical" or "identity" used herein in the context of two or more nucleic acid or polypeptide sequences means that the sequence has a specific percentage of identical residues in a specified region. The percentage can be calculated by the following process: optimally aligning the two sequences, comparing the two sequences in a specified region, determining the number of positions where identical residues occur in the two sequences to obtain the number of matching positions, dividing the number of matching positions by the total number of positions in the specified region, and multiplying the result by 100 to obtain the sequence identity percentage. If the two sequences have different lengths, or the alignment produces one or more staggered ends, and the specified comparison region includes only a single sequence, the residues of the single sequence are included in the denominator of the calculation, but not in the numerator. When comparing DNA and RNA, thymine (T) and uracil (U) can be considered to be equivalent. Identity can be performed manually or by using a computer sequence algorithm such as BLAST or BLAST 2.0. The identity of related peptides can be easily calculated by known methods. Such methods include, but are not limited to, those described in Computational Molecular Biology, Lesk, AM, ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, DW, ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, AM and Griffin, HG, ed., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Sequence Analysis Primer, Gribskov, M. and Devereux, J., ed., M. Stockton Press, New York, 1991; and Carillo et al., SIAM J. Applied Math. 48, 1073 (1988), incorporated herein by reference in their entirety.

[0066] As used herein, the terms "mutant gene" or "mutated gene" are used interchangeably herein and refer to a gene that has undergone a detectable mutation. A mutant gene has undergone a change, such as a loss, gain or exchange of genetic material, which affects the normal transmission and expression of the gene. A "disrupted gene" as used herein refers to a mutant gene having a mutation that results in a premature stop codon. A disrupted gene product is truncated relative to the full-length non-disrupted gene product.

[0067] As used herein, the term "epigenetically modified modulator" refers to an agent that targets gene expression by epigenetic modification (e.g., by histone acetylation or methylation, or in a regulatory element of a target gene, such as DNA methylation on a promoter, enhancer, or transcription start site). Chromatin remodeling and DNA methylation are two major mechanisms for regulating gene transcription. Specific epigenetic markers (e.g., DNA methylation) structurally or biochemically guide gene transcription or gene silencing / repression. For example, DNA methylation in a region that regulates transcriptional activity changes gene expression without changing the basic DNA sequence. Transcriptional regulation using epigenetic modifications (e.g., DNA methylation) allows targeted regulation of gene expression without affecting the expression of other gene products.

[0068] The term "non-homologous end joining (NHEJ) pathway" as used herein refers to a pathway that repairs double-strand breaks in DNA by directly connecting the broken ends without the need for a homologous template. The template-independent reconnection of the DNA ends by NHEJ is a random, error-prone repair process that introduces random micro-insertions and micro-deletions (indels) at the DNA breakpoints. The method can be used to intentionally destroy, delete or change the reading frame of the target gene sequence. NHEJ typically uses short homologous DNA sequences known as microhomologies to guide repair. These microhomologies typically appear in single-stranded overhangs at the ends of double-strand breaks. When the overhangs are fully compatible, NHEJ typically accurately repairs the break, however, inaccurate repairs that result in nucleotide loss may also occur, but are much more common when the overhangs are incompatible.

[0069] The term "normal gene" as used herein refers to a gene that has not undergone changes such as loss, gain, or exchange of genetic material. A normal gene undergoes normal gene transmission and gene expression.

[0070] The term "nuclease-mediated NHEJ" as used herein refers to NHEJ initiated after a nuclease such as cas9 cuts double-stranded DNA.

[0071] As used herein, the term "nucleic acid" or "oligonucleotide" or "polynucleotide" refers to at least two nucleotides covalently linked together. The description of a single strand also defines the sequence of the complementary strand. Therefore, nucleic acid also includes the complementary strand of the described single strand. Many variants of nucleic acid can be used for the same purpose as a given nucleic acid. Therefore, nucleic acid also includes substantially identical nucleic acids and their complementary sequences. The single strand provides a probe that can hybridize with a target sequence under stringent hybridization conditions. Therefore, nucleic acid also includes probes that hybridize under stringent hybridization conditions. Nucleic acid can be single-stranded or double-stranded, or can contain parts having both double-stranded and single-stranded sequences. Nucleic acid can be DNA (genomic DNA and cDNA), RNA or a hybrid, wherein the nucleic acid can contain a combination of deoxyribonucleotides and ribonucleotides, and a combination of bases including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine, hypoxanthine, isocytosine and isoguanine. Nucleic acid can be obtained by chemical synthesis or recombinant methods.

[0072] As used herein, the term "operably linked" means that the expression of a gene is under the control of a promoter to which it is spatially linked. A promoter may be located 5' (upstream) or 3' (downstream) of the gene it controls. The distance between a promoter and a gene may be about the same as the distance between the promoter and the gene it controls in the gene from which it is derived. As is known in the art, variations in this distance may be accommodated without loss of promoter function.

[0073] The term "partially functional" as used herein describes a protein encoded by a mutant gene whose biological activity is lower than that of a functional protein but higher than that of a non-functional protein. In one embodiment, a partially functional protein exhibits a biological activity that is lower than 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35% or 30% of the biological activity of the corresponding functional protein.

[0074] The terms "premature stop codon" or "out-of-frame stop codon", used interchangeably herein, refer to a nonsense mutation in a DNA sequence that results in a stop codon at a position that is not normally present in the wild-type gene. A premature stop codon can result in a protein that is truncated or shortened compared to the full-length form of the protein.

[0075] The term "promoter" as used herein refers to a molecule of synthetic or natural origin that can confer, activate or enhance the expression of nucleic acids in cells. The promoter may include one or more specific transcriptional regulatory sequences to further enhance the expression of nucleic acids and / or change the spatial expression and / or temporal expression of nucleic acids. The promoter may also include distal enhancer or repressor elements, which may be located at a position up to thousands of base pairs from the transcription start site. The promoter may be derived from sources including viruses, bacteria, fungi, plants, insects and animals. The promoter may constitutively regulate the expression of gene components, or relative to the cells, tissues or organs in which expression occurs, or relative to the developmental stage when expression occurs, or in response to external stimuli such as physiological stress, pathogens, metal ions or inducers, and differentially regulate the expression of gene components. Representative examples of promoters include bacteriophage T7 promoter, bacteriophage T3 promoter, SP6 promoter, lac operator-promoter, tac promoter, SV40 late promoter, SV40 early promoter, RSV-LTR promoter and CMV IE promoter.

[0076] The term "target gene" as used herein refers to any nucleotide sequence encoding a known or putative gene product. The target gene may be a mutant gene associated with a genetic disease or disorder.

[0077] As used herein, the term "target region" refers to the region of a target gene to which a site-specific nuclease is designed to bind.

[0078] As used herein, the term "transgenic" refers to a gene or genetic material containing a gene sequence that has been isolated from one organism and introduced into a different organism. Alternatively, the term "transgenic" also refers to a gene or genetic material that has been chemically synthesized and introduced into an organism. This non-natural DNA segment may retain the ability to produce RNA or protein in the transgenic organism, or it may alter the normal function of the genetic code of the transgenic organism. The introduction of a transgenic has the potential to change the phenotype of an organism.

[0079] As used herein, the term "variant" when applied to nucleic acids means (i) a portion or fragment of a reference nucleotide sequence; (ii) a complementary sequence to a reference nucleotide sequence or a portion thereof; (iii) a nucleic acid substantially identical to a reference nucleic acid or its complementary sequence; or (iv) a nucleic acid that hybridizes to a reference nucleic acid, its complementary sequence, or a sequence substantially identical thereto under stringent conditions. "Variant" refers to a peptide or polypeptide that differs in amino acid sequence by insertion, deletion, or conservative substitution of amino acids, but retains at least one biological activity.

[0080] Variant may also mean a protein having an amino acid sequence substantially identical to a reference protein, the reference protein having an amino acid sequence retaining at least one biological activity. Conservative substitution of amino acids, i.e., replacing amino acids with different amino acids having similar properties (e.g., hydrophilicity, degree and distribution of charged regions), is considered in the art to generally involve minor changes. As understood in the art, these minor changes can be identified in part by considering the hydropathic index of amino acids. Kyte et al., J. Mol. Biol. 157: 105-132 (1982), incorporated herein by reference in its entirety. The hydropathic index of amino acids is based on considerations of their hydrophobicity and charge. It is known in the art that amino acids with similar hydropathic indexes can be substituted, but still retain protein function. On the one hand, amino acids with a hydropathic index of ±2 are substituted. The hydrophilicity of amino acids can also be used to reveal substitutions that can lead to proteins retaining biological functions. Considering the hydrophilicity of amino acids in the case of peptides allows the calculation of the maximum local average hydrophilicity of the peptide. Amino acids with hydrophilicity values ​​that differ from each other within ±2 can be substituted. The hydrophobicity index and hydrophilicity value of an amino acid are both influenced by the specific side chain of that amino acid. Consistent with this observation, amino acid substitutions compatible with biological function are understood to depend on the relative similarity of the amino acids (particularly those amino acid side chains), as disclosed in terms of hydrophobicity, hydrophilicity, charge, size, and other properties.

[0081] As used herein, the term "vector" refers to a nucleic acid sequence containing a replication origin. The vector may be a viral vector, a bacteriophage, a bacterial artificial chromosome, or a yeast artificial chromosome. The vector may be a DNA or RNA vector. The vector may be a self-replicating extrachromosomal vector, such as a DNA plasmid.

[0082] As used herein, the terms "gene transfer," "gene delivery," and "gene transduction" refer to methods or systems for reliably inserting specific nucleotide sequences (eg, DNA or RNA), fusion proteins, polypeptides, etc., into target cells.

[0083] As used herein, the terms "adeno-associated virus (AAV) vector", "AAV gene therapy vector" and "gene therapy vector" refer to vectors with functional or partially functional ITR sequences and transgenes. As used herein, the term "ITR" refers to an inverted terminal repeat (ITR). The ITR sequence may be derived from an adeno-associated virus serotype, including but not limited to AAV-1, AAV-2, AAV-3, AAV-4, AAV-5 and AAV-6. However, the ITR does not have to be a wild-type nucleotide sequence and may be altered (e.g., by insertion, deletion or substitution of nucleotides) as long as the sequence retains the function of providing functional rescue, replication and packaging. The AAV vector may have one or more AAV wild-type genes (preferably rep and / or cap genes) that are completely or partially deleted but retain functional flanking ITR sequences. Functional ITR sequences play a role in, for example, rescuing, replicating and packaging AAV virions or particles. Therefore, "AAV vector" is defined herein as including at least those sequences required for inserting a transgene into a subject's cells. Optionally, those cis sequences (e.g., functional ITRs) necessary for viral replication and packaging are included.

[0084] As used herein, the term "gene therapy" refers to a method of treating a patient in which a polypeptide or nucleic acid sequence is transferred into the patient's cells to modulate the activity and / or expression of a particular gene. In certain embodiments, the expression of a gene is inhibited. In certain embodiments, the expression of a gene is enhanced. In certain embodiments, the temporal or spatial pattern of gene expression is modulated.

[0085] A "transgenic" may comprise a transgenic sequence or a native or wild-type DNA sequence. The transgenic may become part of the genome of a primate subject. The transgenic sequence may be partially or completely species heterologous, i.e., the transgenic sequence or a portion thereof may be from a species different from the cell into which it is introduced.

[0086] As used herein, the term "stably maintained" refers to a characteristic of a transgenic subject (e.g., a human or non-human primate) that maintains at least one of its transgenic elements (i.e., a desired element) in multiple generations of cells. For example, the term is intended to include many cell division cycles of the initially transfected cells. The term "stable transfection" or "stably transfected" refers to the introduction and integration of foreign DNA into the genome of a cell. The term "stable transfectant" refers to a cell that has stably integrated foreign DNA into genomic DNA.

[0087] As used herein, the terms "transgene encoding", "nucleic acid molecule encoding", "DNA sequence encoding", and "DNA encoding" refer to the order or sequence of deoxyribonucleotides along a deoxyribonucleic acid chain. For example, the order of these deoxyribonucleotides can determine the order of amino acids along a polypeptide (protein) chain. Thus, a DNA sequence can encode an amino acid sequence.

[0088] As used herein, the term "wild type" (wt) refers to a gene or gene product having the characteristics of the gene or gene product when isolated from a natural source. A wild-type gene is the gene most commonly observed in a population and is therefore arbitrarily designed to be the "normal" or "wild-type" form of a gene. In contrast, the term "modified" or "mutant" refers to a gene or gene product that exhibits modifications (i.e., altered characteristics) in sequence and / or functional properties when compared to a wild-type gene or gene product. Note that naturally occurring mutants can be isolated and identified by obtaining altered characteristics compared to a wild-type gene or gene product.

[0089] As used herein, the term "transfection" refers to the uptake of foreign nucleic acids (e.g., DNA or RNA) by a cell. A cell is "transfected" when the foreign nucleic acid (DNA or RNA) has been introduced into the cell membrane. Many transfection techniques are well known in the art (see, e.g., Graham et al., Virol., 52:456 (1973); Sambrook et al., Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Laboratories, New York (1989); Davis et al., Basic Methods in Molecular Biology, Elsevier, (1986); and Chu et al., Gene 13:197 (1981), incorporated herein by reference in their entirety). Such techniques can be used to introduce one or more foreign DNA moieties (such as gene transfer vectors and other nucleic acid molecules) into suitable recipient cells.

[0090] As used herein, the terms "stable transfection" and "stably transfected" refer to the introduction and integration of foreign DNA into the genome of the transfected cell. The term "stable transfectant" refers to a cell that has stably integrated foreign DNA into genomic DNA.

[0091] As used herein, the term "transient transfection" or "transiently transfected" refers to the introduction of foreign DNA into a cell, wherein the foreign DNA fails to integrate into the genome of the transfected cell and remains in episomal form. During this period, the foreign DNA is subject to regulatory control that governs the expression of endogenous genes in the chromosome. The term "transient transfectant" refers to a cell that has taken up foreign DNA but failed to integrate the DNA. As used herein, the term "transduction" means the delivery of a DNA molecule to a recipient cell in vivo or in vitro by a replication-defective viral vector, such as by a recombinant AAV virion.

[0092] As used herein, the term "recipient cell" refers to a cell that has been or is capable of being transfected or transduced with a nucleic acid construct or vector carrying a selected nucleotide sequence of interest. The term includes the progeny of a parent cell, whether or not the progeny is identical to the original parent in morphology or genetic composition, as long as the selected nucleotide sequence is present. The recipient cell can be a cell of a subject to whom gene therapy particles and / or gene therapy vectors have been administered.

[0093] As used herein, the term "recombinant DNA molecule" refers to a DNA molecule composed of DNA segments linked together by molecular biology techniques.

[0094] As used herein, the term "regulatory element" refers to a genetic element that can control the expression of a nucleic acid sequence. For example, a promoter is a regulatory element that promotes the initiation of transcription of an operably linked coding region. Other regulatory elements are splicing signals, polyadenylation signals, termination signals, etc.

[0095] The term DNA "control sequences" collectively refers to regulatory elements, such as promoter sequences, polyadenylation signals, transcription termination sequences, upstream regulatory domains, replication origins, internal ribosome entry sites ("IRES"), enhancers, etc., which together provide for replication, transcription, and translation of coding sequences in recipient cells. Not all of these control sequences need to be present.

[0096] Transcription control signals in eukaryotes typically include "promoter" and "enhancer" elements. Promoters and enhancers consist of short arrays of DNA sequences that specifically interact with cellular proteins involved in transcription (Maniatis et al., Science 236:1237 (1987), incorporated herein by reference). Promoter and enhancer elements have been isolated from various eukaryotic sources (including genes in yeast, insect and mammalian cells and viruses) (similar control sequences, i.e., promoters, are also present in prokaryotes). The selection of specific promoters and enhancers depends on the recipient cell type. Some eukaryotic promoters and enhancers have a wide host range, while other promoters and enhancers have functions in limited cell type subsets (for review, see, e.g., Voss et al., Trends Biochem. Sci., 11:287 (1986); and Maniatis et al., supra, incorporated herein by reference in their entirety). For example, the SV40 early gene enhancer is very active in a variety of cell types from many mammalian species and has been used to express proteins in a wide range of mammalian cells (Dijkema et al., EMBO J. 4:761 (1985), incorporated herein by reference in its entirety). Promoter and enhancer elements derived from the human elongation factor 1-alpha gene (Uetsuki et al., J. Biol. Chem., 264:5791 (1989); Kim et al., Gene 91:217 (1990); and Mizushima and Nagata, Nucl. Acids. Res., 18:5322 (1990)), the long terminal repeat of Rous sarcoma virus (Gorman et al., Proc. Natl. Acad. Sci. USA 79:6777 (1982)), and human cytomegalovirus (Boshart et al., Cell 41:521 (1985)) can also be used to express proteins in different mammalian cell types, which are incorporated herein by reference in their entirety. Promoters and enhancers can occur alone or together in nature. For example, retroviral long terminal repeats contain promoter and enhancer elements. In general, promoters and enhancers can function independently of the gene being transcribed or translated. Thus, the enhancers and promoters used may be "endogenous," "exogenous," or "heterologous" relative to the gene to which they are operably linked. An "endogenous" enhancer / promoter is one that is naturally associated with a given gene in the genome. An "exogenous" or "heterologous" enhancer or promoter is one that has been juxtaposed to a gene by genetic manipulation (i.e., molecular biology techniques) such that transcription of the gene is directed by the associated enhancer / promoter.

[0097] As used herein, the term "tissue specificity" refers to regulatory elements or control sequences, such as promoters, enhancers, etc., in which expression of a nucleic acid sequence is significantly higher in one or more specific cell types or tissues.

[0098] The presence of a "splicing signal" on an expression vector generally results in a higher level of recombinant transcript expression. Splicing signals mediate the removal of introns from primary RNA transcripts and consist of splicing donor and acceptor sites (Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, New York (1989), pp. 16.7-16.8, incorporated herein by reference in its entirety). Commonly used splicing donor and acceptor sites are the splice junctions of the 16S RNA from SV40.

[0099] Transcription termination signals are usually present downstream of the polyadenylation signal and are hundreds of nucleotides in length. The term "poly A site" or "poly A sequence" used herein refers to a DNA sequence that directs the termination and polyadenylation of a nascent RNA transcript. Efficient polyadenylation of recombinant transcripts is required because transcripts lacking a poly A tail are unstable and rapidly degraded. The poly A signal used in the expression vector can be "heterologous" or "endogenous". An endogenous poly A signal is a poly A signal naturally present at the 3' end of the coding region of a given gene in the genome. A heterologous poly A signal is a poly A signal that has been isolated from a gene and operably connected to the 3' end of another gene. A commonly used heterologous poly A signal is the SV40 poly A signal. The SV40 poly A signal is contained on a 237 bp BamHI / BclI restriction fragment and directs termination and polyadenylation (Sambrook et al., supra, at 16.6-16.7, incorporated herein by reference in its entirety).

[0100] As used herein, the terms "subject" and "patient" are used interchangeably herein and refer to humans and non-human animals. The term "non-human animal" of the present disclosure includes all vertebrates, e.g., mammals and non-mammals, such as non-human primates, sheep, dogs, cats, horses, cows, chickens, amphibians, reptiles, etc.

[0101] As defined herein, a "therapeutically effective amount" or "therapeutically effective dose" is an amount or dose of a fusion protein, polypeptide, nucleic acid, lipid nanoparticle, liposome, one or more AAV particles, or one or more virions that produces sufficient amounts of the desired protein to modulate protein activity in the desired manner (thereby providing a palliative tool for clinical intervention). In some embodiments, a therapeutically effective amount or dose of a transfected fusion protein, polypeptide, nucleic acid, one or more AAV particles, or one or more virions as described herein is sufficient to inhibit the gene targeted by the fusion protein / gene therapy construct.

[0102] As used herein, the term "treating," e.g., a disorder, means that a subject (e.g., a human) who suffers from, is at risk of having, and / or experiences symptoms of a disorder, will, in embodiments, suffer less severe symptoms and / or will recover faster when administered a fusion molecule or a nucleic acid encoding a fusion molecule and / or a gRNA or a nucleic acid encoding a gRNA (e.g., as described herein) than if the fusion molecule or a nucleic acid encoding a fusion molecule and / or a gRNA or a nucleic acid encoding a gRNA had never been administered. DETAILED DESCRIPTION OF THE INVENTION Construct In one aspect, provided herein are constructs comprising a polynucleotide encoding DNMT3A or a portion thereof, a polynucleotide encoding DNMT3L or a portion thereof, a polynucleotide encoding dCas9, a polynucleotide encoding KRAB or a portion thereof, a polynucleotide encoding a gene expression regulator, and a polynucleotide encoding (i) an epitope capable of binding to an antibody or an antigen-binding fragment thereof or (ii) a polypeptide sequence capable of binding to a nucleic acid structural element. In some embodiments, the constructs provided herein have a structure of Formula I: 5'-(A m1 -B m2 ) n1 -CasN-(A m3 -B m4 ) n2 -CasC-T p -E-3'.

[0104] In Formula I, one of A and B is a polynucleotide encoding DNMT3A or a portion thereof; and the other of A and B is a polynucleotide encoding DNMT3L or a portion thereof. CasN and CasC are polynucleotides encoding the N-terminal portion of dCas9 and the C-terminal portion of dCas9, respectively. E is 5'-(A m5 -B m6 ) n3 -K r -D q -3' or 5'-K r -D q -(A m5 -B m6 )n3 -3'. K is a polynucleotide encoding KRAB or a portion thereof. D is a polynucleotide encoding a gene expression regulator. The gene expression regulator can be, for example, a Kruppel-associated repression box (KRAB), enhancer 2 (EZH2) of zete homologs, G9A, lysine-specific histone demethylase 1A (LSD1), heterochromatin protein 1 (HP1), friend of GATA protein 1 (FOG1), histone deacetylase (HDAC3) and / or DOT1L. T comprises a polynucleotide encoding an epitope that can bind to an antibody or its antigen-binding fragment (e.g., a single domain antibody, scFv, Fab, VH, VHH or antibody mimetic) or a polypeptide sequence that can bind to a nucleic acid structural element. The polypeptide that can bind to an antibody or its antigen-binding fragment can be, for example, GCN4. The polypeptide sequence that can bind to a nucleic acid structural element can be, for example, MS2 bacteriophage coat protein (MCP). Polypeptides encoding DNMT3A, DNMT3L, CasN, CasC, KRAB, and gene expression regulators are described in more detail below.

[0105] In Formula I, m1, m2, m3, m4, m5 and m6 are each independently an integer selected from 0 to 3; n1, n2 and n3 are each independently an integer selected from 0 to 2; p is an integer selected from 0 to 20; q is an integer selected from 0 to 5; r is an integer selected from 0 to 5; and when p is 0, at least one of m1, m2, m3 and m4 is not 0, at least one of n1 and n2 is not 0, and at least one of q and r is not 0.

[0106] In some embodiments, the constructs provided herein have the structure of Formula II: 5'-CasN-(A m3 -B m4 ) n2 -CasC-K r -D q -3', wherein: n2 is an integer selected from 1 and 2; r is an integer selected from 1 to 5; q is an integer selected from 0 to 5; and at least one of m3 and m4 is not 0. In some embodiments, the construct comprises the structure of Formula IIa: 5'-CasN-(AB)-CasC-K r -D q -3'. Exemplary constructs having the structure of Formula IIa are shown in the second, third and fourth schematic diagrams of FIG. 1B .

[0107] In some embodiments, the constructs provided herein have the structure of Formula III: 5'-(A m1 -B m2 ) n1 -CasN-(A m3 -B m4) n2 -CasC-T p -E-3', wherein p is an integer selected from 1 to 20. Exemplary constructs having the structure of Formula III are shown in Figures 2B and 3B. In some embodiments, the construct has the structure of Formula IIIa: 5'-CasN-CasC-T p -3'. In the case of the construct of Formula IIIa, DNMT3A, DNMT3L and KRAB are expressed on separate constructs.

[0108] In some embodiments, the constructs provided herein have the structure of Formula IIIb: 5'-(A m1 -B m2 )-CasN-CasC-T p -E-3', wherein at least one of m1 and m2 is not 0. An exemplary construct having a structure of Formula IIIb is shown in the second schematic diagram in FIG2B and the second schematic diagram in FIG3B. In some embodiments, the construct has a structure of Formula IIIb-1: 5'-(AB)-CasN-CasC-T p -K r -D q -3', wherein: r is an integer selected from 1 to 5; and q is an integer selected from 0 to 5.

[0109] In some embodiments, the constructs provided herein have the structure of Formula IIIc: 5'-CasN-CasC-T p -E-3', wherein: n3 is an integer selected from 1 and 2; r is an integer selected from 1 to 5; and q is an integer selected from 0 to 5; and at least one of m5 and m6 is not 0. Exemplary constructs having the structure of Formula IIIc are shown in the third and fourth schematic diagrams in Figure 12B and the third and fourth schematic diagrams in Figure 3B. In some embodiments, the construct has the structure of Formula IIIc-1: 5'-CasN-CasC-T p -(A m5 -B m6 ) n3 -K r -D q -3'. In some embodiments, the construct has the structure of Formula IIIc-2: 5'-CasN-CasC-T p -K r -D q -(A m5 -B m6 ) n3 -3'.

[0110] The sequences of the constructs described herein are shown in Table 1, wherein dCas9 is shown in bold and underlined ,DNMT3A is shown in italic , DNMT3L is shown underlined , KRAB is shown in bold and italic , EZH2, G9A, LSD1, HP1, FOG1, DHAC3, DOT1L, 10×GCN4, MCP, and ScFV are shown in bold.

[0111] Table 1: Exemplary construct sequences

[0112]

[0113]

[0114]

[0115]

[0116]

[0117]

[0118]

[0119]

[0120]

[0121]

[0122]

[0123]

[0124]

[0125]

[0126]

[0127]

[0128]

[0129]

[0130]

[0131]

[0132]

[0133]

[0134]

[0135]

[0136]

[0137]

[0138]

[0139]

[0140]

[0141]

[0142]

[0143]

[0144]

[0145]

[0146]

[0147]

[0148]

[0149]

[0150]

[0151]

[0152]

[0153]

[0154]

[0155]

[0156]

[0157]

[0158]

[0159]

[0160]

[0161]

[0162]

[0163]

[0164]

[0165]

[0166]

[0167]

[0168]

[0169]

[0170]

[0171]

[0172]

[0173]

[0174]

[0175]

[0176]

[0177]

[0178]

[0179]

[0180]

[0181]

[0182]

[0183]

[0184]

[0185]

[0186]

[0187]

[0188]

[0189]

[0190]

[0191]

[0192]

[0193]

[0194]

[0195]

[0196]

[0197]

[0198]

[0199]

[0200]

[0201]

[0202]

[0203]

[0204]

[0205]

[0206]

[0207]

[0208]

[0209]

[0210]

[0211]

[0212]

[0213]

[0214]

[0215]

[0216]

[0217]

[0218]

[0219]

[0220]

[0221]

[0222]

[0223]

[0224]

[0225] The nucleic acid sequence of KRAB (KOX1) is as follows: CGGACACTGGTGACCTTCAAGGATGTATTTGTGGACTTCACCAGGGAGGAGTGGAAGCTGCTGGACACTGCTCAGCAGATCGTGTACAGAAATGTGATGCTGGAGAACTATAAGAACCTGGTTTCCTTGGGTTATCAGCTTACTAAGCCAGATGTGATCCTCCGGTTGGAGAAGGGAGAAGAGCCC (SEQ ID NO: 52).

[0226] (2) DNMT3A - DNMT3L - dCas9 - KRAB(ZIM3) RTLVTFEDVTVNFTQGEWQRLNPEQRNLYRDVMLENYSNLVSVGQGETTKPDVILRLEQGKEPWL(SEQ ID NO: 204) , The nucleic acid sequence of KRAB (ZIM3) is: CGGACACTGGTGACCTTCGAGGACGTGACCGTGAACTTCACCCAAGGCGAGTGGCAGAGACTGAACCCCGAGCAGAGAAACCTGTACCGGGACGTGATGCTGGAAAACTACAGCAACCTGGTGTCCGTCGGCCAGGGCGAGACAACAAAGCCTGACGTGATCCTGCGGCTGGAACAGGGCAAAGAACCTTGGCTG (SEQ ID NO: 54).

[0227] (3) DNMT3A - DNMT3L - dCas9 - KRAB (ZNF680) RTLLTFRDVAIEFSLEEWQCLDTAQRNLYRKVMFENYRNLVFLGIAVSKPHLITCLEQGKEPWN(SEQ ID NO: 205) , The nucleic acid sequence of KRAB (ZNF680) is: CGGACACTGCTGACCTTCAGAGATGTGGCCATCGAGTTCAGCCTGGAAGAGTGGCAGTGCCTGGACACAGCCCAGCGGAACCTGTACAGAAAAGTGATGTTCGAGAACTACCGGAACCTCGTGTTCCTGGGAATCGCCGTGTCTAAGCCCCACCTGATCACCTGTCTCGAGCAAGGGAAAGAACCCTGGAAC (SEQ ID NO: 206).

[0228] (4) DNMT3A - DNMT3L - dCas9 - KRAB (ZNF554) RTLVTFEDVSMDFSQEEWELLEPAQKNLYREVMLENYRNVVSLEALKNQCTDVGIKEGPLSPAQT(SEQ ID NO: 207) , The nucleic acid sequence of KRAB (ZNF554) is: CGGACACTGGTGACATTTGAGGATGTCTCCATGGACTTCAGCCAAGAGGAATGGGAGCTGCTGGAACCCGCTCAGAAGAACCTGTATAGGGAAGTCATGCTCGAAAATTACCGGAATGTGGTGTCCCTGGAAGCCCTGAAGAACCAGTGTACCGACGTGGGCATCAAAGAGGGCCCACTGTCTCCAGCTCAGACC (SEQ ID NO: 208).

[0229] (5) DNMT3A - DNMT3L - dCas9 - KRAB (ZNF264) RTLVTFDDVAVTFTKEEWGQLDLAQRTLYQEVMLENCGLLVSLGCPVPKAELICHLEHGQEPWT(SEQ ID NO: 209) , The nucleic acid sequence of KRAB (ZNF264) is: CGGACACTGGTGACTTTCGACGATGTGGCCGTGACCTTTACCAAAGAAGAGTGGGGCCAGCTGGATCTGGCCCAGAGAACACTGTACCAAGAAGTTATGCTGGAGAACTGCGGCCTGCTGGTGTCTCTGGGATGTCCTGTGCCTAAGGCCGAGCTGATCTGCCACCTGGAACACGGACAAGAGCCTTGGACC (SEQ ID NO: 210).

[0230] (6) DNMT3A - DNMT3L - dCas9 - KRAB (ZNF582) RTLELFRDVAIVFSQEEWQWLAPAQRDLYRDVMLETYSNLVSLGLAVSKPDVISFLEQGKEPWM(SEQ ID NO: 211) , The nucleic acid sequence of KRAB (ZNF582) is: CGGACACTGGAGCTGTTCCGCGACGTGGCCATTGTGTTCTCTCAAGAGGAATGGCAGTGGCTGGCCCCTGCTCAGAGAGATCTCTACCGCGACGTTATGCTGGAGACATACTCCAATCTCGTGTCCCTCGGCCTGGCCGTGTCCAAACCTGATGTGATCAGCTTCCTCGAGCAGGGAAAAGAACCTTGGATG (SEQ ID NO: 212).

[0231] (7) DNMT3A - DNMT3L - dCas9 - KRAB (ZNF324) RTLMAFEDVAVYFSQEEWGLLDTAQRALYRRVMLDNFALVASLGLSTSRPRVVIQLERGEEPWV(SEQ ID NO: 213) , The nucleic acid sequence of KRAB (ZNF324) is: CGGACACTGATGGCCTTTGAGGACGTCGCCGTGTATTTTTCCCAAGAAGAATGGGGACTGCTCGACACTGCCCAGAGAGCCCTGTATCGCAGAGTCATGCTGGACAACTTCGCCCTGGTGGCCTCCCTGGGCCTGTCTACAAGCAGACCCAGAGTGGTCATTCAGCTGGAAAGAGGCGAGGAACCCTGGGTC (SEQ ID NO: 214).

[0232] (8) DNMT3A - DNMT3L - dCas9 - KRAB (ZNF669) RTLVAFEDVAVNFTQEEWALLDSSQKNLYREVMQETCRNLASVGSQWKDQNIEDHFEKPGKDIRN(SEQ ID NO: 215) , The nucleic acid sequence of KRAB (ZNF669) is: CGGACACTGGTCGCCTTTGAAGATGTGGCTGTGAATTTCACCCAAGAAGAGTGGGCTCTGCTGGACAGCAGCCAGAAGAATCTCTACCGCGAAGTGATGCAAGAGACATGCCGGAACCTGGCCTCTGTGGGCTCTCAGTGGAAGGACCAGAACATCGAGGACCACTTCGAGAAGCCCGGCAAGGACATCAGAAAC (SEQ ID NO: 216).

[0233] (9) DNMT3A - DNMT3L - dCas9 - KRAB (ZNF354A) RTLLTFEDVAVLFTRDEWRKLAPSQRNLYRDVMLENYRNLVSLGLPFTKPKVISLLQQGEDPWE(SEQ ID NO: 217) , The nucleic acid sequence of KRAB (ZNF354A) is: CGGACACTGCTGACATTCGAAGATGTCGCAGTGCTGTTCACCCGGGACGAGTGGAGGAAACTGGCTCCCAGCCAGCGCAATCTGTATAGAGATGTGATGCTGGAGAATTACAGAAATCTCGTCAGCCTGGGGCTGCCCTTCACCAAGCCTAAAGTGATCAGCCTGCTGCAACAAGGCGAGGATCCTTGGGAA (SEQ ID NO: 218).

[0234] (10) DNMT3A - DNMT3L - dCas9 - KRAB (ZNF82) RTLVMFSDVSIDFSPEEWEYLDLEQKDLYRDVMLENYSNLVSLGCFISKPDVISSLEQGKEPWK(SEQ ID NO: 219) , The nucleic acid sequence of KRAB (ZNF82) is: CGGACACTGGTTATGTTCTCCGACGTGTCCATCGACTTTAGCCCCGAAGAGTGGGAGTATCTGGACCTGGAACAGAAGGATCTGTATCGCGACGTGATGCTCGAGAATTACTCTAACCTGGTGAGCCTGGGCTGCTTCATCAGCAAGCCCGATGTGATCTCTAGCCTGGAGCAAGGCAAAGAGCCATGGAAA (SEQ ID NO: 220). (11) DNMT3A - DNMT3L - dCas9 - KRAB (ZNF595) RTLVTFRDVAIEFSPEEWKCLDPAQQNLYRDVMLENYRNLVSLGFVISNPDLVTCLEQIKEPCN(SEQ ID NO: 221) , The nucleic acid sequence of KRAB (ZNF595) is: CGGACACTGGTCACCTTCCGGGACGTCGCAATCGAATTCAGCCCCGAGGAATGGAAATGTCTGGACCCCGCACAGCAAAACCTCTACAGAGATGTCATGCTCGAAAACTATAGGAACCTGGTCTCCCTGGGCTTCGTGATCAGCAACCCTGATCTCGTGACCTGCCTCGAACAGATCAAAGAGCCCTGCAAC (SEQ ID NO: 222).

[0235] (12) DNMT3A - DNMT3L - dCas9 - KRAB (ZNF419) RTLVTFEDVAVYFSQEEWRLLDDAQRLLYRNVMLENFTLLASLGLASSKTHEITQLESWEEPFM(SEQ ID NO: 223) , The nucleic acid sequence of KRAB (ZNF419) is: CGGACACTGGTTACCTTCGAAGATGTTGCCGTGTACTTCAGCCAAGAAGAGTGGCGGCTGCTGGATGACGCCCAGAGACTGCTGTATCGGAATGTTATGCTCGAAAACTTCACCCTGCTGGCTTCCCTGGGACTCGCCAGCTCTAAGACCCACGAGATTACCCAGCTGGAATCCTGGGAAGAACCCTTCATG (SEQ ID NO: 224).

[0236] (13) DNMT3A - DNMT3L - dCas9 - KRAB (ZNF566) RTLVMFSDVSVDFSQEEWECLNDDQRDLYRDVMLENYSNLVSMGHSISKPNVISYLEQGKEPWL(SEQ ID NO: 225) , The nucleic acid sequence of KRAB (ZNF566) is: CGGACACTGGTCATGTTCAGCGACGTGTCCGTGGACTTTAGCCAAGAGGAATGGGAATGCCTGAACGACGACCAGCGGGACCTCTATAGGGATGTCATGCTCGAGAACTACAGCAATCTCGTTTCCATGGGCCACAGCATCTCCAAGCCAAACGTCATCAGCTATCTCGAACAAGGCAAAGAGCCCTGGCTG (SEQ ID NO: 226).

[0237] (14) DNMT3A - DNMT3L - dCas9 - KRAB (ZIM2) RTLVTFEDVLVDFSPEELSSLSAAQRNLYREVMLENYRNLVSLGHQFSKPDIISRLEEEESYAM(SEQ ID NO: 227) , The nucleic acid sequence of KRAB (ZIM2) is: CGGACACTGGTCACCTTCGAGGATGTGCTGGTGGATTTCAGCCCTGAGGAACTGAGCAGCCTGTCCGCCGCACAGAGAAATCTCTATCGGGAAGTGATGCTGGAGAACTATCGGAATCTGGTGTCTCTGGGCCACCAGTTCAGCAAGCCTGACATCATCAGCAGACTGGAAGAAGAGGAATCCTACGCCATG (SEQ ID NO: 228).

[0238] The construct can be DNA or RNA. In some embodiments, the construct is mRNA. In some embodiments, the construct is double-stranded DNA. In some embodiments, the construct is double-stranded RNA. In some embodiments, the construct is single-stranded DNA. In some embodiments, the construct is single-stranded RNA.

[0239] CRISPR-Cas system The present disclosure provides an engineered system based on CRISPR / Cas9 for genome editing and treating genetic diseases. The engineered system based on CRISPR / Cas9 can be designed to target any gene, including genes involved in angiogenesis, such as VEGFA. The present disclosure provides a CRISPR-Cas system, which comprises a genetically engineered Cas protein and / or guide RNA with desired specificity and activity (e.g., reducing or eliminating the expression of the VEGFA gene product). The system based on CRISPR / Cas9 may include a Cas9 protein, a mutated Cas9 protein or a Cas9 fusion protein (e.g., a DNMT3A-DNMT3L (3A3L)-dCas9-KRAB fusion molecule) and at least one sgRNA (e.g., VEGFA sgRNA). For example, the Cas9 fusion protein may include a domain different from the endogenous activity of Cas9 (e.g., DNMT3A, DNMT3L or KRAB).

[0240] The Cas9 protein can be cleaved into an N-terminal portion (CasN) and a C-terminal portion (CasC).

[0241] Typically, Cas proteins (used interchangeably herein with CRISPR proteins, CRISPR enzymes, CRISPR-Cas proteins, CRISPR-Cas enzymes, Cas, CRISPR effectors, or Cas effector proteins) and / or guide sequences are components of CRISPR-Cas systems. CRISPR-Cas systems or CRISPR systems are collectively referred to as transcripts and other elements that are involved in the expression of CRISPR-associated ("Cas") genes or direct their activity, including sequences encoding Cas genes, tracr (trans-activating CRISPR) sequences (e.g., tracrRNA or active partial tracrRNA), tracr-mate sequences (including "direct repeat sequences" and tracrRNA-processed partial direct repeat sequences in the case of endogenous CRISPR systems), guide sequences (also referred to as "spacers" in the case of endogenous CRISPR systems), or "one or more RNAs" as the term is used herein (e.g., one or more RNAs that guide Cas, such as CRISPR RNA and trans-activating (tracr) RNA or single guide RNA (also known as sgRNA; chimeric RNA)) or other sequences and transcripts from CRISPR loci.

[0242] In general, CRISPR systems are characterized by elements that promote the formation of CRISPR complexes at target sequence sites (also referred to as protospacers in the case of endogenous CRISPR systems). In the engineered systems of the present disclosure, the direct repeat sequence may include a naturally occurring sequence or a non-naturally occurring sequence. The direct repeat sequence of the present disclosure is not limited to the length and sequence of naturally occurring ones. In addition, the direct repeat sequence of the present disclosure may include the insertion of nucleotides such as aptamers or sequences that bind to adapter proteins (for associating with functional domains). In certain embodiments, one end of the direct repeat sequence such as an insertion is roughly the first half of a short direct repeat (DR), and the other end is roughly the second half of a short direct repeat (DR). In the context of forming a CRISPR complex, a "target sequence" or "target polynucleotide" refers to a sequence to which a guide sequence is designed to have complementarity, wherein hybridization between the target sequence and the guide sequence promotes the formation of a CRISPR complex. The target sequence may comprise any polynucleotide, such as a DNA or RNA polynucleotide. In some embodiments, the target sequence is located in the nucleus or cytoplasm.

[0243] Typically, the guide sequence (or spacer sequence) can be any polynucleotide sequence that has sufficient complementarity with the target polynucleotide sequence to hybridize with the target sequence and guide the sequence-specific binding of the CRISPR complex to the target sequence. In some embodiments, when optimally aligned using a suitable alignment algorithm, the degree of complementarity between the guide sequence and its corresponding target sequence is about or greater than about 50%, 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more.

[0244] In certain embodiments, the efficiency of cleavage can be adjusted by introducing mismatches (e.g., 1 or more mismatches, such as 1 or 2 mismatches between the spacer sequence and the target sequence, including the position of the mismatches along the spacer / target). For example, the closer the double mismatch is to the center (i.e., not 3' or 5'), the more the efficiency of cleavage is affected. Therefore, by selecting the position of the mismatch along the spacer, the efficiency of cleavage can be adjusted. For example, if less than 100% target cleavage is desired (e.g., in a cell population), 1 or more, such as preferably 2, mismatches between the spacer and the target sequence can be introduced into the spacer sequence. The closer the mismatch position is to the center of the spacer, the lower the percentage of cleavage.

[0245] The CRISPR-Cas system or its components can be used to introduce one or more mutations in a target locus or nucleic acid sequence. The one or more mutations can include the introduction, deletion or substitution of one or more nucleotides produced on each target sequence of one or more cells by one or more guide RNAs or one or more sgRNAs. The mutation can include the introduction, deletion or substitution of 1-75 nucleotides produced on each target sequence of the one or more cells by one or more guide RNAs.

[0246] Typically, in the case of an endogenous CRISPR-Cas system, formation of a CRISPR complex (comprising a guide sequence hybridized to a target sequence and complexed with one or more Cas proteins) results in cleavage in or near the target sequence (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50 or more base pairs), but this may depend on, for example, secondary structure, particularly in the case of RNA targets. In some cases, in the case of an endogenous CRISPR system, formation of a CRISPR complex (comprising a guide sequence hybridized to a target sequence and complexed with one or more Cas proteins) results in cleavage of one or both strands (if applicable) in or near the target sequence (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50 or more base pairs).

[0247] In some embodiments, the guide RNA (capable of directing Cas to a target locus) may comprise (1) a guide sequence capable of hybridizing to a target locus (a polynucleotide target locus, such as an RNA target locus) in a eukaryotic cell; (2) a direct repeat (DR) sequence present in a single RNA (i.e., sgRNA (arranged in a 5' to 3' direction) or crRNA).

[0248] For general information regarding CRISPR-Cas systems, components thereof, and delivery of such components, including methods, materials, delivery vehicles, vectors, particles, AAVs, and preparation and use thereof (including amounts and formulations), all of which are useful in the practice of the present disclosure, see: U.S. Patent Nos. 8,999,641; 8,993,233; 8,945,839; 8,932,814; 8,906,616; 8,895,308; 8,889,418; 8,889,356; 8,871,445; 8,865,406; 8,795,965; 8,771,945; and 8,697,359; U.S. Patent Publication Nos. US 2014-0310830; US Patent Nos. 2014-0287938 A1, US 2014-0273234 A1, US 2014-0273232 A1, US 2014-0273231 A1, US 2014-0256046 A1, US 2014-0248702 A1, US 2014-0242700 A1, US 2014-0242699 A1, US 2014-0242664 A1, US 2014-0234972 A1, US 2014-0227787 A1, US 2014-0189896 A1, US 2014-0186958, US 2014-0186919 A1, US 2014-0186843 A1, US 2014-0179770 A1 and US2014-0179006 A1, US 2014-0170753; European patents EP 2784162 B1 and EP 2771468 B1; European patent applications EP 2771468, EP 2764103 and EP 2784162;and PCT patent publications WO 2021 / 183807A1 (PCT / US2021 / 021973), WO 2014 / 093661 (PCT / US2013 / 074743), WO 2014 / 093694 (PCT / US2013 / 074790), WO 2014 / 093595 (PCT / US2013 / 074611), WO 2014 / 093718 (PCT / US2013 / 074825), WO 2014 / 093709 (PCT / US2013 / 074812), WO 2014 / 093622 (PCT / US2013 / 074667), WO 2014 / 093635 (PCT / US2013 / 074691), WO 2014 / 093655 (PCT / US2013 / 074736), WO 2014 / 093712 (PCT / US2013 / 074819), WO 2014 / 093701 (PCT / US2013 / 074800), WO 2014 / 018423 (PCT / US2013 / 051418), WO 2014 / 204723 (PCT / US2014 / 041790), WO 2014 / 204724 (PCT / US2014 / 041800), WO2014 / 204725 (PCT / US2014 / 041803)、WO 2014 / 204726 (PCT / US2014 / 041804), WO 2014 / 204727 (PCT / US2014 / 041806), WO 2014 / 204728 (PCT / US2014 / 041808), WO 2014 / 204729 (PCT / US2014 / 041809), each of which is incorporated herein by reference in its entirety. ;

[0249] Cas proteins Cas proteins (e.g., engineered Cas proteins) may have nuclease activity substantially the same as that of wild-type corresponding Cas proteins (e.g., 80% to 100%, 90% to 100%, 95% to 100%, 98% to 100%, 99% to 100%, 99.9% to 100%, or about 100%). In some cases, engineered Cas proteins have nuclease activity that is higher (e.g., at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%) than that of wild-type corresponding Cas proteins.

[0250] Alternatively or additionally, the Cas protein (e.g., engineered Cas protein) may have a specificity of at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% higher than the wild-type corresponding Cas protein. In a specific example, the Cas protein (e.g., engineered Cas protein) has a specificity of at least 30% higher than the wild-type corresponding Cas protein. As used herein, the term "specificity" of Cas may correspond to the number or percentage of on-target polynucleotide cleavage events relative to the number or percentage of all polynucleotide cleavage events (including on-target and off-target events). The activity and specificity of the Cas protein are consistent with those described in the following literature (Hsu PD et al., DNA targeting specificity of RNA-guided Cas9 nucleases, Nat Biotechnol. 2013 Sep; 31(9):827- 832; and Slaymaker IM et al., Rationally engineered Cas9 nucleases with improved specificity, Science. 2016 Jan 1; 351(6268): 84-88, which also describe examples of methods for detecting the activity and specificity of Cas proteins and are incorporated herein by reference in their entirety and described in detail elsewhere herein).

[0251] In some embodiments, the Cas protein (e.g., its RuvC domain) can slide one base upstream (relative to the PAM) and produce a staggered cut, which can be filled and result in the duplication of a single base (i.e., a +1 insertion). Zuo, Z. and Liu, J. (2016) describe examples of +1 insertion positions. Cas9-catalyzed DNA cleavage produces staggered ends: evidence from Molecular Dynamics Simulations. Scientific Reports 6, 37584. In some embodiments, the engineered Cas protein has a +1 insertion frequency different from that of the wild-type corresponding Cas protein. For example, the +1 insertion frequency when guanine is present at position -2 relative to PAM is higher than the +1 insertion frequency when thymidine, cytidine, or adenine is present at position -2 relative to PAM. In some cases, +1 insertion depends on the host mechanism in human cells. In some examples, the Cas protein can produce staggered cuts. Staggered cuts can be 5' overhangs of 1-bp or 1-nucleotide. Staggered cuts can be 3' overhangs of 1-bp or 1-nucleotide.

[0252] The nucleic acid molecule encoding Cas can be codon optimized. In this case, an example of a codon optimized sequence is a sequence optimized for expression in a eukaryote (e.g., a human (i.e., optimized for expression in a human)), or a sequence optimized for another eukaryote, animal, or mammal discussed herein; see, for example, WO 2014 / 093622 (PCT / US2013 / 074667) SaCas9 human codon optimized sequence. Although this is preferred, it should be understood that other examples are also possible, and codon optimization for host species other than humans, or codon optimization for specific organs is known. In some embodiments, the enzyme coding sequence encoding Cas is codon optimized for expression in a specific cell such as a eukaryotic cell. The eukaryotic cell can be a cell of a specific organism or a cell derived from a specific organism, the organism being such as a mammal, including but not limited to a human or non-human eukaryote or an animal or mammal as described herein, such as a mouse, rat, rabbit, dog, livestock, or a non-human mammal or primate. In some embodiments, methods for changing human germline genetic identity and / or methods for changing animal genetic identity can be excluded, which may cause humans or animals to suffer, without any substantial medical benefits to humans or animals and animals produced by such methods. In general, codon optimization refers to the process of modifying nucleic acid sequences to enhance expression in target host cells by replacing at least one codon of a native sequence with a codon that is more frequently or most frequently used in the gene of the host cell, while maintaining the native amino acid sequence. Different species show specific biases to specific codons of specific amino acids. Codon bias (differences in codon usage between organisms) is usually related to the translation efficiency of messenger RNA (mRNA), which is considered to depend on the properties of the codons translated and the availability of specific transfer RNA (tRNA) molecules, etc. The dominant position of selected tRNA in cells is usually the reflection of the most commonly used codons in peptide synthesis. Thus, genes can be tailored for optimal gene expression in a given organism based on codon optimization.Codon usage tables are readily available, for example, in the "Codon Usage Database" available at www.kazusa.orjp / codon / , and these tables can be modified in a variety of ways.See Nakamura, Y. et al. "Codonusage tabulated from the international DNA sequence databases: status for theyear 2000" Nucl. Acids Res. 28:292 (2000). Computer algorithms for codon optimization of specific sequences for expression in specific host cells are also available, such as Gene Forge (Aptagen; Jacobus, PA). In some embodiments, one or more codons (e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 50 or more, or all codons) in the sequence encoding Cas correspond to the most commonly used codons for a specific amino acid.

[0253] In some embodiments, Cas protein may have nucleic acid cleavage activity. Cas protein may have RNA binding and DNA cleavage function. In some embodiments, Cas can be at or near the position of the target sequence, such as within the target sequence and / or within the complementary sequence of the target sequence or on a sequence related to the target sequence (e.g., within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500 or more base pairs from the first or last nucleotide of the target sequence) to guide the cutting of one or two nucleic acid chains. In some embodiments, the Cas protein can guide more than one cleavage (e.g., 1, 2, 3, 4, 5, or more cleavages) of one or both chains within the target sequence and / or within the complementary sequence of the target sequence or on a sequence related to the target sequence and / or within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500 or more base pairs from the first or last nucleotide of the target sequence. In some embodiments, the cleavage can be blunt-ended, i.e., produce a blunt end. In some embodiments, the cleavage can be staggered, i.e., produce a sticky end.

[0254] In some embodiments, the vector encodes a nucleic acid-targeting Cas protein that can be mutated relative to the corresponding wild-type enzyme, such that the mutated nucleic acid-targeting Cas protein lacks the ability to cleave one or both strands of a target polynucleotide containing a target sequence, for example, a change or mutation in the HNH domain produces a mutated Cas that is substantially lacking all DNA cleavage activity, for example, the DNA cleavage activity of the mutated enzyme is no more than about 25%, 10%, 5%, 1%, 0.1%, 0.01% or less of the nucleic acid cleavage activity of the non-mutated form of the enzyme; an example can be when the nucleic acid cleavage activity of the mutant form is zero or negligible compared to the non-mutated form. As used herein, the term "derived" with respect to an enzyme means that the derived enzyme is largely based on the wild-type enzyme in the sense of having a high degree of sequence homology to the wild-type enzyme, but it has been mutated (modified) in a manner known in the art or described herein.

[0255] Typically, in the case of an endogenous nucleic acid targeting system, the formation of a nucleic acid targeting complex (comprising a guide RNA or crRNA hybridized to a target sequence and complexed with one or more nucleic acid targeting effector proteins) results in the cleavage of one or more DNA strands in or near the target sequence (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50 or more base pairs). As used herein, the term "one or more sequences associated with a target locus of interest" refers to sequences that are near a target sequence (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50 or more base pairs from a target sequence, wherein the target sequence is contained within the target locus of interest).

[0256] It will be understood that effector proteins are based on or derived from enzymes, and thus in some embodiments, the term "effector protein" certainly includes "enzymes". However, it will also be understood that, as required in some embodiments, effector proteins may have DNA or RNA binding activity, but not necessarily cleavage or incision activity, including dead Cas protein function.

[0257] In some embodiments, Cas proteins may form components of inducible systems. The inducible nature of the system will allow the use of a form of energy to control gene editing or gene expression in time and space. The form of energy may include, but is not limited to, electromagnetic radiation, acoustic energy, chemical energy, and thermal energy. Examples of inducible systems include tetracycline inducible promoters (Tet-On or Tet-Off), small molecule dual hybrid transcriptional activation systems (FKBP, ABA, etc.), or light-inducible systems (phytochrome, LOV domain, or cryptochrome). In one embodiment, the CRISPR effector protein may be part of a light-inducible transcriptional effector (LITE) to guide changes in transcriptional activity in a sequence-specific manner. The components of light may include CRISPR effector proteins, light-responsive cytochrome heterodimers (e.g., from Arabidopsis thaliana), and transcriptional activation / repression domains. Other examples of inducible DNA binding proteins and methods of using them are provided in US 61 / 736465 and US 61 / 721,283 and WO 2014018423 A2 (which are hereby incorporated by reference in their entirety).

[0258] In some embodiments, the mutated Cas may have one or more mutations that result in reduced off-target effects, for example, an improved CRISPR enzyme (such as when complexed with a guide RNA) for achieving modification of the target locus but reducing or eliminating activity toward off-targets, and an improved CRISPR enzyme (such as when complexed with a guide RNA) for enhancing CRISPR enzyme activity. It should be understood that the mutated enzyme as described below can be used in any method according to the present disclosure as described elsewhere herein. Any methods, products, compositions and uses described elsewhere herein are also applicable to mutated CRISPR enzymes, as further described below.

[0259] Methods and mutations that can be used in various combinations to increase or decrease the activity and / or specificity of the target relative to off-target activity, or to increase or decrease the binding and / or specificity of the target relative to off-target binding, can be used to compensate for or enhance mutations or modifications performed to promote other effects. Such mutations or modifications performed to promote other effects include mutations or modifications to Cas and / or mutations or modifications to guide RNA. The methods and mutations disclosed herein are used to modulate Cas nuclease activity and / or binding to chemically modified guide RNAs.

[0260] In certain embodiments, the catalytic activity of the Cas protein of the present disclosure is changed or improved. It should be understood that if the catalytic activity is different from the catalytic activity of the corresponding wild-type Cas protein (e.g., unmutated Cas protein), the mutated Cas has a changed or improved catalytic activity. The catalytic activity can be determined by methods known in the art. For example, but not limited to, the catalytic activity can be determined in vitro or in vivo by measuring the insertion / deletion (indel) percentage (e.g., after a given time, or at a given dose). In certain embodiments, the catalytic activity is enhanced. In certain embodiments, the catalytic activity is enhanced by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 100%. In certain embodiments, the catalytic activity is reduced. In certain embodiments, the catalytic activity is reduced by at least 5%, preferably at least 10%, more preferably at least 20%, such as at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or (substantially) 100%. One or more mutations herein can inactivate catalytic activity, which can significantly reduce overall catalytic activity, reduce activity to below detectable levels, or reduce to no measurable catalytic activity.

[0261] One or more features of the engineered Cas protein may be different from the corresponding wild-type Cas protein. Examples of such features include catalytic activity, gRNA binding, specificity of the Cas protein (e.g., specificity of the target determined by editing), stability of the Cas protein, off-target binding, target binding, protease activity, nickase activity, PFS recognition. In some examples, the engineered Cas protein may include one or more mutations of the corresponding wild-type Cas protein. In some embodiments, the catalytic activity of the engineered Cas protein is enhanced compared to the corresponding wild-type Cas protein. In some embodiments, the catalytic activity of the engineered Cas protein is reduced compared to the corresponding wild-type Cas protein. In some embodiments, the gRNA binding of the engineered Cas protein is enhanced compared to the corresponding wild-type Cas protein. In some embodiments, the gRNA binding of the engineered Cas protein is weakened compared to the corresponding wild-type Cas protein. In some embodiments, the specificity of the Cas protein is enhanced compared to the corresponding wild-type Cas protein. In some embodiments, the specificity of the Cas protein is reduced compared to the corresponding wild-type Cas protein. In some embodiments, the stability of the Cas protein is enhanced compared to the corresponding wild-type Cas protein. In some embodiments, the stability of the Cas protein is reduced compared to the corresponding wild-type Cas protein. In some embodiments, the engineered Cas protein further comprises one or more mutations that inactivate catalytic activity. In some embodiments, the off-target binding of the Cas protein is increased compared to the corresponding wild-type Cas protein. In some embodiments, the off-target binding of the Cas protein is reduced compared to the corresponding wild-type Cas protein. In some embodiments, the target binding of the Cas protein is increased compared to the corresponding wild-type Cas protein. In some embodiments, the target binding of the Cas protein is reduced compared to the corresponding wild-type Cas protein. In some embodiments, the engineered Cas protein has higher protease activity or polynucleotide binding ability compared to the corresponding wild-type Cas protein. In some embodiments, PFS recognition is changed compared to the corresponding wild-type Cas protein.

[0262] Examples of Cas proteins Examples of Cas proteins include Class I (e.g., Type I, Type III, and Type IV) and Class 2 (e.g., Type II, Type V, and Type VI) Cas proteins, e.g., Cas9, Cas12 (e.g., Cas12a, Cas12b, Cas12c, Cas12d), Cas13 (e.g., Cas13a, Cas13b, Cas13c, Cas13d), CasX, CasY, Cas14, variants thereof (e.g., mutant forms, truncated forms), homologs thereof, and orthologs thereof. The terms "orthologs" and "homologs" are well known in the art. By further guidance, a "homolog" of a protein used herein is a protein of the same species that performs the same or similar function as a protein that is a homolog thereof. Homologous proteins may be, but need not be, structurally related, or only partially structurally related. As used herein, a "ortholog" of a protein is a protein of a different species that performs the same or similar function as a protein that is a homolog thereof. Orthologous proteins may, but need not, be structurally related, or only partially structurally related.

[0263] Class 2 Cas proteins In some embodiments, the Cas protein is a Class 2 Cas protein, i.e., a Class 2 CRISPR-Cas system Cas protein. Class 2 CRISPR-Cas systems can be subtypes, such as Type II-A, Type II-B, Type II-C, Type VA, Type VB, Type VC, or Type VU. In some embodiments, the Cas protein is Cas9, Cas12a, Cas12b, Cas12c, or Cas12d. In some embodiments, Cas9 can be SpCas9, SaCas9, StCas9, and other Cas9 orthologs. Cas12 can be Cas12a, Cas12b, and Cas12c, including FnCas12a or its homologs or orthologs. Definitions and exemplary members of CRISPR-Cas systems include those described in Kira S. Makarova and Eugene V. Koonin, Annotation and Classification of CRISPR-Cas systems, Methods Mol Biol. 2015; 1311: 47-75; and Sergey Shmakov et al., Diversity and evolution of class 2 CRISPR-Cas systems, Nat Rev Microbial. 2017 Mar; 15(3): 169-182:.

[0264] Cas protein adaptors In some examples, the Cas protein includes at least one RuvC domain and at least one HNH domain. The Cas protein may also include the first and second joint domains connecting the RuvC domain and the HNH domain. In Nishimasu, H et al. "Crystal structure of Cas9 in complex with guide RNA and target RNA" Cell 156 (February 27, 2014): 935-949 and Ribeiro, L. et al. (2018) "Protein engineering strategies to expand CRISPR-Cas9 applications" International Journal of Genomics Volume 2018, Article ID 1652567 (doi.org / 10.1155 / 2018 / 1652567) studies describe the first joint (L1) and the second joint (L2) connecting the HNH and RuvC domains in Cas9. Figure 1 of Ribeiro (particularly incorporated herein by reference) shows the overall organization, structure and function of Cas9. Specifically, Figure 1A shows a schematic diagram of the domain organization of SpCas9, indicating the genetic architecture of the HNH and RuvC domains including linkers L1 (spanning amino acids 765-780) and L2 (spanning amino acids 906-918) as described herein.

[0265] Similarly, when it comes to the first and second linker domains, the domain organization of Staphylococcus aureus Cas9 (SaCas9) can be utilized. In one aspect, the linker 1 domain region spans residues 481-519 and will connect the RuvC-II domain in SaCas9 with the HNH domain. In some embodiments, the linker 2 region spans residues 629-649 and connects the RuvC-III domain and the HNH domain of SaCas9. Thus, the first and / or second linker domains can be mutated in a Cas9 ortholog, and reference can be made to the amino acid residues corresponding to the amino acids of wild-type SaCas9. See, Nishimasu, Cell. Aug. 27, 2015; 162(5): 1113-1126; doi: 10.1016 / j.cell.2015.08.007, incorporated herein by reference. In particular, Figures 1, S1-S3 of Nishimasu describe in detail the domain organization of the Cas9 protein and are specifically incorporated by reference for their teachings.

[0266] The first and second joints may comprise about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 or more amino acids. The first and second joints may correspond to wild-type joints. In some aspects, the first and second joints may comprise one or more mutations in the first and / or second joints. On the one hand, the first and / or second joints comprise one or more mutations that improve the specificity of the Cas9 protein.

[0267] In some embodiments, the linkers L1 and L2 connecting the HNH and RuvC domains of Cas9 contain wild-type amino acid sequences. In some embodiments, the linkers connecting the HNH and RuvC domains contain mutations in one or more amino acids. In an exemplary embodiment, the first linker (L1) comprises a mutation corresponding to the amino acid T769I of SpCas9, and / or the second linker (L2) comprises a mutation corresponding to the amino acid G915M of SpCas9. In an exemplary embodiment, one or more linker mutations, such as T769I and G915M, confer increased specificity to the Cas9 protein.

[0268] In one embodiment, one or more mutations in the first and second linkers can be combined with one or more mutations in other parts of the Cas9 protein to further improve specificity and / or maintain activity substantially equivalent to that of a wild-type Cas9 protein, as described herein. In one embodiment, the methods detailed herein can be used to identify mutations in the linkers and / or additional mutations in the Cas protein that enhance / improve specificity and substantially retain the wild-type activity of the wild-type Cas9.

[0269] Class 2, type II Cas proteins (e.g., Cas9) In some embodiments, the Cas protein can be a Cas protein (Type II Cas protein) of a Type II CRISPR-Cas system of Class 2. In some embodiments, the Cas protein can be a Type II Cas protein of Class 2, such as Cas9. In some embodiments, a system based on CRISPR / Cas9 may include a Cas9 protein or a fragment thereof, a Cas9 fusion protein, a nucleic acid encoding a Cas9 protein or a fragment thereof, or a nucleic acid encoding a Cas9 fusion protein. "Cas9 (CRISPR-associated protein 9)" refers to a polypeptide or a fragment thereof having at least about 85% amino acid identity with NCBI accession number NP_269215 and having RNA binding activity, DNA binding activity and / or DNA cleavage activity (e.g., endonuclease or nickase activity). "Cas9 function" can be determined by any of a variety of assays, including but not limited to nucleic acid binding assays based on fluorescence polarization, chain invasion assays based on fluorescence polarization, transcription assays, EGFP destruction assays, DNA cleavage assays and / or Surveyor assays, for example, as described herein. "Cas9 nucleic acid molecule" refers to a polynucleotide encoding a Cas 9 polypeptide or a fragment thereof. An exemplary Cas9 nucleic acid molecule sequence is provided in genomic sequence number NC_002737. In some embodiments, disclosed herein are inhibitors of Cas9 (e.g., naturally occurring Cas9 in Streptococcus pyogenes (SpCas9) or Staphylococcus aureus (SaCas9)) or its variants. Cas9 utilizes the base pairing of the protospacer adjacent motif (PAM) sequence and guide RNA (gRNA) to target DNA to identify foreign DNA. The relative ease with which Cas9 induces targeted chain breaks on any genomic locus enables efficient genome editing in a variety of cell types and organisms. Cas9 derivatives can also be used as transcriptional activators / repressors.

[0270] In some cases, CRISPR-Cas protein is Cas9 or its variant.In some instances, Cas9 can be wild-type Cas9, including any naturally occurring bacterial Cas9.Cas9 orthologs generally share the general organization of 3-4 RuvC domains and one HNH domain.5'The most end of the RuvC domain cuts the non-complementary chain, and the HNH domain cuts the complementary chain.All symbols are reference guide sequences.By comparing the homology of the target Cas9 with other Cas9 orthologs (from Streptococcus pyogenes II type CRISPR loci, Streptococcus thermophilus CRISPR loci 1, Streptococcus thermophilus CRISPR loci 3 and Franciscilla novicida II type CRISPR loci), the catalytic residues in the 5'RuvC domain are identified, and the conservative Asp residue (D10) is mutated to alanine to convert Cas9 into a complementary chain nickase.Therefore, the Cas enzyme can be wild-type Cas9, including any naturally occurring bacterial Cas9. CRISPR, Cas or Cas9 enzymes can be codon-optimized or modified forms, including any chimeras, mutants, homologs or orthologs. In another aspect of the present disclosure, the Cas9 enzyme can comprise one or more mutations and can be used as a universal DNA binding protein fused with or without a functional domain.

[0271] The mutation may be an artificially introduced mutation or a gain-of-function mutation or a loss-of-function mutation. In some embodiments, the transcriptional activation domain may be VP64. In some embodiments, the transcriptional repressor domain may be KRAB or SID4X. Other aspects of the disclosure relate to mutated Cas9 enzymes fused to domains, including but not limited to nucleases, transcriptional activators, repressors, recombinases, transposases, histone remodeling factors, demethylases, DNA methyltransferases, cryptochromes, light-inducible / controllable domains or chemically inducible / controllable domains. The disclosure may relate to sgRNA or tracrRNA or guide sequences or chimeric guide sequences, which allow the performance of these RNAs in cells to be enhanced. This type II CRISPR enzyme may be any Cas enzyme. In some cases, the Cas9 enzyme is from or derived from SpCas9 or SaCas9. As used herein, the term "derived" with respect to an enzyme means that the derived enzyme is largely based on the wild-type enzyme in the sense of having a high degree of sequence homology with the wild-type enzyme, but it has been mutated (modified) in a manner known in the art or described herein. In an example, the mutation may include one or more mutations in the first joint domain, the second joint domain and / or other parts of the protein. Relative to the wild-type enzyme, the high sequence homology may include at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more.

[0272] Cas enzyme can be identified as Cas9, because this can refer to the general category of enzymes with the largest nuclease with multiple nuclease domains from type II CRISPR system that share homology. In some cases, Cas9 enzyme is from or derived from SpCas9 (Streptococcus pyogenes Cas9) or saCas9 (Staphylococcus aureus Cas9). "StCas9" refers to wild-type Cas9 (UniProt ID: G3ECR1) from Streptococcus thermophilus. Similarly, "SpCas9" refers to wild-type Cas9 (UniProt ID: Q99ZW2) from Streptococcus pyogenes. As used herein, the term "derived" for enzyme means that the derived enzyme is largely based on the wild-type enzyme in the sense of having a high degree of sequence homology with the wild-type enzyme, but it has been mutated (modified) in a manner known in the art or described herein. It should be understood that, unless otherwise stated, the terms Cas and CRISPR enzyme are generally used interchangeably herein. As described above, many residue numbers used herein refer to Cas9 enzymes from type II CRISPR loci in Streptococcus pyogenes.

[0273] In a particular embodiment, the effector protein is a Cas9 effector protein from or derived from an organism of the genus Streptococcus ( Streptococcus ), Campylobacter spp. Campylobacter ), Nitratifractor , Staphylococcus Staphylococcus ), Parvibaculum , Roseburia Roseburia ), Neisseria species ( Neisseria ), Gluconacetobacter spp. Gluconacetobacter ), Azospirillum ( Azospirillum ), sphaerocephala ( Sphaerochaeta ), Lactobacillus ( Lactobacillus ), Eubacteria ( Eubacterium ), Corynebacterium ( Corynebacte ), Carnobacterium spp. Carnobacterium ), Rhodobacterium ( Rhodobacter ), Listeria spp. Listeria ), Porphyromonas ( Paludibacter ), Clostridium ( Clostridium )、Lachnospiraceae( Lachnospiraceae ), Clostridium spp. Clostridiaridium ), Leptotrichia ( Leptotrichia ), Francisella spp. Francisella ), Legionella spp. Legionella ), Alicyclobacillus ( Alicyclobacillus ), Methanotrophic bacteria ( Methanomethyophilus ), Porphyromonas ( Porphyromonas ), Prevotella ( Prevotella ), Bacteroides ( Bacteroidetes ), Vulnificus ( Helicobacter ), Leptospira spp. Letospira ), Desulfovibrio ( Desulfovibrio ), Desulfovibacterium Desulfonatron )、Fengyou Fungus family( Opitutaceae ), Bacillus spp.( Tuberculosis ), Bacillus, Brevibacillus ( Brevibacillus ), Methylobacterium ( Methylobacterium ) or Acidaminococcus ( Acidaminococci ), Streptococcus, Campylobacter, Nitrate fractionator , Staphylococcus, Small stick , Roseburia, Neisseria, Gluconacetobacter, Azospirillum, Glomerella, Lactobacillus ( Lactobacillus ), Eubacterium, Corynebacterium, Sutterella ( Sutterella ), Legionella, Treponema ( Treponema ), genus Pseudomonas ( Filament maker), Eubacteria, Streptococcus ( Streptococcus ), Lactobacillus ( Lactobacillus ), Mycoplasma spp. Mycoplasma ), Bacteroides, Freundii ( Flaviivolae ), Flavobacterium ( Flavobacterium ), Coccospirillum, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, and Parvibacillum ( Small stick ), Staphylococcus, Nitrate-lysing Bacteria ( Nitrate fractionator ), Mycoplasma spp., or Campylobacter spp.

[0274] In some embodiments, the Cas9 protein is from or derived from a bacterium selected from Streptococcus mutans ( S. mutans ), Streptococcus agalactiae ( S. agalactiae ), Streptococcus equi S. equisimilis ), Streptococcus sanguinis ( Blood S. ), Streptococcus pneumoniae ( S. pneumoniae jejuni ( C. jejuni ), Escherichia coli ( C. coli ); Brine nitrate-lysing bacteria ( N salty )、( N. tergarcus ); Staphylococcus auris ( S. auricularis ), Staphylococcus carnosus ( S. fleshy ); Neisseria meningitidis ( N meningitis ), Neisseria gonorrhoeae ( N gonorrhoeae ), Listeria monocytogenes ( L. monocytogenes ), Listeria monocytogenes ( L. ivanovii ); Clostridium botulinum ( C. botulinum ), Clostridium difficile ( C. difficile ), Clostridium tetani ( C. tetani ) or Clostridium sordellii ( C. dirty ), Francisella tularensis ( Francisella tularensis1 ), Francisella tularensis subspecies novo Francisella tularensis subsp. newcomers ), Prevotella alberta ( Prevotella from Albania ), Lachnospiraceae bacteria MC2017 1( Lachnospiraceae bacterium MC2017 1 ), butyrivibrio proteolyticus ( Butyrivibrio proteoclasticus ), Allopatrical bacteria GW2011 GWA2_33_10 ( Peregrine bacteria GW2011 GWA2_33_10 ), GW2011 GWC2_44_17 ( Parcubacteria bacterium GW2011 GWC2_44_17 ), a species of Smithia SCADC ( Smithella sp. SCADC ), Acidaminococcus species BV3L6 ( Acidaminococcus sp. BV3L6)、Lachnospiraceae MA2020 ( Lachnospiraceae bacterium MA2020 ), Methanoplasma termitum tentative species ( Candidate Methanoplasma termite ), Eubacterium fastidiosa ( Eubacterium electigens )、Moracella 237( Moraxella bovoculi 237 ), Leptospira borgpetersenii ( Leptospira inadai ), Lachnospiraceae bacteria ND2006 ( Lachnospiraceae bacterium Nd2006 ), Porphyromonas canis oralis 3 ( Porphyromonas crevioricanis 3 ), Prevotella glycopeptone ( Prevotella dissident ) and Porphyromonas macaques ( Porphyromonas macacae ). In some embodiments, the Cas9 effector protein from an organism is from or derived from Streptococcus pyogenes, Staphylococcus aureus, or Streptococcus thermophilus Cas9.

[0275] In a more preferred embodiment, the Cas9 protein is derived from a bacterial species selected from Streptococcus pyogenes, Staphylococcus aureus or Streptococcus thermophilus Cas9. In certain embodiments, Cas9 is derived from a bacterial species selected from the following bacteria: Francisella tularensis 1, Prevotella alberta, Lachnospiraceae MC20171, butyric acid vibrio proteolyticus, Allopatricial bacteria GW2011 GWA2_33_10, Thripatis total bacteria GW2011 GWC2_44_17, a certain SCADC of Smith's genus, a certain BV3L6 of the genus Acidococcus, Lachnospiraceae MA2020, Methanoplasma termitaris tentative species, Eubacterium fastidious, Moraxella 237, Leptospira bodensis, Lachnospiraceae ND2006, Porphyromonas canis oralis 3, Prevotella saccharolyticus and Porphyromonas macaques. In certain embodiments, the Cas9 protein is derived from a bacterial species selected from a certain species of Acidaminococcus BV3L6, Lachnospiraceae MA2020. In certain embodiments, the effector protein is derived from a subspecies of Francisella tularensis 1, including but not limited to Francisella tularensis subspecies novicida.

[0276] Cas9 enzymes include, but are not limited to, Streptococcus pyogenes serotype M1 (UniProt ID: Q99ZW2), Staphylococcus aureus Cas9 (UniProt ID: J7RUA5), Eubacterium convexogastricum Cas9 (UniProt ID: A5Z395), Azospirillum (strain B510) Cas9 (UniProt ID: D3NT09), Gluconobacter diazoacetobacter (strain ATCC 49037) Cas9 (UnitProt ID: A9HKP2), Neisseria griseus Cas9 (UniProt ID: D0W2Z9), Roseburia rosella intestinalis Cas9 (UniProt ID: C7G697), Bacterium nitrate-lysing bacteria (strain DS-1) Cas9 (UniProt ID: A7HP89), Brine nitrate-lysing bacteria (strain DSM 16511) Cas9 (UniProt ID: ID: E6WZS9), Campylobacter gullus Cas9 (UniProt ID: G1UFN3).

[0277] The enzymatic action of Cas9 derived from Streptococcus pyogenes or any closely related Cas9 produces a double-strand break at a target site sequence that hybridizes to 20 nucleotides of a guide sequence and has a protospacer adjacent motif (PAM) sequence (examples include NGG / NRG or a PAM that can be determined as described herein) after the 20 nucleotides of the target sequence. The CRISPR activity of site-specific DNA recognition and cleavage by Cas9 is defined by the guide sequence, the tracr sequence that partially hybridizes to the guide sequence, and the PAM sequence. Further aspects of the CRISPR system are described in Karginov and Hannon, The CRISPR system: small RNA-guided defense in bacteria and archaea, Mole Cell 2010, January 15; 37(1): 7. Type II CRISPR locus from Streptococcus pyogenes SF370, which contains a cluster of four genes Cas9, Cas1, Cas2 and Csnl, and two non-coding RNA elements, tracrRNA and a feature array of repetitive sequences (forward repeats) spaced by short segments of non-repetitive sequences (spacers, each about 30bp). In this system, targeted DNA double-strand breaks (DSBs) are produced in four consecutive steps. First, two non-coding RNAs, pre-crRNA arrays and tracrRNA are transcribed from the CRISPR locus. Second, tracrRNA hybridizes with the forward repeats of pre-crRNA and is then processed into a mature crRNA containing a single spacer sequence. Third, the mature crRNA:tracrRNA complex is formed by a heteroduplex between the crRNA spacer and the pre-spacer sequence DNA, and Cas9 is directed to a DNA target consisting of a pre-spacer sequence and a corresponding PAM. Finally, Cas9 mediates the cutting of the target DNA upstream of PAM to produce DSBs in the pre-spacer sequence. A pre-crRNA array consisting of a single spacer flanked by two forward repeats (DRs) is also included in the term "tracr-mate sequence". In certain embodiments, Cas9 may be constitutively present or inducibly present or conditionally present or administered or delivered. Cas9 optimization can be used to enhance function or develop new functions. People can produce chimeric Cas9 proteins, and Cas9 can be used as a universal DNA binding protein. The structural information provided for Cas9 can be used to further engineer and optimize the CRISPR-Cas system, and this can also be extrapolated to interrogate structure-function relationships in other CRISPR enzyme systems, particularly other type II CRISPR enzymes or Cas9 orthologs. Structure-function relationships.Crystal structure information (described in U.S. Provisional Applications 61 / 915,251, filed December 12, 2013; 61 / 930,214, filed January 22, 2014; 61 / 980,012, filed April 15, 2014; and Nishimasu et al., “Crystal Structure of Cas9 in Complex with Guide RNA and Target DNA,” Cell 156(5):935-949, DOI: http: / / dx.doi.org / 10.1016 / j.cell.2014.02.001 (2014), each and all of which are incorporated herein by reference) provides structural information for truncating and generating modular or multipartite CRISPR enzymes that can be incorporated into inducible CRISPR Cas systems. In particular, structural information for Streptococcus pyogenes Cas9 (SpCas9) is provided, which can be extrapolated to other Cas9 orthologs or other type II CRISPR enzymes. The Cas9 gene is found in several different bacterial genomes, often in the same locus as the cas1, cas2, and cas4 genes and the CRISPR box. In addition, the Cas9 protein contains an easily identifiable C-terminal region that is homologous to the transposon ORF-B and includes an active RuvC-like nuclease, an arginine-rich region.

[0278] dCas9 The Cas9 protein can be mutated to inactivate the nuclease activity. The inactivated Cas9 protein (iCas9, also referred to as "dCas9") from Streptococcus pyogenes without endonuclease activity has recently been targeted by gRNA to genes in bacteria, yeast and human cells to silence gene expression by steric hindrance. As used herein, "dCas molecule" may refer to dCas protein or a fragment thereof. As used herein, "dCas9 molecule" may refer to dCas9 protein or a fragment thereof. As used herein, the terms "iCas" and "dCas" are used interchangeably to refer to CRISPR-associated proteins without catalytic activity. In one embodiment, the dCas molecule includes one or more mutations in the DNA cleavage domain. In one embodiment, the dCas molecule includes one or more mutations in the RuvC or HNH domain. In one embodiment, the dCas molecule includes one or more mutations in both the RuvC and HNH domains. In one embodiment, the dCas molecule is a fragment of a wild-type Cas molecule. In one embodiment, the dCas molecule includes a functional domain from a wild-type Cas molecule, wherein the functional domain is selected from a Reel domain, a bridge helical domain or a PAM interaction domain. In one embodiment, the nuclease activity of the dCas molecule is reduced by at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99% compared to the nuclease activity of the corresponding wild-type Cas molecule. An exemplary amino acid sequence of a wild-type dCas9 protein is shown in SEQ ID NO: 1. An exemplary nucleic acid sequence encoding a wild-type dCas9 is shown in SEQ ID NO: 26.

[0279] Suitable dCas molecules can be derived from wild-type Cas molecules. Cas molecules can be from type I, type II or type III CRISPR-Cas systems. In one embodiment, suitable dCas molecules can be derived from Cas1, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 or Cas10 molecules. In one embodiment, dCas molecules are derived from Cas9 molecules. For example, dCas9 molecules can be obtained by introducing point mutations (e.g., substitutions, deletions or additions) in the DNA cleavage domains, such as nuclease domains, such as RuvC and / or HNH domains of Cas9 molecules. See, for example, Jinek et al., (2012) 337: 816-21, incorporated herein by reference in its entirety. For example, introducing two point mutations in RuvC and HNH domains reduces Cas9 nuclease activity while retaining Cas9 sgRNA and DNA binding activity. In one embodiment, two point mutations in RuvC and HNH active sites are D10A and H840A mutations of Streptococcus pyogenes Cas9 molecules. Alternatively, D10 and H840 of the S. pyogenes Cas9 molecule can be deleted to eliminate Cas9 nuclease activity while retaining its sgRNA and DNA binding activity. In one embodiment, the two point mutations within the RuvC and HNH active sites are D10A and N580A mutations of the S. pyogenes Cas9 molecule.

[0280] In one embodiment, the dCas molecule is a Staphylococcus aureus dCas9 molecule comprising a mutation at D10 and / or N580 (numbered according to SEQ ID NO: 1). In one embodiment, the dCas molecule is a Staphylococcus aureus dCas9 molecule comprising a D10A and / or N580A mutation (numbered according to SEQ ID NO: 1).

[0281] In one embodiment, the dCas9 molecule is a Staphylococcus aureus dCas9 molecule comprising the amino acid sequence of SEQ ID NO: 1, a sequence substantially identical to SEQ ID NO: 1 (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity), or a sequence having 1, 2, 3, 4, 5 or more changes (e.g., amino acid substitutions, insertions, or deletions) relative to SEQ ID NO: 1 or any fragment thereof.

[0282] Similar mutations can also be applied to any other naturally occurring Cas9 (e.g., Cas9 from other species) or engineered Cas9 molecules. In certain embodiments, dCas9 includes Streptococcus pyogenes dCas9 molecules, Staphylococcus aureus dCas9 molecules, Campylobacter jejuni dCas9 molecules, Corynebacterium diphtheriae dCas9 molecules, Eubacterium convexum dCas9 molecules, Streptococcus pasteurianum dCas9 molecules, Lactobacillus salviae dCas9 molecules, Chaetomium sphericalum dCas9 molecules, Azospirillum (e.g., strain B510) dCas9 molecules, diazogluconate acetobacter dCas9 molecules, Neisseria grayi dCas9 molecules, intestinal Roseberyella dCas9 molecules, Detergent microbaculum dCas9 molecules, brine nitrate lysing bacteria (e.g., strain DSM 16511) dCas9 molecules, Red-headed gull Campylobacter (e.g., strain CF89-12) dCas9 molecules, Streptococcus thermophilus (e.g., strain LMD-9) dCas9 molecules or fragments thereof.

[0283] In certain embodiments, the present invention provides a vector comprising a nucleotide encoding a Streptococcus pyogenes dCas9 molecule, a Staphylococcus aureus dCas9 molecule, a Campylobacter jejuni dCas9 molecule, a Corynebacterium diphtheriae dCas9 molecule, a Eubacterium convexogastricum dCas9 molecule, a Streptococcus pasteurianum dCas9 molecule, a Lactobacillus fargesii dCas9 molecule, a Chaetomium sphaeroides dCas9 molecule, a Azospirillum (e.g., strain B510) dCas9 molecule, a diazogluconobacter dCas9 molecule, a Neisseria cinerea dCas9 molecule, a Roseburia intestinalis dCas9 molecule, a Detergent's micrococcus dCas9 molecule, a brine nitrate-lysing bacterium (e.g., strain DSM 16511) dCas9 molecule, a Campylobacter gullus (e.g., strain CF89-12) dCas9 molecule, a Streptococcus thermophilus (e.g., strain LMD-9) dCas9 molecule, or a fragment thereof.

[0284] In some embodiments, the dCas9 protein comprises the sequence shown in any one of SEQ ID NOs: 106-122.

[0285] The dCas9 molecules in the constructs provided herein can be continuous or cleaved into an N-terminal portion (dCas9N) and a C-terminal portion (dCas9C). In some embodiments, the N-terminal and C-terminal portions are separated by DNMT3A and / or DNMT3L. Therefore, a construct is provided herein, which comprises, in order from N-terminus to C-terminus: dCas9N, DNMT3A, DNMT3L, and dCas9C.

[0286] Those skilled in the art will appreciate that any dCas9 protein can be cleaved at different sites in the protein sequence, as long as the fusion protein can be refolded into a functional dCas9 molecule. Table 2 lists exemplary sequences of dCas9-N and dCas9-C sequences. The N-terminal and C-terminal sequences are preferably paired according to their numbers, for example, dCas9N-1 is used with dCas9C-1, dCas9N-2 is used with dCas9C-2, and so on. In some embodiments, the construct provided herein comprises a dCas9N containing the sequence shown in SEQ ID NO: 2 and a dCas9C containing the sequence shown in SEQ ID NO: 3. In some embodiments, the construct provided herein comprises a dCas9N containing the sequence shown in SEQ ID NO: 4 and a dCas9C containing the sequence shown in SEQ ID NO: 5. In some embodiments, the construct provided herein comprises a dCas9N containing the sequence shown in SEQ ID NO: 6 and a dCas9C containing the sequence shown in SEQ ID NO: 7. In some embodiments, the constructs provided herein comprise a dCas9N comprising the sequence shown in SEQ ID NO: 8 and a dCas9C comprising the sequence shown in SEQ ID NO: 9. In some embodiments, the constructs provided herein comprise a dCas9N comprising the sequence shown in SEQ ID NO: 10 and a dCas9C comprising the sequence shown in SEQ ID NO: 11. In some embodiments, the constructs provided herein comprise a dCas9N comprising the sequence shown in SEQ ID NO: 12 and a dCas9C comprising the sequence shown in SEQ ID NO: 13. In some embodiments, the constructs provided herein comprise a dCas9N comprising the sequence shown in SEQ ID NO: 14 and a dCas9C comprising the sequence shown in SEQ ID NO: 15. In some embodiments, the constructs provided herein comprise a dCas9N comprising the sequence shown in SEQ ID NO: 16 and a dCas9C comprising the sequence shown in SEQ ID NO: 17. In some embodiments, the constructs provided herein comprise a dCas9N comprising the sequence shown in SEQ ID NO: 18 and a dCas9C comprising the sequence shown in SEQ ID NO: 19. In some embodiments, the constructs provided herein comprise a dCas9N comprising the sequence shown in SEQ ID NO: 20 and a dCas9C comprising the sequence shown in SEQ ID NO: 21. In some embodiments, the constructs provided herein comprise a dCas9N comprising the sequence shown in SEQ ID NO: 22 and a dCas9C comprising the sequence shown in SEQ ID NO: 23.In some embodiments, the constructs provided herein comprise a dCas9N comprising the sequence set forth in SEQ ID NO: 24 and a dCas9C comprising the sequence set forth in SEQ ID NO: 25.

[0287] In some embodiments, dCas9N is encoded by a polynucleotide comprising a nucleic acid sequence in SEQ ID NO: 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, or 49. In some embodiments, dCas9C is encoded by a polynucleotide comprising a nucleic acid sequence shown in SEQ ID NO: 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, or 50.

[0288] Table 2: Exemplary dCas9 and cleaved dCas9 sequences

[0289]

[0290]

[0291]

[0292]

[0293]

[0294]

[0295]

[0296]

[0297] Cas9 fusion protein A CRISPR / Cas9-based system may include a fusion molecule (e.g., DNMT3A-DNMT3L (3A3L)-dCas9-KRAB). In some embodiments, the fusion molecule includes dCas9, KRAB, DNMT3A, and DNMT3L. In some embodiments, the methods and compositions disclosed herein include a fusion molecule comprising a dCas9 molecule fused to DNMT3A or a fragment thereof. In some embodiments, the methods and compositions disclosed herein include a fusion molecule comprising a dCas9 molecule fused to DNMT3L or a fragment thereof. In some embodiments, the methods and compositions disclosed herein include a fusion molecule comprising a dCas9 molecule fused to DNMT3L and DNMT3L or a fragment thereof. In some embodiments, the methods and compositions disclosed herein include a fusion molecule comprising a dCas9 molecule fused to a DNMT3A-DNMT3L fusion peptide.

[0298] DNMT3A: MNHDQEFDPPKVYPPVPAEKRKPIRVLSLFDGIATGLLVLKDLGIQVDRYIASEVCEDSITVGMVRHQGKIMYVGDVRSVTQKHIQEWGPFDLVIGGSPCNDLSIVNPARKGLYEGTGRLFFEFYRLLHDARPKEGDDRPFFWLFENVVAM GVSDKRDISRFLESNPVMIDAKEVSAAHRARYFWGNLPGMNRPLASTVNDKLELQECLEHGRIAKFSKVRTITTRSNSIKQGKDQHFPVFMNEKEDILWCTEMERVFGFPVHYTDVSNMSRLARQRLLGRSWSVPVIRHLFAPLKEYFACV (SEQ ID NO: 69) DNMT3L: MGPMEIYKTVSAWKRQPVRVLSLFRNIDKVLKSLGFLESGSGSGGGTLKYVEDVTNVVRRDVEKWGPFDLVYGSTQPLGSSCDRCPGWYMFQFHRILQYALPRQESQ RPFFWIFMDNLLLTEDDQETTTRFLQTEAVTLQDVRGRDYQNAMRVWSNIPGLKSKHAPLTPKEEEYLQAQVRSRSKLDAPKVDLLVKNCLLPLREYFKYFSQNSLPL (SEQ ID NO: 70) DNMT3A-DNMT3L fusion peptide: MNHDQEFDPPKVYPPVPAEKRKPIRVLSLFDGIATGLLVLKDLGIQVDRYIASEVCEDSITVGMVRHQGKIMYVGDVRSVTQKHIQEWGPFDLVIGGSPCNDLSIVNPARKGLYEGTGRLFFEFYRLLHDARPKEG DDRPFFWLFENVVAMGVSDKRDISRFLESNPVMIDAKEVSAAHRARYFWGNLPGMNRPLASTVNDKLELQECLEHGRIAKFSKVRTITTRSNSIKQGKDQHFPVFMNEKEDILWCTEMERVFGFPVHYTDVSNMSR LARQRLLGRSWSVPVIRHLFAPLKEYFACVSSGNSNANSRGPSFSSGLVPLSLRGSHMGPMEIYKTVSAWKRQPVRVLSLFRNIDKVLKSLGFLESGSGSGGGTLKYVEDVTNVVRRDVEKWGPFDLVYGSTQPLG SSCDRCPGWYMFQFHRILQYALPRQESQRPFFWIFMDNLLLTEDDQETTTRFLQTEAVTLQDVRGRDYQNAMRVWSNIPGLKSKHAPLTPKEEEYLQAQVRSRSKLDAPKVDLLVKNCLLPLREYFKYFSQNSLPL (SEQ ID NO: 71) In some embodiments, DNMT3A is a human DNMTA. In some embodiments, DNMT3A is a non-human DNMT3A, such as a rodent DNMT3A. In some embodiments, DNMT3A is selected from Mus musculus DNMT3L, Murus castellani DNMT3L, Murus sikkim DNMT3L, Rattus norvegicus DNMT3L, Rattus norvegicus DNMT3L, Rattus nigra DNMT3L, Rattus juncea DNMT3L, Rattus juncea DNMT3L, or Rattus leucopus DNTM3L.

[0299] In some embodiments, DNMT3L is human DNMT3L (SEQ ID NO: 74). In some embodiments, DNMT3L is non-human DNMT3L, such as rodent DNMT3L. In some embodiments, DNMT3L is selected from Mus musculus DNMT3L (SEQ ID NO: 75), Murrelia kaempferi DNMT3L (SEQ ID NO: 76), Murrelia sikkimica DNMT3L (SEQ ID NO: 77), Rattus norvegicus DNMT3L (SEQ ID NO: 78), Rattus norvegicus DNMT3L (SEQ ID NO: 79), Rattus nilotica DNMT3L (SEQ ID NO: 80), Rattus juncea DNMT3L (SEQ ID NO: 81), and Rattus leucopus DNTM3L (SEQ ID NO: 82).

[0300] In some embodiments, DNMT3L is encoded by a polynucleotide comprising the nucleic acid sequence shown in any one of SEQ ID NOs: 83-92.

[0301] In one embodiment, the Cas9 fusion protein further comprises a nuclear localization sequence (NLS), such as n NLSs fused to the N-terminus and / or C-terminus of Cas9.

[0302] Nuclear localization sequences are known in the art. In one embodiment, the NLS comprises an amino acid sequence of SEQ ID NO: 72, 73, 125 or 126, a sequence substantially identical to SEQ ID NO: 72, 73, 125 or 126 (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical), or a sequence having 1, 2, 3, 4, 5 or more changes (e.g., amino acid substitutions, insertions or deletions) relative to SEQ ID NO: 72 or 73, or any fragment thereof.

[0303] SEQ ID NO: 72 (Exemplary nuclear localization sequence): APKKKRKVGIHGVPAA SEQ ID NO: 73 (Exemplary nuclear localization sequence): KRPAATKKAGQAKKKK SEQ ID NO: 125 (BPNLS):KRTADGSEFESPKKKRKV SEQ ID NO: 126 (SV40 NLS): PKKKRKV The construct may also include a gene expression regulator. Different gene expression regulators are known in the art, see, for example, Thakore et al., Nat Methods.2016; 13: 127-37, incorporated herein by reference in its entirety. Non-limiting examples of gene expression regulators include Kruppel associated repression box (KRAB), enhancer 2 of zeste homologs (EZH2), G9A, lysine-specific histone demethylase 1A (LSD1), heterochromatin protein 1 (HP1), GATA protein friend 1 (FOG1), histone deacetylase (HDAC3) and DOT1L, each of which will be described in more detail below.

[0304] In some embodiments, the modulator of epigenetic modification may have DNA methylase activity. For example, the modulator of epigenetic modification may have methylase activity, which involves transferring a methyl group to DNA, RNA, protein, small molecule, cytosine or adenine.

[0305] In some embodiments, the system based on CRISPR / Cas9 may include dCas9 molecules and gene expression regulators, or nucleic acids encoding dCas9 molecules and gene expression regulators. In one embodiment, the dCas9 molecule and the gene expression regulator are covalently linked. In one embodiment, the gene expression regulator is directly covalently fused with the dCas9 molecule. In one embodiment, the gene expression regulator is indirectly (for example, by a non-regulator or a joint, or by a second regulator) covalently fused with the dCas9 molecule. In one embodiment, the gene expression regulator is located at the N-terminus and / or C-terminus of the dCas9 molecule. In one embodiment, the dCas9 molecule and the gene expression regulator are non-covalently linked. Exemplary sequences include but are not limited to those listed in Table 3. In some embodiments, the joint between dCas9 and at least one gene expression regulator comprises an amino acid sequence corresponding to the joint listed in Table 3.

[0306] Table 3: Exemplary linker sequences

[0307] In one embodiment, the dCas9 molecule is fused to a first tag, such as a first peptide tag. In one embodiment, the gene expression regulator is fused to a second tag, such as a second peptide tag. In one embodiment, the first and second tags, such as a first peptide tag and a second peptide tag, interact with each other non-covalently, thereby bringing the dCas9 molecule and the gene expression regulator into close proximity.

[0308] In one embodiment, the CRISPR / Cas9-based system includes a fusion molecule or a nucleic acid encoding a fusion molecule. In one embodiment, the fusion molecule comprises a sequence comprising a dCas9 fused to a gene expression regulator. In one embodiment, the dCas9 molecule includes a Streptococcus pyogenes dCas9 molecule, a Staphylococcus aureus dCas9 molecule, a Campylobacter jejuni dCas9 molecule, a Corynebacterium diphtheriae dCas9 molecule, a Eubacterium convexogastricum dCas9 molecule, a Streptococcus pasteurianum dCas9 molecule, a Lactobacillus fargesii dCas9 molecule, a Chaetomium sphaeroides dCas9 molecule, a Azospirillum (e.g., strain B510) dCas9 molecule, a diazogluconate acetobacter dCas9 molecule, a Neisseria cinerea dCas9 molecule, a Roseburia intestinalis dCas9 molecule, a Detergent's microbacterium dCas9 molecule, a brine nitrate-lysing bacterium (e.g., strain DSM 16511) dCas9 molecule, a red-headed Campylobacter gull (e.g., strain CF89-12) dCas9 molecule, a Streptococcus thermophilus (e.g., strain LMD-9) dCas9 molecule, or a fragment thereof.

[0309] Gene expression regulator In some embodiments, the construct provided herein comprises one or more gene expression regulators.Gene expression regulators can be repressors of gene expression or activators of gene expression.Repressors can be any known gene expression repressors, for example, selected from Kruppel associated box (KRAB) domain, mSin3 interaction domain (SID), MAX-interacting protein 1 (MXI1), chromo shadow domain, EAR repressor domain (SRDX), eukaryotic release factor 1 (ERF1), eukaryotic release factor 3 (ERF3), tetracycline repressor, lad repressor, periwinkle G box binding factor 1 and 2, Drosophila Groucho, containing triple motif 28 (TRTM28), nuclear receptor co-repressor 1, nuclear receptor co-repressor 2 or its fragment or fusion repressor.Activator can be any known gene expression activator, for example, VP16 activation domain, VP64 activation domain, p65 activation domain, Epstein-Barr virus R transactivation structure Rta molecule or its fragment. Activators that can be used with dCas9 molecules are known in the art. See Chavez et al., Nat Methods. (2016) 13: 563-67, incorporated herein by reference in its entirety.

[0310] In a specific embodiment, the methods and compositions disclosed herein include fusion molecules, which include dCas9 molecules fused to gene expression regulators. In some embodiments, gene expression regulators include regulators of epigenetic modification. In one embodiment, the fusion molecule is epigenetically modified by regulating the expression of the target gene on the regulatory element (e.g., promoter, enhancer or transcription start site) of the target gene, for example, by histone acetylation or methylation, or DNA methylation. The regulator can be any known regulator of epigenetic modification, for example, histone acetyltransferase (e.g., p300 catalytic domain), histone deacetylase, histone methyltransferase (e.g., SUV39H1 or G9a (EHMT2)), histone demethylase (e.g., LSD1), DNA methyltransferase (e.g., DNMT3a or DNMT3a-DNMT3L), DNA demethylase (e.g., TET1 catalytic domain or TDG) or its fragment.

[0311] Kruppel-associated box (KRAB) The KRAB domain is a type of transcriptional repression domain that is present in the N-terminal portion of many zinc finger protein-based transcription factors. When tethered to the target DNA through the DNA binding domain, the KRAB domain acts as a transcriptional repressor. The KRAB domain is rich in charged amino acids and can be divided into subdomains A and B. The KRAB A and B subdomains can be separated by variable spacer segments, and many KRAB proteins contain only the A subdomain. The 45 amino acid sequence in the KRAB A subdomain has been shown to be important for transcriptional repression. The B subdomain does not inhibit transcription itself, but enhances the repression exerted by the KRAB A subdomain. The KRAB domain recruits the co-repressors KAP1 (KRAB-associated protein-1, also known as transcription mediator 1β, KAP1-A interacting protein and tripartite motif protein 28) and heterochromatin protein 1 (Hp1), as well as other chromatin regulatory proteins, leading to transcriptional repression through heterochromatin formation. In one embodiment, the methods and compositions disclosed herein include a fusion molecule comprising a dCas9 molecule fused to a KRAB domain or a fragment thereof. In one embodiment, a KRAB domain or a fragment thereof is fused to the N-terminus of a dCas9 molecule. In one embodiment, a KRAB domain or a fragment thereof is fused to the C-terminus of a dCas9 molecule. In one embodiment, a KRAB domain or a fragment thereof is fused to both the N-terminus and the C-terminus of a dCas9 molecule. In one embodiment, a KRAB domain or a fragment thereof is fused to both the N-terminus and the C-terminus of a dCas9 molecule. In one embodiment, a fusion molecule comprises a KRAB domain, which comprises a sequence of SEQ ID NO: 51, 53 or 230-241, a sequence substantially identical to SEQ ID NO: 51, 53 or 230-241 (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identity), or a sequence having 1, 2, 3, 4 or 5 or more changes (e.g., amino acid substitutions, insertions or deletions), or any fragment thereof.

[0312] Exemplary KRAB domain sequences: RTLVTFKDVFVDFTREEWKLLDTAQQIVYRNVMLENYKNLVSLGYQLTKPDVILRLEKGEEP (SEQID NO: 51).

[0313] In one embodiment, the fusion molecule is a DNMT3A-DNMT3L (3A3L)-dCas9-KRAB fusion molecule, which comprises, from N-terminus to C-terminus: a DNMT3A-DNMT3L fusion peptide (3A3L), a dCas9 peptide, and a KRAB peptide domain fused directly or indirectly (e.g., via a linker).

[0314] In one embodiment, the fusion molecule is a DNMT3A-DNMT3L (3A3L)-dCas9-KRAB fusion molecule, which comprises, from N-terminus to C-terminus: a DNMT3A-DNMT3L fusion peptide (3A3L), a dCas9 peptide, and a KRAB peptide domain fused directly or indirectly (e.g., via a linker).

[0315] In one embodiment, the fusion molecule comprises the amino acid sequence of SEQ ID NO: 96, a sequence substantially identical to SEQ ID NO: 97 (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity), or a sequence having 1, 2, 3, 4, 5 or more changes (e.g., substitutions, insertions, or deletions) relative to SEQ ID NO: 96, or any fragment thereof.

[0316] DNMT3A-DNMT3L(3A3L)-dCas9-KRAB: MNHDQEFDPPKVYPPVPAEKRKPIRVLSLFDGIATGLLVLKDLGIQVDRYIASEVCEDSITVGMVRHQ GKIMYVGDVRSVTQKHIQEWGPFDLVIGGSPCNDLSIVNPARKGLYEGTGRLFFEFYRLLHDARPKEGDDRPFFWL FENVVAMGVSDKRDISRFLESNPVMIDAKEVSAAHRARYFWGNLPGMNRPLASTVNDKLELQECLEHGRIAKFSKV RTITTRSNSIKQGKDQHFPVFMNEKEDILWCTEMERVFGFPVHYTDVSNMSRLARQRLLGRSWSVPVIRHLFAPLK EYFACV SSGNSNANSRGPSFSSGLVPLSLRGSHMGPMEIYKTVSAWKRQPVRVLSLFRNIDKVLKSLGFLESGSGSGGTTLKYVEDVTNVVRRDVEKWGPFDLVYGSTQPLGSSCDRCPGWYMFQFH RILQYALPRQESQRPFFWIFMDNLLLTEDDQETTTRFLQTEAVTLQDVRGRDYQNAMRVWSNIPGLKSKHAPLTPKEEEYLQAQVRSRSKLDAPKVDLLVKNCLLPLREYFKYFSQNSLPL GGPSSGAPPPSGGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPT STEEGTSTEPSEGSAPGTSTEPSE PKKKRKV MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKK NLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGN IVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFE ENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDD DLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKE IFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRR QEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKN LPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDS VEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKR RRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAG SPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQ LQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKN YWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVIT LKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKAT AKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKES ILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAK GYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQ HKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYT STKEVLDATLIHQSITGLYETRIDLSQLGGDAYPYDVPDYASLGSGS PKKKRKV ED PKKKRKV DG SGSETPGTSES ATPES RTLVTFKDVFVDFTREEWKLLDTAQQIVYRNVMLENYKNLVSLGYQLTKPDVILRLEKGEEP (SEQ ID NO: 96) In some embodiments, the KRAB domain is a zinc finger imprinting 3 (ZIM3) KRAB domain. The ZIM3 KRAB domain is a potent repressor of gene expression. In some embodiments, the ZIM3 KRAB domain comprises a sequence of SEQ ID NO: 53, a sequence substantially identical to SEQ ID NO: 53 (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher sequence identity), or a sequence or any fragment thereof having 1, 2, 3, 4, 5 or more changes (e.g., amino acid substitutions, insertions or deletions) relative to SEQ ID NO: 53. In some embodiments, the ZIM3 KRAB domain is encoded by the sequence shown in SEQ ID NO: 54.

[0317] Enhancer of zeste homolog 2 (EZH2) In one embodiment, the constructs provided herein comprise an Enhancer of Zeste homolog 2 (EZH2) domain. EZH2 is a histone methyltransferase that regulates several aspects of cell cycle progression. Methyl groups are removed from monomethylated and dimethylated lysine 4 and / or lysine 9 (H3K4me1 / 2 and H3K9me1 / 2) on histone H3. In some embodiments, the EZH2 domain comprises a sequence of SEQ ID NO: 55, a sequence substantially identical to SEQ ID NO: 55 (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more sequence identity), or a sequence having 1, 2, 3, 4, 5 or more changes (e.g., amino acid substitutions, insertions or deletions) relative to SEQ ID NO: 55, or any fragment thereof. In some embodiments, the EZH2 domain is encoded by the sequence shown in SEQ ID NO: 56.

[0318] G9a (euchromatic histone lysine methyltransferase 2, EHMT2) , In some embodiments, the constructs provided herein include a G9A or EhMT2 domain. EHMT2 is a methyltransferase that methylates lysine residues of histone H3. In some embodiments, the EHMT2 structure is fused to the C-terminal domain of the dCas9 protein. In some embodiments, the EHMT2 domain is fused to the C-terminal end of the KRAB domain.

[0319] In some embodiments, the EHMT2 domain comprises a sequence of SEQ ID NO: 57, a sequence substantially identical to SEQ ID NO: 57 (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more sequence identity), or a sequence having 1, 2, 3, 4, 5 or more changes (e.g., amino acid substitutions, insertions or deletions) relative to SEQ ID NO: 57, or any fragment thereof. In some embodiments, the EZH2 domain is encoded by the sequence shown in SEQ ID NO: 58.

[0320] Lysine-specific histone demethylase 1A (LSD1) , In some embodiments, the constructs provided herein comprise an LSD1 domain. LSD1 is a histone demethylase that removes methyl groups from monomethylated and dimethylated lysine 4 and / or lysine 9 (H3K4me1 / 2 and H3K9me1 / 2) on histone H3. In some embodiments, the LSD1 domain is fused to the C-terminus of the dCas9 protein. In some embodiments, the LSD1 domain is fused to the C-terminus of the KRAB domain.

[0321] In some embodiments, the LSD1 domain comprises the sequence of SEQ ID NO: 59, a sequence substantially identical to SEQ ID NO: 59 (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more sequence identity), or a sequence having 1, 2, 3, 4, 5 or more changes (e.g., amino acid substitutions, insertions, or deletions) relative to SEQ ID NO: 59, or any fragment thereof. In some embodiments, the LSD1 domain is encoded by the sequence shown in SEQ ID NO: 60.

[0322] Heterochromatin protein 1 (HP1) In some embodiments, the constructs provided herein include an HP1 domain. HP1 promotes the formation of heterochromatic structures. In some embodiments, the HP1 domain is fused to the C-terminus of the dCas9 protein. In some embodiments, the HP1 domain is fused to the C-terminus of the KRAB domain.

[0323] In some embodiments, the HP1 domain comprises the sequence of SEQ ID NO: 61, a sequence substantially identical to SEQ ID NO: 61 (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more sequence identity), or a sequence having 1, 2, 3, 4, 5 or more changes (e.g., amino acid substitutions, insertions or deletions) relative to SEQ ID NO: 61, or any fragment thereof. In some embodiments, the LSD1 domain is encoded by the sequence shown in SEQ ID NO: 62.

[0324] Friend of GATA protein 1 (FOG1) In some embodiments, the constructs provided herein include friend of GATA protein 1 (FOG1). FOG1 is a cofactor of the GATA1 transcription factor that regulates cell differentiation. In some embodiments, the FOG1 domain is fused to the C-terminus of the dCas9 protein. In some embodiments, the FOG1 domain is fused to the C-terminus of the KRAB domain.

[0325] In some embodiments, the FOG1 domain comprises a sequence of SEQ ID NO: 63, a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical) to SEQ ID NO: 63, or a sequence having 1, 2, 3, 4, 5 or more changes (e.g., amino acid substitutions, insertions or deletions) relative to SEQ ID NO: 63, or any fragment thereof. In some embodiments, the FOG1 domain is encoded by the sequence shown in SEQ ID NO: 64.

[0326] Histone deacetylase (HDAC3) In some embodiments, the constructs provided herein include HDAC3. HDAC3 promotes the deacetylation of lysine residues on the N-terminal portion of core histones (H2A, H2B, H3 and H4). In some embodiments, the HDAC3 domain is fused to the C-terminus of the dCas9 protein. In some embodiments, the HDAC3 domain is fused to the C-terminus of the KRAB domain.

[0327] In some embodiments, the HDAC3 domain comprises the sequence of SEQ ID NO: 65, a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or higher identity) to SEQ ID NO: 65, or a sequence having 1, 2, 3, 4, 5 or more changes (e.g., amino acid substitutions, insertions or deletions) relative to SEQ ID NO: 65, or any fragment thereof. In some embodiments, the HDAC3 domain is encoded by the sequence shown in SEQ ID NO: 66.

[0328] DOT1-like histone lysine methyltransferase (DOT1L) In some embodiments, the constructs provided herein comprise DOT1L. DOT1L is a histone methyltransferase that methylates lysine-79 of histone H3. In some embodiments, the DOT1L domain is fused to the C-terminus of the dCas9 protein. In some embodiments, the DOT1L domain is fused to the C-terminus of the KRAB domain.

[0329] In some embodiments, the DOT1L domain comprises a sequence of SEQ ID NO: 67, a sequence substantially identical (e.g., at least 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or more identical) to SEQ ID NO: 67, or a sequence having 1, 2, 3, 4, 5 or more changes (e.g., amino acid substitutions, insertions or deletions) relative to SEQ ID NO: 67, or any fragment thereof. In some embodiments, the DOT1L domain is encoded by the sequence shown in SEQ ID NO: 68.

[0330] Histone modification activity In some embodiments, the modulator of epigenetic modification may have histone modification activity. Histone modification activity may include, but is not limited to, histone deacetylase, histone acetyltransferase, histone demethylase, or histone methyltransferase activity.

[0331] In some embodiments, the regulator of epigenetic modification may have histone acetyltransferase activity.Histone acetyltransferase can be p300 or CREB binding protein (CBP) protein or its fragment.In some embodiments, the methods and compositions disclosed herein include fusion molecules, which include dCas9 molecules fused with acetyltransferase p300 or its fragment (such as the catalytic core of p300).In some embodiments, the methods and compositions disclosed herein include fusion molecules, which include dCas9 molecules fused with CREB binding protein (CBP) protein or its fragment.

[0332] In some embodiments, the regulator of epigenetic modification may have histone demethylase activity. For example, the regulator of epigenetic modification may include an enzyme that removes methyl (CH3-) groups from nucleic acids or proteins (e.g., histones). In some embodiments, the methods and compositions disclosed herein include a fusion molecule comprising a dCas9 molecule fused to a Lys-specific histone demethylase 1 (LSD1) or a fragment thereof.

[0333] In some embodiments, the regulator of epigenetic modification may have histone methyltransferase activity. In some embodiments, the methods and compositions disclosed herein include a fusion molecule comprising a dCas9 molecule fused to SUV39H1 or a fragment thereof. In some embodiments, the methods and compositions disclosed herein include a fusion molecule comprising a dCas9 molecule fused to G9a (EHMT2) or a fragment thereof.

[0334] DNA demethylase activity In some embodiments, the regulator of epigenetic modification may have DNA demethylase activity. For example, the regulator of epigenetic modification can convert methyl into hydroxymethylcytosine, which is a mechanism for demethylating DNA. In some embodiments, the methods and compositions disclosed herein include a fusion molecule comprising a dCas9 molecule fused to 10-11 translocation methylcytosine dioxygenase 1 (TET1) or a fragment thereof. In some embodiments, the methods and compositions disclosed herein include a fusion molecule comprising a dCas9 molecule fused to thymine DNA glycosylase (TDG) or a fragment thereof.

[0335] gRNA As used herein, the term "guide sequence" in the context of the CRISPR-Cas system includes any polynucleotide sequence having sufficient complementarity with the target nucleic acid sequence to hybridize with the target nucleic acid sequence and guide the nucleic acid targeting complex to the sequence-specific binding of the target nucleic acid sequence. The guide sequence can form a duplex with the target sequence. The duplex can be a DNA duplex, an RNA duplex, or an RNA / DNA duplex. The terms "guide molecule", "guide RNA", and "single guide RNA" are used interchangeably herein and refer to RNA-based molecules that can form a complex with the CRISPR-Cas protein and include a guide sequence that has sufficient complementarity with the target nucleic acid sequence to hybridize with the target nucleic acid sequence and guide the complex to the sequence-specific binding of the target nucleic acid sequence. As described herein, guide molecules or guide RNAs specifically include RNA-based molecules with one or more chemical modifications (e.g., by chemically linking two ribonucleotides or by replacing one or more ribonucleotides with one or more deoxyribonucleotides).

[0336] The guide molecule or guide RNA of the CRISPR-Cas protein may include a tracr-mate sequence (including a "direct repeat sequence" in the case of an endogenous CRISPR system) and a guide sequence (also referred to as a "spacer" in the case of an endogenous CRISPR system). In some embodiments, the CRISPR-Cas system or complex described herein does not include a tracr sequence and / or does not rely on the presence of a tracr sequence. In certain embodiments, the guide molecule may include, consist essentially of, or consist of a direct repeat sequence fused or linked to a guide sequence or a spacer sequence.

[0337] In general, CRISPR-Cas systems are characterized by elements that promote the formation of CRISPR complexes at the site of target sequences. In the context of forming a CRISPR complex, a "target sequence" refers to a sequence to which a guide sequence is designed to have complementarity, wherein hybridization between a target DNA sequence and a guide sequence promotes the formation of a CRISPR complex.

[0338] In certain embodiments, the guide sequence or spacer of the guide molecule is 15 to 50 nucleotides in length. In certain embodiments, the spacer of the guide RNA is at least 15 nucleotides in length. In certain embodiments, the spacer is 15 to 17 nucleotides in length, 17 to 20 nucleotides in length, 20 to 24 nucleotides in length, 23 to 25 nucleotides in length, 24 to 27 nucleotides in length, 27 to 30 nucleotides in length, 30 to 35 nucleotides in length, or greater than 35 nucleotides in length.

[0339] In some embodiments, the guide sequence is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209,

[0340] In some embodiments, the sequence of the guide molecule (forward repeats and / or spacers) is selected to reduce the degree of secondary structure in the guide molecule. In some embodiments, when optimally folded, about or less than about 75%, 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 1% or less nucleotides of the nucleic acid targeting guide RNA participate in self-complementary base pairing. Optimal folding can be determined by any suitable polynucleotide folding algorithm. Some programs are based on calculating the minimum Gibbs free energy. An example of such an algorithm is mFold, as described by Zuker and Stiegler (Nucleic Acids Res.9 (1981), 133-148). Another example folding algorithm is the online web server RNAfold developed by the Institute of Theoretical Chemistry at the University of Vienna, which uses a centroid structure prediction algorithm (see, e.g., AR Gruber et al., 2008, Cell 106(1): 23-24; and PA Carr and GM Church, 2009, Nature Biotechnology 27(12): 1151-62).

[0341] As described above, the CRISPR / Cas9 system uses gRNA to provide targeting of the CRISPR / Cas9-based system. gRNA is a fusion of two non-coding RNAs (crRNA and tracrRNA). By exchanging the sequence encoding the 20 bp protospacer, the sgRNA can target any desired DNA sequence, and the protospacer confers targeting specificity by complementary base pairing with the desired DNA target. gRNA mimics the naturally occurring crRNA: tracRNA duplex involved in the type II effector system. The duplex can include, for example, a 42-nucleotide crRNA and a 75-nucleotide tracrRNA, as a guide for Cas9 to cut the target nucleic acid.

[0342] The terms "target region," "target sequence," or "protospacer sequence," used interchangeably herein, refer to the region of a target gene targeted by a CRISPR / Cas9-based system. A CRISPR / Cas9-based system can include at least one gRNA, wherein the gRNAs target different DNA sequences. The target DNA sequences can be overlapping. The target sequence or protospacer sequence is followed by a PAM sequence located at the 3' end of the protospacer sequence. Different type II systems have different PAM requirements. For example, the Streptococcus pyogenes type II system uses an "NGG" sequence, where "N" can be any nucleotide.

[0343] In some embodiments, the number of gRNAs administered to the cells can be at least 1 gRNA, at least 2 different gRNAs, at least 3 different gRNAs, at least 4 different gRNAs, at least 5 different gRNAs, at least 6 different gRNAs, at least 7 different gRNAs, at least 8 different gRNAs, at least 9 different gRNAs, at least 10 different gRNAs, at least 11 different gRNAs, at least 12 different gRNAs, at least 13 different gRNAs, at least 14 different gRNAs, at least 15 different gRNAs, at least 16 different gRNAs, at least 17 different gRNAs, at least 18 different gRNAs, at least 19 different gRNAs, at least 20 different gRNAs, at least 25 different gRNAs, at least 30 different gRNAs, at least 35 different gRNAs, at least 40 different gRNAs, at least 45 different gRNAs, or at least 50 different gRNAs.

[0344] In some embodiments, the number of gRNAs administered to a cell can be from at least 1 gRNA to at least 50 different gRNAs, from at least 1 gRNA to at least 45 different gRNAs, from at least 1 gRNA to at least 40 different gRNAs, from at least 1 gRNA to at least 35 different gRNAs, from at least 1 gRNA to at least 30 different gRNAs, from at least 1 gRNA to at least 25 different gRNAs, from at least 1 gRNA to at least 20 different gRNAs, from at least 1 gRNA to at least 16 different gRNAs, from at least 1 gRNA to at least 12 different gRNAs, from at least 1 gRNA to at least 8 different gRNAs, from at least 1 gRNA to at least 4 different gRNAs, from at least 4 gRNAs to at least 50 different gRNAs, from at least 4 different gRNAs to at least 45 different gRNAs. gRNAs, at least 4 different gRNAs to at least 40 different gRNAs, at least 4 different gRNAs to at least 35 different gRNAs, at least 4 different gRNAs to at least 30 different gRNAs, at least 4 different gRNAs to at least 25 different gRNAs, at least 4 different gRNAs to at least 20 different gRNAs, at least 4 different gRNAs to at least 16 different gRNAs, at least 4 different gRNAs to at least 12 different gRNAs, at least 4 different gRNAs to at least 8 different gRNAs, at least 8 different gRNAs to at least 50 different gRNAs, at least 8 different gRNAs to at least 45 different gRNAs, at least 8 different gRNAs to at least 40 different gRNAs, at least 8 different gRNAs to at least 35 different gRNAs, 8 different gRNAs to at least 30 different gRNAs, at least 8 different gRNAs to at least 25 different gRNAs, 8 different gRNAs to at least 20 different gRNAs, at least 8 different gRNAs to at least 16 different gRNAs, or 8 different gRNAs to at least 12 different gRNAs.

[0345] In some embodiments, gRNA is selected to increase or decrease the transcription of a target gene. In some embodiments, gRNA targets a region upstream of a transcription start site (TSS) of a target gene (eg, VEGFA), such as between 0-1000 bp upstream of the transcription start site of the target gene. In some embodiments, the gRNA targets a region between 0 and 50 bp, between 0 and 100 bp, between 0 and 150 bp, between 0 and 200 bp, between 0 and 250 bp, between 0 and 300 bp, between 0 and 350 bp, between 0 and 400 bp, between 0 and 450 bp, between 0 and 500 bp, between 0 and 550 bp, between 0 and 600 bp, between 0 and 650 bp, between 0 and 700 bp, between 0 and 750 bp, between 0 and 800 bp, between 0 and 850 bp, between 0 and 900 bp, between 0 and 950 bp, or between 0 and 1000 bp upstream of the transcription start site of the target gene. In some embodiments, the gRNA targets a region within about 100 bp, about 200 bp, about 300 bp, about 400 bp, about 500 bp, about 600 bp, about 700 bp, about 800 bp, about 900 bp, about 1000 bp, about 1100 bp, about 1200 bp, about 1300 bp, about 1400 bp, or about 1500 bp upstream of the transcription start site of the target gene. In one embodiment, the gRNA targets a region 0 to 300 bp upstream of the TSS of the target gene.

[0346] In some embodiments, the gRNA targets a region downstream of the target gene transcription start site (e.g., between 0 and 1000 bp downstream of the target gene transcription start site). In some embodiments, the gRNA targets a region between 0 and 50 bp, between 0 and 100 bp, between 0 and 150 bp, between 0 and 200 bp, between 0 and 250 bp, between 0 and 300 bp, between 0 and 350 bp, between 0 and 400 bp, between 0 and 450 bp, between 0 and 500 bp, between 0 and 550 bp, between 0 and 600 bp, between 0 and 650 bp, between 0 and 700 bp, between 0 and 750 bp, between 0 and 800 bp, between 0 and 850 bp, between 0 and 900 bp, between 0 and 950 bp, or between 0 and 1000 bp downstream of the target gene transcription start site. In some embodiments, the gRNA targets a region within about 100 bp, about 200 bp, about 300 bp, about 400 bp, about 500 bp, about 600 bp, about 700 bp, about 800 bp, about 900 bp, about 1000 bp, about 1100 bp, about 1200 bp, about 1300 bp, about 1400 bp, or about 1500 bp downstream of the transcription start site of the target gene. In one embodiment, the gRNA targets a region 0 to 300 bp downstream of the TSS of the target gene.

[0347] The present disclosure provides sgRNA sequences targeting human VEGFA target genes and sgRNA sequences targeting mouse VEGFA target genes. The sequence of human VEGFA is provided in NCBI reference sequence: NG_008732.1. The sequence of mouse VEGFA is provided in NCBI reference sequence: NC_000083.7. The sequence of rhesus monkey VEGFA is provided in NCBI reference sequence: NC_041757.1. The present disclosure provides sgRNA sequences that also target CD151, CD81, and PCSK9 target genes. Exemplary sgRNAs include, but are not limited to, those listed in Table 4.

[0348] Table 4. Exemplary sgRNAs

[0349] In one embodiment, the gRNA targets the promoter region of the target gene. In one embodiment, the gRNA targets the enhancer region of the target gene. The gRNA can be divided into a target binding region, a Cas9 binding region, and a transcription termination region. The target binding region hybridizes with the target region in the target gene. The method for designing such a target binding region is known in the art, see, for example, Doench et al., Nat Biotechnol. (2014) 32: 1262-7; and Doench et al., Nat Biotechnol. (2016) 34: 184-91, incorporated herein by reference in its entirety. Design tools can be obtained from target Finder of Feng Zhang Laboratory, Target Finder (E-CRISP) of Michael Boutros Laboratory, RGEN tool (Cas-OF Finder), CasFinder and CRISPR Optimal Target Finder, etc. In certain embodiments, the target binding region may be between about 15 and about 50 nucleotides in length (about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or about 50 nucleotides in length). In certain embodiments, the target binding region may be between about 19 and about 21 nucleotides in length. In one embodiment, the target binding region is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length.

[0350] In one embodiment, the target binding region is complementary to the target region in the target gene, e.g., fully complementary. In one embodiment, the target binding region is substantially complementary to the target region in the target gene. In one embodiment, the target binding region comprises no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides that are not complementary to the target region in the target gene.

[0351] In one embodiment, the target binding region is engineered to improve stability or extend half-life, for example, by incorporating non-natural nucleotides or modified nucleotides into the target binding region, by removing or modifying RNA destabilizing sequence elements, by adding RNA stabilizing sequence elements, or by enhancing the stability of the Cas9 / gRNA complex. In one embodiment, the target binding region is engineered to enhance its transcription. In one embodiment, the target binding region is engineered to reduce secondary structure formation. In one embodiment, the Cas9 binding region of the gRNA is modified to enhance the transcription of the gRNA. In one embodiment, the Cas9 binding region of the gRNA is modified to improve the stability or assembly of the Cas9 / gRNA complex.

[0352] Delivery System The present disclosure also provides delivery systems for introducing components of the systems and compositions herein into cells, tissues, organs or organisms.The delivery system can include one or more delivery vehicles and / or cargos.

[0353] goods The delivery system may include one or more goods. The goods may include one or more components of the systems and compositions herein. The goods may include one or more of the following: i) a plasmid encoding one or more Cas proteins; ii) a plasmid encoding one or more guide RNAs, iii) mRNAs of one or more Cas proteins; iv) one or more guiding RNAs; v) one or more Cas proteins; vi) any combination thereof. In some examples, the goods may include a plasmid encoding one or more Cas proteins and one or more (e.g., multiple) guide RNAs. In some embodiments, the goods may include mRNAs encoding one or more Cas proteins and one or more guide RNAs.

[0354] In some examples, goods can include one or more Cas proteins and one or more guide RNAs, for example, in the form of ribonucleoprotein complexes (RNPs). The ribonucleoprotein complexes can be delivered by the methods and systems herein. In some cases, ribonucleoproteins can be delivered by shuttle agents based on polypeptides. In one example, ribonucleoproteins can be delivered using synthetic peptides, which include endosome leakage domains (endosome leakage domain) (ELD) operably connected to a cell penetration domain (CPD), a histidine-rich domain, and a CPD, for example, as described in WO2016161516.

[0355] Physical delivery In some embodiments, the cargo can be introduced into the cell by a physical delivery method. Examples of physical methods include microinjection, electroporation, and hydrodynamic delivery.

[0356] Microinjection Microinjection of cargo directly into cells can achieve high efficiencies, e.g., greater than 90% or about 100%. In some embodiments, microinjection can be performed using a microscope and a needle (e.g., 0.5-5.0 μm in diameter) to pierce the cell membrane and deliver the cargo directly to a target site within the cell. Microinjection can be used for both in vitro and ex vivo delivery.

[0357] Plasmids and / or guide RNAs containing coding sequences for Cas proteins and / or guide RNAs, mRNAs can be microinjected. In some cases, microinjection can be used to i) deliver DNA directly to the nucleus, and / or ii) deliver mRNA (e.g., in vitro transcribed) to the nucleus or cytoplasm. In certain embodiments, microinjection can be used to deliver sgRNA directly to the nucleus and deliver Cas encoding mRNA to the cytoplasm, for example, to promote translation of Cas and shuttling of Cas to the nucleus.

[0358] Microinjection can be used to produce genetically modified animals. For example, gene editing cargo can be injected into fertilized eggs to allow efficient germline modification. This method can produce normal embryos and full-term mouse pups containing one or more desired modifications. Microinjection can also be used to transiently upregulate or downregulate (e.g., using CRISPRa and CRISPRi) specific genes within the genome of a cell.

[0359] Electroporation In some embodiments, cargo and / or delivery vehicles can be delivered by electroporation. Electroporation can use a pulsed high voltage current to temporarily open nanometer-sized holes in the cell membrane of cells suspended in a buffer, thereby allowing components with a hydrodynamic diameter of tens of nanometers to flow into the cell. In some cases, electroporation can be used for various cell types and efficiently transfer cargo into cells. Electroporation can be used for in vitro and ex vivo delivery.

[0360] Electroporation can also be used to deliver cargo to the nucleus of mammalian cells by applying specific voltages and reagents, such as by nuclear transfection. Such methods include Wu Y et al. (2015). Cell Res 25: 67-79; Ye L et al. (2014). Proc Natl Acad Sci USA 111: 9591-6; Choi PS, Meyerson M. (2014). Nat Commun 5: 3728; Wang J, Quake SR. (2014). Proc Natl Acad Sci 111: those described in 13157-62. Electroporation can also be used to deliver cargo in vivo, for example, using the method described by Zuckermann M et al. (2015). Nat Commun 6: 7391.

[0361] Fluid Power Delivery Fluid power delivery can also be used to deliver goods, such as for in vivo delivery. In some instances, fluid power delivery can be performed by rapidly pushing a large volume (8-10% body weight) solution containing gene editing goods into the bloodstream of a subject (e.g., an animal or a human) (e.g., for a mouse) via the tail vein. Because blood is incompressible, a large mass of liquid can lead to an increase in fluid power pressure, which temporarily enhances the permeability to endothelial cells and parenchymal cells, thereby allowing goods that are generally unable to pass through cell membranes to enter cells. This method can be used to deliver naked DNA plasmids and proteins. The goods delivered can be enriched in the liver, kidneys, lungs, muscles and / or heart.

[0362] Transfection The cargo, e.g., nucleic acid, can be introduced into the cell by a transfection method for introducing nucleic acid into the cell. Examples of transfection methods include calcium phosphate-mediated transfection, cationic transfection, liposome transfection, dendrimer transfection, heat shock transfection, magnetofection, lipofection, impalefection, optical transfection, and nucleic acid uptake enhanced by proprietary agents.

[0363] Delivery vehicle Delivery systems can include one or more delivery vehicles. Delivery vehicles can deliver goods to cells, tissues, organs or organisms (e.g., animals or plants). Goods can be packaged, transported or otherwise combined with delivery vehicles using delivery vehicles. Delivery vehicles can be selected based on the type of goods to be delivered, and / or delivery is in vitro and / or in vivo. Examples of delivery vehicles include vectors, viruses, non-viral vehicles and other delivery agents described herein.

[0364] Delivery vehicles according to the present disclosure may have a maximum dimension (e.g., diameter) of less than 100 microns (µm). In some embodiments, the maximum dimension of the delivery vehicle is less than 10 µm. In some embodiments, the maximum dimension of the delivery vehicle may be less than 2000 nanometers (nm). In some embodiments, the maximum dimension of the delivery vehicle may be less than 1000 nanometers (nm). In some embodiments, the maximum dimension of the delivery vehicle may be less than 900 nm, less than 800 nm, less than 700 nm, less than 600 nm, less than 500 nm, less than 400 nm, less than 300 nm, less than 200 nm, less than 150 nm or less than 100 nm, less than 50 nm. In some embodiments, the maximum dimension of the delivery vehicle may be between 25 nm and 200 nm.

[0365] In some embodiments, the delivery vehicle can be a particle or include a particle. For example, the delivery vehicle can be a nanoparticle (e.g., a particle with a maximum size (e.g., diameter) of no more than 1000nm) or include the nanoparticle. The particle can be in different forms, for example, as a solid particle (e.g., a metal such as silver, gold, iron, titanium), a non-metal, a lipid-based solid, a polymer), a suspension of particles, or a combination thereof. Metals, dielectrics, and semiconductor particles, as well as hybrid structures (e.g., core-shell particles) can be prepared.

[0366] Carrier The system, composition and / or delivery system may include one or more vectors. The present disclosure also includes a vector system. The vector system may include one or more vectors. In some embodiments, a vector refers to a nucleic acid molecule capable of transporting another nucleic acid connected thereto. The vector includes single-stranded, double-stranded or partially double-stranded nucleic acid molecules; nucleic acid molecules comprising one or more free ends, no free ends (e.g., circular); nucleic acid molecules comprising DNA, RNA or both; and other polynucleotide species known in the art. The vector may be a plasmid, such as a circular double-stranded DNA loop into which an additional DNA segment may be inserted, such as by standard molecular cloning techniques. Certain vectors may be capable of autonomous replication in host cells into which they are introduced (e.g., bacterial vectors and additional mammalian vectors having a bacterial origin of replication). Some vectors (e.g., non-additional mammalian vectors) are integrated into the genome of the host cell after being introduced into the host cell, thereby replicating with the host genome. In some instances, the vector may be an expression vector, for example, capable of directing the expression of genes operably connected thereto. In some cases, an expression vector may be used for expression in eukaryotic cells. Expression vectors commonly used in recombinant DNA technology are generally in the form of plasmids.

[0367] Examples of vectors include pGEX, pMAL, pRIT5, E. coli expression vectors (e.g., pTrc, pET11d), yeast expression vectors (e.g., pYepSec1, pMFa, pJRY88, pYES2, and picZ), baculovirus vectors (e.g., for expression in insect cells such as SF9 cells) (e.g., pAc series and pVL series), mammalian expression vectors (e.g., pCDM8 and pMT2PC).

[0368] The vector may contain i) one or more Cas coding sequences, and / or ii) a single or at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 12, at least 14, at least 16, at least 32, at least 48, at least 50 guide RNA coding sequences. In a single vector, each RNA coding sequence can have a promoter. Alternatively or additionally, in a single vector, there can be promoters that control (e.g., drive transcription and / or expression) multiple RNA coding sequences.

[0369] Regulatory elements The vector may include one or more regulatory elements. The regulatory element may be operably connected to the coding sequence of the Cas protein, the auxiliary protein, the guide RNA (e.g., a single guide RNA, crRNA and / or tracrRNA) or a combination thereof. The term "operably connected" is intended to refer to the connection of the target nucleotide sequence to one or more regulatory elements in a manner that allows the nucleotide sequence to be expressed (e.g., in an in vitro transcription / translation system, or in a host cell when the vector is introduced into a host cell). In some instances, the vector may include: a first regulatory element operably connected to a nucleotide sequence encoding a Cas protein, and a second regulatory element operably connected to a nucleotide sequence encoding a guide RNA.

[0370] Examples of regulatory elements include promoters, enhancers, internal ribosome entry sites (IRES) and other expression control elements (e.g., transcription termination signals, such as polyadenylation signals and poly-U sequences). For example, such regulatory elements are described in Goeddel, GENEEXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif (1990). Regulatory elements include elements that direct the constitutive expression of nucleotide sequences in many types of host cells and elements that direct the expression of nucleotide sequences only in certain host cells (e.g., tissue-specific regulatory sequences). Tissue-specific promoters can be mainly directed to expression in desired tissues (such as muscle, neurons, bone, skin, blood), specific organs (e.g., liver, pancreas) or specific cell types (e.g., lymphocytes) of the purpose. Regulatory elements can also be directed to expression in a time-dependent manner, such as in a cell cycle-dependent or developmental stage-dependent manner, which may or may not be tissue or cell type specific.

[0371] Examples of promoters include one or more pol III promoters (e.g., 1, 2, 3, 4, 5 or more pol III promoters), one or more pol II promoters (e.g., 1, 2, 3, 4, 5 or more pol II promoters), one or more pol I promoters (e.g., 1, 2, 3, 4, 5 or more pol I promoters), or a combination thereof. Examples of pol III promoters include, but are not limited to, U6 and HI promoters. Examples of pol Ii promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with CMV enhancer), the SV40 promoter, the dihydrofolate reductase promoter, the actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1a promoter.

[0372] Viral vectors Goods can be delivered by viruses. In some embodiments, viral vectors are used. Viral vectors may include DNA or RNA sequences of viral origin for packaging into viruses (e.g., retroviruses, replication-defective retroviruses, adenoviruses, replication-defective adenoviruses, and adeno-associated viruses). Viral vectors also include polynucleotides carried by the virus for transfection into host cells. Viruses and viral vectors can be used for in vitro, ex vivo, and / or in vivo delivery.

[0373] Adeno-associated virus (AAV) The systems and compositions herein can be delivered by adeno-associated virus (AAV). AAV vectors can be used for such delivery. AAV belongs to the genus Dependovirus and the family Parvoviridae and is a single-stranded DNA virus. In some embodiments, AAV can provide a lasting source of the DNA provided, because the genomic material delivered by AAV can, for example, be present in the cell indefinitely as exogenous DNA, or, after certain modifications, be directly integrated into the host DNA. In some embodiments, AAV does not cause any disease in a person or is associated with any disease in a person. The virus itself can infect cells efficiently, with little or no innate or adaptive immune response or associated toxicity.

[0374] Examples of AAVs that can be used herein include AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-8, and AAV-9. The type of AAV can be selected according to the cells to be targeted; for example, AAV serotypes 1, 2, 5 or hybrid capsids AAV1, AAV2, AAV5, or any combination thereof can be selected to target brain or neuronal cells; and AAV4 can be selected to target cardiac tissue. AAV8 is used for delivery to the liver. AAV-2-based vectors were initially proposed for delivery of CFTR to CF airways, and other serotypes such as AAV-1, AAV-5, AAV-6, and AAV-9 showed improved gene transfer efficiency in a variety of lung epithelial models. Examples of cell types targeted by AAV are described in Grimm, D. et al., J. Virol. 82: 5887-5911 (2008)) and WO 2021 / 183807A1, which are incorporated herein by reference in their entirety.

[0375] CRISPR-Cas AAV particles can be produced in HEK 293 T cells. Once particles with specific tropism are produced, they are used to infect target cell lines in a manner very similar to natural viral particles. This allows the CRISPR-Cas components to persist in the infected cell type, which makes this form of delivery particularly suitable for situations where long-term expression is required. Examples of doses and formulations of AAV that can be used include those described in U.S. Pat. Nos. 8,454,972 and 8,404,658.

[0376] Various strategies can be used to deliver the systems and compositions herein with AAV. In some instances, the coding sequences of Cas and gRNA can be directly packaged on a DNA plasmid vector and delivered by an AAV particle. In some instances, AAV can be used to deliver gRNA to cells that have been previously engineered to express Cas. In some instances, the coding sequences of Cas and gRNA can be made into two independent AAV particles for co-transfection of target cells. In some instances, markers, tags and other sequences can be packaged in the same AAV particles with the coding sequences of Cas and / or gRNA.

[0377] Lentivirus The systems and compositions herein can be delivered via lentivirus. Lentiviral vectors can be used for such delivery. Lentiviruses are complex retroviruses that have the ability to infect and express their genes in mitotic and post-mitotic cells.

[0378] Examples of lentiviruses include human immunodeficiency virus (HIV), which can use the envelope glycoproteins of other viruses to target a wide range of cell types; minimal non-primate lentiviral vectors based on equine infectious anemia virus (EIAV), which can be used for ocular treatment. In certain embodiments, self-inactivating lentiviral vectors with siRNA targeting common exons shared by HIV tat / rev, nucleolar localization TAR decoys, and anti-CCR5 specific hammerhead ribozymes (see, e.g., DiGiusto et al. (2010) Sci Transl Med 2:36ra43) can be used and / or adapted for use in the nucleic acid targeting system herein.

[0379] Lentiviruses can be pseudotyped with other viral proteins, such as the G protein of vesicular stomatitis virus. In this process, the cell tropism of the lentivirus can be changed to be broad or narrow as desired. In some cases, to improve safety, second- and third-generation lentiviral systems can split essential genes onto three plasmids, which can reduce the possibility of accidental reconstitution of live virus particles within the cell.

[0380] In some examples, by exploiting the ability to integrate, lentiviruses can be used to create libraries of cells containing various genetic modifications, for example, for screening and / or studying genes and signaling pathways.

[0381] Adenovirus The systems and compositions herein can be delivered by adenovirus. Adenoviral vectors can be used for such delivery. Adenoviruses include non-enveloped viruses with an icosahedral nucleocapsid containing a double-stranded DNA genome. Adenoviruses can infect both dividing and non-dividing cells. In some embodiments, adenoviruses are not integrated into the genome of the host cell, which can be used to limit the off-target effects of the CRISPR-Cas system in gene editing applications.

[0382] Non-viral vectors Delivery vehicles may include non-viral vehicles. Generally, methods and vehicles capable of delivering nucleic acids and / or proteins can be used to deliver the system compositions herein. Examples of non-viral vehicles include lipid nanoparticles, cell penetrating peptides (CPPs), DNA nanoclews, gold nanoparticles, streptolysin 0, multifunctional coated nanodevices (MENDs), lipid-coated mesoporous silica particles, and other inorganic nanoparticles.

[0383] Lipid particles The delivery vehicle may comprise lipid particles, such as lipid nanoparticles (LNPs) and liposomes.

[0384] Lipid Nanoparticles (LNP) LNP can be encapsulated in cationic lipid particles (for example, liposomes) by nucleic acid, and can be delivered to cells relatively easily. In some instances, lipid nanoparticles do not contain any viral components, which helps to minimize safety and immunogenicity issues. Lipid particles can be used for external, in vitro and in vivo delivery. Lipid particles can be used for cell populations of various sizes.

[0385] In some instances, LNP can be used to deliver DNA molecules (e.g., those DNA molecules comprising the coding sequence of Cas and / or gRNA) and / or RNA molecules (e.g., mRNA of Cas, gRNA). In some cases, LNP can be used to deliver the RNP complex of Cas / gRNA.

[0386] In some embodiments, LNPs are used to deliver mRNA and gRNA (e.g., an mRNA fusion molecule comprising DNMT3A-DNMT3L (3A-3L)-dCas9-KRAB and at least one sgRNA targeting VEGFA).

[0387] The components of LNP can include cationic lipids 1,2-dioleoyl-3-dimethylammonium-propane (DLinDAP), 1,2-dioleyloxy-3-N,N-dimethylaminopropane (DLinDMA), 1,2-dioleyloxyketo-N,N-dimethyl-3-aminopropane (DLinK-DMA), 1,2-dioleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLinKC2-DMA), 3-o-[2-(methoxypolyethylene glycol 2000) succinyl]-1,2-dimyristoyl-sn-diol (PEG-S-DMG), R-3-[(ro-methoxy-poly(ethylene glycol) 2000) carbamoyl]-1,2-dimyristoyloxypropyl-3-amine (PEGC-DOMG), and any combination thereof. The preparation and encapsulation of LNPs can be adapted from Conway et al., Molecular Therapy, Vol. 27, No. 4, pp. 866-877, April 2019 and Rosin et al., Molecular Therapy, Vol. 19, No. 12, pp. 1286-2200, December 2011.

[0388] In some embodiments, LNPs may include ionizable lipids. In some embodiments, ionizable lipids include, but are not limited to, pH-responsive ionizable lipids, thermally responsive ionizable lipids, and light-responsive ionizable lipids. In some embodiments, ionizable lipids include cationic lipids and anionic lipids that ionize under certain conditions, such as, but not limited to, pH, temperature, or light. In some embodiments, the molar ratio of ionizable lipids of LNPs is 20% to about 70%. (e.g., from about 20% to about 70%, from about 20% to about 65%, from about 20% to about 60%, from about 20% to about 55%, from about 20% to about 50%, from about 20% to about 45%, from about 20% to about 40%, from about 20% to about 35%, from about 20% to about 30%, from about 20% to about 25%, from about 30% to about 70%, from about 30% to about 65%, from about 30% to about 60%, from about 30% to about 55%, from about 30% to about 50%, from about 30% to about 45%, from about 30% to about 40%, from about 30% to about 35%, from about 40% to about 70%, from about 40% to about 65%, from about 40% to about 60%, from about 40% to about 55%, from about 40% to about 50%, from about 40% to about 45%, from about 50% to about 70%, from about 50% to about 65%, from about 50% to about 60%, from about 50% to about 55%, from about 60% to about 70%, or from about 60% to about 65%).

[0389] In some embodiments, LNP may comprise PEGylated lipid. In some embodiments, the mol ratio of the PEGylated lipid of LNP is 0% to about 30% (e.g., about 0% to about 30%, about 0% to about 25%, about 0% to about 20%, about 0% to about 15%, about 0% to about 10%, about 10% to about 30%, about 10% to about 25%, about 10% to about 20%, about 10% to about 15%, about 20% to about 30%, or about 20% to about 25%).

[0390] In some embodiments, LNP may include supporting lipids. In some embodiments, the molar ratio of the supporting lipids of LNP is 30% to about 50% (e.g., about 30% to about 50%, about 30% to about 45%, about 30% to about 40%, about 30% to about 35%, about 40% to about 50% or about 40% to about 45%).

[0391] In some embodiments, LNP can comprise cholesterol.In some embodiments, the mol ratio of the cholesterol of LNP is 10% to about 50% (for example, about 10% to about 50%, about 10% to about 45%, about 10% to about 40%, about 10% to about 35%, about 10% to about 30%, about 10% to about 25%, about 10% to about 20%, about 10% to about 15%, about 20% to about 50%, about 20% to about 45%, about 20% to about 40%, about 20% to about 35%, about 20% to about 30%, about 20% to about 25%, about 30% to about 50%, about 30% to about 45%, about 30% to about 40%, about 30% to about 35%, about 40% to about 50%, or about 40% to about 45%).

[0392] In some embodiments, the LNP may comprise a mixture of ionizable lipids (20%-70%, molar ratio), PEGylated lipids (0%-30%, molar ratio), supporting lipids (30%-50%, molar ratio), and cholesterol (10%-50%, molar ratio).

[0393] Liposomes In some embodiments, the lipid particle can be a liposome. Liposomes are spherical vesicle structures, consisting of a monolayer or multilayer lipid bilayer around an internal water chamber and a relatively impermeable external lipophilic phospholipid bilayer. In some embodiments, liposomes are biocompatible, nontoxic, can deliver hydrophilic and lipophilic drug molecules, protect their cargo from being degraded by plasma enzymes, and transport their loads across biological membranes and the blood-brain barrier (BBB).

[0394] Liposomes can be made from several different types of lipids, such as phospholipids. Liposomes can contain natural phospholipids and lipids such as 1,2-distearoyl-sn-glycero-3-phosphatidylcholine (DSPC), sphingomyelin, phosphatidylcholine, monosialogangliosides, or any combination thereof.

[0395] In order to change the structure and properties of liposomes, several other additives can be added to liposomes. For example, liposomes can also include cholesterol, sphingomyelin and / or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), for example, to enhance stability and / or prevent leakage of liposome internal cargo.

[0396] Stable Nucleic Acid Lipid Particles (SNALP) In some embodiments, the lipid particle can be a stable nucleic acid lipid particle (SNALP). SNALP may include ionizable lipids (DLinDMA) (e.g., cationic at low pH), neutral auxiliary lipids, cholesterol, diffusible polyethylene glycol (PEG)-lipids, or any combination thereof. In some examples, SNALP may include synthetic cholesterol, dipalmitoylphosphatidylcholine, 3-N-[(w-methoxypolyethylene glycol) 2000) carbamoyl]-1,2-dimyrestyloxypropylamine, and cationic 1,2-dilinoleyloxy-3-N,N-dimethylaminopropane. In some examples, SNALP may include synthetic cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine, PEG-cDMA, and 1,2-dilinoleyloxy-3-(N;N-dimethyl)aminopropane (DLinDMA).

[0397] Other lipids The lipid particles may also contain one or more other types of lipids, for example cationic lipids such as the amino lipids 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), DLin-KC2-DMA4, Cl2-200 and the colipids distearoylphosphatidylcholine, cholesterol and PEG-DMG.

[0398] Lipoplexes and / or polyplexes In some embodiments, the delivery vehicle comprises a lipoplex and / or a polymer complex. The lipoplex can bind to a negatively charged cell membrane and induce endocytosis into the cell. An example of a lipoplex can be a complex comprising one or more lipid and non-lipid components. Examples of lipoplexes and polymer complexes include FuGENE-6 reagents, non-liposomal solutions containing lipids and other components, zwitterionic amino lipids (ZAL), Ca2p (e.g., forming DNA / Ca2+ microcomplexes), polyethyleneimine (PEI) (e.g., branched PEI) and poly (L-lysine) (PLL).

[0399] Cell Penetrating Peptides In some embodiments, the delivery vehicle comprises a cell penetrating peptide (CPP). CPPs are short peptides that facilitate cellular uptake of a variety of molecular cargoes (e.g., from nano-sized particles to small chemical molecules and large DNA fragments).

[0400] CPPs can have different sizes, amino acid sequences and charges. In some instances, CPPs can transport plasma membranes and facilitate the delivery of various molecular cargoes to the cytoplasm or organelles. CPPs can be introduced into cells by different mechanisms (e.g., direct penetration of the membrane, endocytosis-mediated entry, and transfer through the formation of transitional structures).

[0401] CPP can have the amino acid composition that comprises relatively abundant positively charged amino acid (such as lysine or arginine), or have the sequence that comprises polar / charged amino acid and nonpolar, hydrophobic amino acid alternating pattern.These two types of structures are respectively called polycationic or amphipathic.The third type of CPP is hydrophobic peptide, comprises only nonpolar residue, has low net charge or has hydrophobic amino acid group that is crucial for cellular uptake.Another type of CPP is the transactivation transcription activator (Tat) from human immunodeficiency virus I (HIV-I).The example of CPP includes penetratin, Tat (48-60), transporter and (R-AhX-R4) (Ahx refers to aminocaproyl).The example of CPP and related application also includes those described in U.S. Patent No. 8,372,951.

[0402] CPPs can be easily used for in vitro and ex vivo work and often require extensive optimization for each cargo and cell type. In some instances, CPPs can be covalently linked directly to Cas proteins, which are then complexed with gRNA and delivered to cells. In some instances, CPP-Cas and CPP-gRNA can be delivered separately to multiple cells. CPPs can also be used to deliver RNPs.

[0403] DNA nanowires In some embodiments, the delivery vehicle comprises a DNA nanocluster. A DNA nanocluster refers to a ball-like structure of DNA (e.g., having the shape of a ball of yarn). The nanocluster can be synthesized by rolling circle amplification with a palindromic sequence, which facilitates the self-assembly of the structure. The sphere can then be loaded with a payload. Examples of DNA nanocluster are described in Sun W et al., J Am Chem Soc. 2014 Oct 22; 136(42): 14722-5 and Sun W et al., Angew Chem Int Ed Engl. 2015 Oct 5; 54(41): 12029-33. The DNA nanocluster can have a palindromic sequence that is complementary to the gRNA portion of the Cas:gRNA ribonucleoprotein complex. The DNA nanocluster can be coated (e.g., coated with PEI) to induce endosomal escape.

[0404] Gold Nanoparticles In some embodiments, the delivery vehicle comprises gold nanoparticles (also referred to as AuNPs or colloidal gold). The gold nanoparticles can form a complex with the cargo Cas:gRNA RNP. The gold nanoparticles can be coated (e.g., coated in silicate and endosome-destroying polymer PAsp (DET)). Examples of gold nanoparticles include AuraSense Therapeutics' Spherical Nucleic Acid (SNA™) constructs, and MMout R, et al. (2017). ACS Nano 11: 2452-8; Lee K et al. (2017). Nat Biomed Eng 1: 889- 901.

[0405] iTOP In some embodiments, the delivery vehicle comprises iTOP. iTOP refers to the combination of small molecules that does not rely on any transduction peptide to drive the efficient intracellular delivery of natural proteins. iTOP can be used for the induction transduction carried out by osmocytosis and propane betaine, using NaCl-mediated hyperosmotic pressure and transduction compounds (propane betaine) to trigger the large phagocytic absorption of extracellular macromolecules into cells. Examples of iTOP methods and reagents are included in those described in D'Astolfo DS, Pagliero RJ, Pras A et al. (2015). Cell 161: 674-690.

[0406] Polymer-based particles In some embodiments, the delivery vehicle may comprise a polymer-based particle (eg, a nanoparticle). In some embodiments, the polymer-based particle may mimic the viral mechanism of membrane fusion. The polymer-based particles can be synthetic copies of influenza virus machinery and form transfection complexes with various types of nucleic acids (siRNA, miRNA, plasmid DNA or shRNA, mRNA) that are taken up by cells through the endocytic pathway, a process involving the formation of acidic compartments. The low pH of the late endosome acts as a chemical switch, making the particle surface hydrophobic and facilitating transmembrane crossing. Once in the cytosol, the particles release their payload for cellular activity. This active endosomal escape technology is safe and maximizes transfection efficiency because it uses the natural uptake pathway. In some embodiments, the polymer-based particles can include alkylated and carboxyalkylated branched polyethyleneimines. In some examples, the polymer-based particles are VIROMER, such as VIROMER RNAi, VIROMER RED, VIROMER mRNA, VIROMER CRISPR. Exemplary methods of delivering the systems and compositions herein include Bawage SS et al., Synthetic mRNA expressed Cas13a mitigates RNAvirus infections, www.biorxiv.org / content / l0.1 l01 / 370460v1.full doi: doi.org / 10.1101 / 370460, Viromer® RED, a powerful tool for transfection of keratinocytes. doi: 10.13140 / RG.2.2.16993.61281, Viromer® Transfection -Factbook 2018: technology, product overview, users' data., doi:10.13140 / RG.2.2.23912.16642.

[0407] Streptolysin O (SLO) The delivery vehicle can be streptolysin O (SLO). SLO is a toxin produced by group A streptococci that acts by creating pores in mammalian cell membranes. SLO can act in a reversible manner, which allows proteins (e.g., up to 100 kDa) to be delivered to the cytosol of cells without compromising overall viability. Examples of SLO include Sierig G et al. (2003). Infect Immun 71: 446-55; Walev I et al. (2001). Proc Natl Acad Sci US A98: 3185-90; Teng Kw et al. (2017). Elife 6: those described in e25460.

[0408] Multifunctional Encapsulated Nanodevice (MEND) The delivery vehicle may include a multifunctional coated nanodevice (MEND). MEND may include concentrated plasmid DNA, a PLL core, and a lipid membrane shell. MEND may also include a cell penetrating peptide (e.g., stearoyl octaarginine). The cell penetrating peptide may be present in a lipid shell. The lipid envelope may be modified with one or more functional components, such as one or more of the following: polyethylene glycol (e.g., to increase vascular circulation time), a ligand targeting a specific tissue / cell, another cell penetrating peptide (e.g., for larger cell delivery), a lipid and nuclear delivery tag that enhances endosomal escape. In some instances, MEND may be a four-layer MEND (T-MEND), which may target the nucleus and mitochondria. In some instances, MEND may be a MEND (PPD-MEND) conjugated with PEG-peptide-DOPE, which may target bladder cancer cells. Examples of MEND include those described in Kogure K et al. (2004). J Control Release 98:317-23; Nakamura T et al. (2012). Ace Chem Res 45:1113-21.

[0409] Lipid-coated mesoporous silica particles The delivery vehicle may include lipid-coated mesoporous silica particles. The lipid-coated mesoporous silica particles may include a mesoporous silica nanoparticle core and a lipid membrane shell. The silica core may have a large internal surface area, resulting in a high cargo loading capacity. In some embodiments, the pore size, pore chemistry, and total particle size may be modified in order to load different types of cargo. The lipid coating of the particles may also be modified to maximize cargo loading, increase circulation time, and provide precise targeting and cargo release. Examples of lipid-coated mesoporous silica particles include those described in Du X et al. (2014). Biomaterials 35: 5580-90; Durfee Pn et al. (2016). ACS Nano 10: 8325-45.

[0410] Inorganic Nanoparticles The delivery vehicle may include inorganic nanoparticles. Examples of inorganic nanoparticles include carbon nanotubes (CNTs) (e.g., as described in Bates K and Kostarelos K. (2013). Adv Drug Deliv Rev 65:2023-33), bare mesoporous silica nanoparticles (MSNPs) (e.g., as described in Luo GF et al. (2014). Sci Rep 4:6064) and dense silica nanoparticles (SiNPs) (e.g., as described in Luo D and Saltzman WM. (2000). Nat Biotechnol 18:893-5).

[0411] How to use The compositions and systems herein can be used for a variety of applications, including modification of non-animal organisms such as plants and fungi, and modification of animals, treatment and diagnosis of diseases in plants, animals and humans. In general, the compositions and systems can be introduced into cells, tissues, organs or organisms, where they alter the expression and / or activity of one or more genes.

[0412] Cells and Organisms The present disclosure provides cells, tissues, organisms comprising engineered Cas proteins, CRISPR-Cas systems, constructs, polynucleotides encoding one or more components of CRISPR-Cas systems, and / or vectors comprising the polynucleotides. The present disclosure also provides nucleotide sequences encoding effector proteins, which are codon-optimized for expression in eukaryotic organisms or eukaryotic cells in any of the methods or compositions described herein. In embodiments of the present disclosure, the codon-optimized effector protein is any Cas protein discussed herein, and codon-optimized for operability in eukaryotic cells or organisms, such as cells or organisms mentioned elsewhere herein, such as, but not limited to, yeast cells or mammalian cells or organisms, including mouse cells, rat cells, and human cells or non-human eukaryotic organisms, such as plants.

[0413] In certain embodiments, modification of the target locus can result in: a eukaryotic cell comprising altered expression of at least one gene product; a eukaryotic cell comprising altered expression of at least one gene product, wherein expression of the at least one gene product is increased; a eukaryotic cell comprising altered expression of at least one gene product, wherein expression of the at least one gene product is decreased; or a eukaryotic cell comprising an edited genome.

[0414] In certain embodiments, the eukaryotic cell can be a mammalian cell or a human cell.

[0415] In additional embodiments, the non-naturally occurring or engineered compositions, vector systems, or delivery systems described in this specification can be used for: site-specific gene knockout; site-specific genome editing; RNA sequence-specific interference; or multiplex genome engineering.

[0416] Also provided are gene products from cells, cell lines or organisms described herein. In certain embodiments, the amount of the expressed gene product can be greater or less than the amount of the gene product from cells of the expression or edited genome that have not been altered. In certain embodiments, the gene product can be altered compared to the gene product from cells of the expression or edited genome that have not been altered.

[0417] Also provided herein are compositions comprising the cells provided herein. In some embodiments, provided herein are pharmaceutical compositions comprising the cells provided herein and a pharmaceutically acceptable carrier.

[0418] Methods for modifying gene expression In another aspect, provided herein are methods of altering gene expression in a cell or altering gene expression in a subject in vivo. Specifically, the methods provided herein can be used to alter the expression of a gene product in a cell while minimizing off-target modifications.

[0419] In some embodiments, provided herein are methods of altering the expression of a gene product in a cell population and minimizing off-target modifications in the cell population, or altering the expression of a gene product in a subject in vivo and minimizing off-target modifications, the method comprising the steps of introducing into the cell population or into the cells of the subject: (i) a construct described herein or one or more polypeptides expressed by the construct; and (ii) at least one sgRNA, wherein the KRAB and / or gene expression regulator provides modification of at least one nucleotide near the gene and / or within the gene regulatory element, thereby altering the expression of the gene product.

[0420] In some embodiments, the construct of step (i) has the structure of the construct of Formula I: 5'-(A m1 -B m2 ) n1 -CasN-(A m3 -B m4 ) n2 -CasC-T p -E-3' (I), wherein one of A and B is a polynucleotide encoding DNMT3A or a portion thereof, and the other of A and B is a polynucleotide encoding DNMT3L or a portion thereof; CasN is a polynucleotide encoding the N-terminal portion of dCas9; CasC is a polynucleotide encoding the C-terminal portion of dCas9; E is 5'-(A m5 -B m6 ) n3 -K r -D q -3' or 5'-K r -D q -(A m5 -B m6 ) n3 -3'; K is a polynucleotide encoding KRAB or a portion thereof; D is a polynucleotide encoding a gene expression regulator; T comprises a polynucleotide encoding (i) an epitope capable of binding to an antibody or an antigen-binding fragment thereof or (ii) a polypeptide sequence capable of binding to a nucleic acid structural element; m1, m2, m3, m4, m5 and m6 are each independently an integer selected from 0 to 3; n1, n2 and n3 are each independently an integer selected from 0 to 2; p is an integer selected from 0 to 20; q is an integer selected from 0 to 5; r is an integer selected from 0 to 5; and wherein when p is 0, at least one of m1, m2, m3 and m4 is not 0, at least one of n1 and n2 is not 0, and at least one of q and r is not 0.

[0421] In some embodiments, the construct has the structure of Formula II: 5'-CasN-(A m3 -B m4 )n2 -CasC-K r -D q -3'(II), wherein n2 is an integer selected from 1 and 2; r is an integer selected from 1 to 5; q is an integer selected from 0 to 5; and at least one of m3 and m4 is not 0.

[0422] In some embodiments, the construct has the structure of Formula IIa: 5'-CasN-(AB)-CasC-K r -D q -3'(IIa). In some embodiments, the construct has the structure of Formula III: 5'-(A m1 -B m2 ) n1 -CasN-(A m3 -B m4 ) n2 -CasC-T p -E-3'(III), wherein p is an integer selected from 1 to 20.

[0423] In some embodiments, the construct has the structure of Formula IIIa: 5'-CasN-CasC-T p -3' (IIIa). In some embodiments, the construct has the structure of Formula IIIb: 5'-(A m1 -B m2 )-CasN-CasC-T p -E-3' (IIIb), wherein at least one of m1 and m2 is not 0. In some embodiments, the construct has the structure of Formula IIIb-1: 5'-(AB)-CasN-CasC-T p -K r -D q -3' (IIIb-1), wherein: r is an integer selected from 1 to 5; and q is an integer selected from 0 to 5.

[0424] In some embodiments, the construct has the structure of Formula IIIc: 5'-CasN-CasC-T p -E-3' (IIIc), wherein: n3 is an integer selected from 1 and 2; r is an integer selected from 1 to 5; and q is an integer selected from 0 to 5; and at least one of m5 and m6 is not 0. In some embodiments, the construct has the structure of formula IIIc-1: 5'-CasN-CasC-T p -(A m5 -B m6 ) n3 -K r -D q-3' (IIIc-1). In some embodiments, the construct has the structure of Formula IIIc-2: 5'-CasN-CasC-T p -K r -D q -(A m5 -B m6 ) n3 -3' (IIIc-2).

[0425] Without wishing to be bound by theory, it is hypothesized that when T comprises a polynucleotide encoding an epitope capable of binding to an antibody or antigen-binding fragment thereof, the 5′-(A m1 -B m2 ) n1 -CasN-(A m3 -B m4 ) n2 -CasC-T p -3' part, 5'-(A m1 -B m2 ) n1 -CasN-(A m3 -B m4 ) n2 -CasC-T p -3' part, 5'-(A m1 -B m2 )-CasN-CasC-T p -3' part, 5'-(AB)-CasN-CasC-T of formula IIIb-1 p -3' part, 5'-CasN-CasC-T of formula IIIc p -3' part, 5'-CasN-CasC-T of formula IIIc-1 p -3' portion or 5'-CasN-CasC-T of formula IIIc-2 p -3' portion of (i), the sgRNA of (ii), and multiple copies of the 5'-E-3' portion of Formula I, the 5'-E-3' portion of Formula III, the 5'-E-3' portion of Formula IIIb, the 5'-K r -D q -3' part, 5'-E-3' part of formula IIIc, 5'-(A m5 -B m6 ) n3 -K r -D q -3' part or 5'-K of formula IIIc-2 r -D q -(A m5 -Bm6 ) n3 -3' portion of (i) is recruited to the genomic locus by binding of the antibody or antigen-binding fragment thereof to the epitope, thereby recruiting the polypeptide expressed by the construct to the genomic locus and altering the expression of the gene product in the cell population.

[0426] In some embodiments, the method further comprises (iii) introducing into the cell a second construct comprising the 5'-(A m5 -B m6 ) n3 -K r -D q -3' or 5'-K r -D q -(A m5 -B m6 ) n3 -3' or a polypeptide expressed by a second construct. Without wishing to be bound by theory, it is believed that the 5'-CasN-CasC-T comprising Formula IIIa p The polypeptide of (i), sgRNA and multiple copies of the polypeptide of (iii) in the -3' portion are recruited to the genomic locus through the binding of the antibody or its antigen-binding fragment to the epitope, thereby recruiting the polypeptides expressed by the construct of (i) and the construct of (iii) to the genomic locus and changing the expression of the gene product in the cell population.

[0427] Without wishing to be bound by theory, it is believed that when T comprises a polypeptide sequence capable of binding to a nucleic acid structural element, the 5'-(A m1 -B m2 ) n1 -CasN-(A m3 -B m4 ) n2 -CasC-T p -3' part, 5'-(A m1 -B m2 ) n1 -CasN-(A m3 -B m4 ) n2 -CasC-T p -3' part, 55'-(A m1 -B m2 )-CasN-CasC-T p -3' part, 55'-(AB)-CasN-CasC-T of formula IIIb-1 p -3' part, 5'-CasN-CasC-T of formula IIIc p -3' part, 5'-CasN-CasC-T of formula IIIc-1p -3' portion or 5'-CasN-CasC-T of formula IIIc-2 p -3' portion of (i), the sgRNA of (ii), and multiple copies of the 5'-E-3' portion of Formula I, the 5'-E-3' portion of Formula III, the 5'-E-3' portion of Formula IIIb, the 5'-K r -D q -3' part, 5'-E-3' part of formula IIIc, 5'-(A m5 -B m6 ) n3 -K r -D q -3' part or 5'-K of formula IIIc-2 r -D q -(A m5 -B m6 ) n3 -3' portion of (i) is recruited to the genomic locus through the binding of the polypeptide sequence capable of binding to the nucleic acid structural element to the nucleic acid structural element, thereby recruiting the polypeptide expressed by the construct to the genomic locus and changing the expression of the gene product in the cell population.

[0428] In some embodiments, the method further comprises (iii) introducing into the cell a second construct comprising the 5'-(A m5 -B m6 ) n3 -K r -D q -3' or 5'-K r -D q -(A m5 -B m6 ) n3 -3' or a polypeptide expressed by a second construct. Without wishing to be bound by theory, it is believed that the 5'-CasN-CasC-T comprising Formula IIIa p The polypeptide of (i) in the -3' portion, the sgRNA of (ii) and the multiple copies of the polypeptide of (iii) are recruited to the genomic locus through the binding of the polypeptide sequence capable of binding to the nucleic acid structural element to the nucleic acid structural element, thereby recruiting the polypeptide expressed by the construct to the genomic locus and changing the expression of the gene product in the cell population.

[0429] The methods provided herein can be used to change gene expression in cultured cells, isolated cells, or in vivo cells (e.g., cells in a subject). In vivo methods for changing gene expression can be used to treat diseases, as further described below.

[0430] In some embodiments, the method provided herein reduces the expression of the target gene. It can be, for example, compared with the gene expression of the target gene product in the cell before being exposed to the construct provided herein, or compared with the unmodified cell, the reduction of target gene expression is measured. In some embodiments, compared with the wild-type cell group, the method provided herein reduces the expression of the target gene by 10%-20%, 20%-30%, 30%-40%, 40%-50%, 50%-60%, 60%-70%, 70%-80%, 80%-90%, 90%-100%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or 100% in a variety of modified cells. In some embodiments, the ratio of the on-target modification of the gene product to the off-target modification of the gene product is about 10: 1, 9: 1, 8: 1, 7: 1, 6: 1, 5: 1, 4: 1, 3: 1 or 2: 1. In some embodiments, the ratio of on-target modifications to off-target modifications does not exceed 10:1.

[0431] The modification of at least one nucleotide introduced by KRAB and / or a gene expression regulator can be, for example, DNA methylation or histone modification. The modification can be located in any region of the target gene (including, for example, the coding sequence of a gene or a regulatory element) in which the modification achieves the desired effect (e.g., reduction in gene expression). In some embodiments, the modification occurs in a core promoter, a proximal promoter, a distal enhancer, a silencer, an insulator element, a boundary element, or a locus control region.

[0432] The modification may occur in a nucleotide located upstream or downstream of the target gene transcription start site. In some embodiments, the modification occurs at a nucleotide located about 100 bp, about 200 bp, about 300 bp, about 400 bp, about 500 bp, about 600 bp, about 700 bp, about 800 bp, about 900 bp, about 1000 bp, about 1100 bp, about 1200 bp, about 1300 bp, about 1400 bp, or about 1500 bp upstream of the gene transcription start site. In some embodiments, the modification occurs at a nucleotide located within about 100 bp, about 200 bp, about 300 bp, about 400 bp, about 500 bp, about 600 bp, about 700 bp, about 800 bp, about 900 bp, about 1000 bp, about 1100 bp, about 1200 bp, about 1300 bp, about 1400 bp, or about 1500 bp downstream of the transcription start site of the gene.

[0433] Exemplary Therapies In another aspect, provided herein is a method for treating or alleviating the symptoms of a gene product-related disorder in a subject, comprising the steps of introducing into a cell of a subject: (i) a construct provided herein or one or more polypeptides expressed by the construct; and (ii) at least one sgRNA, wherein KRAB and / or a gene expression regulator provides modification of at least one nucleotide near a gene and / or within a gene regulatory element, thereby altering the expression of the gene product and treating or alleviating the symptoms of a gene product-related disorder in the subject.

[0434] The present disclosure provides the use of CRISPR-Cas systems for treating a variety of diseases and disorders. In some embodiments, the disclosure described herein relates to a method of treatment, wherein cells are edited in vitro by CRISPR or a base editor to regulate at least one gene, and then the edited cells are applied to patients in need. In some embodiments, editing includes knocking in, knocking out or knocking down the expression of at least one target gene in the cell. In a specific embodiment, editing inserts an exogenous gene, a minigene or a sequence (which may include one or more trans or natural or synthetic exons) into the locus of the target gene, the hotspot locus, the safe harbor locus of the gene genomic position, in which a new gene or genetic element can be introduced without destroying the expression or regulation of adjacent genes, or by inserting or deleting one or more mutations in the DNA sequence encoding the target gene regulatory element to correct. In some embodiments, editing includes introducing one or more point mutations in the nucleic acid (e.g., genomic DNA) of the target cell.

[0435] In some embodiments, treatment is for diseases / disorders of organs, including liver disease, eye disease, muscle disease, heart disease, blood disease, brain disease, kidney disease, or may include treatment for autoimmune diseases, central nervous system diseases, cancer and other proliferative diseases, neurodegenerative diseases, inflammatory diseases, metabolic disorders, musculoskeletal disorders, etc. In some embodiments, the disease is liver disease. In some embodiments, the disease is an eye disease. In some embodiments, the disease is a CNS disease. In some embodiments, the disease is cancer. In some embodiments, the disease is selected from the group consisting of familial hypercholesterolemia (FH), non-alcoholic fatty hepatitis (NASH), Parkinson's disease, liver fibrosis (HF), age-related maculopathy (AMD), Angelman syndrome (AS), type II diabetes, β-thalassemia and hepatocellular carcinoma.

[0436] In some embodiments, the modulation is affected by modifications in the target genes VEGFA, PCSK9, ANGPTL3, PTBP1, TTR, Ube3a-ATS, Ptp1b, APOC3, hsd17b13, bcl11a, or TGFβ. VEGFA plays an important role in angiogenesis and is overexpressed in several cancers. PCSK9 plays a key role in cholesterol management. ANGPTL3 plays a role in the metabolism of triglycerides. PTBP1 encodes a nuclear protein of the cell nucleus and is involved in the regulation of transcription. TTR encodes the transporter transthyretin. Ube3a-ATS encodes a ubiquitin ligase, and mutations in Ube3a-ATS are associated with Angelman syndrome. Ptp1b encodes protein tyrosine phosphatase 1B, which regulates insulin signaling. APOC3 encodes apolipoprotein C3, which plays a key role in lipid transport and metabolism. hsd17b13 encodes liver-specific hydroxysteroid 17β-dehydrogenase 13. BCL11A is a transcriptional repressor. TGFβ regulates several cellular pathways, importantly those related to proliferation and differentiation.

[0437] The terms "subject" and "patient" are used interchangeably herein. In some embodiments, the subject is a human. Example

[0438] Design and construction of plasmids containing constructs of the present disclosure Epigenetic modification editors (e.g., including Dnmt3a CD, Dnmt3l CD, dSpCas9, KRAB and / or other histone modifiers) with HA epitopes, P2A and BFP were optimized into nucleic acid sequences suitable for mammalian expression and synthesis by Genscript, and then cloned into a pLV-CAG vector with a CAG promoter and WPRE, which expresses the complete epigenetic modification editor and self-cleaved BFP.

[0439] When optimizing different functional elements and the order of different functional elements, different functional elements are optimized into nucleic acid sequences suitable for mammalian expression and synthesis by Genscript. First, the vector except the element to be replaced is amplified by PCR, and then the element to be replaced is amplified from the sequence synthesized by the company, and the homology arm sequence is introduced at the same time. Finally, the different elements are recombined into the vector by NEBuilder reagent to construct the final expression plasmid.

[0440] Example 1: Constructs for epigenetic modification of CD151 and CD81 genes According to the above method, different sets of constructs targeting CD151 gene and / or CD81 were generated, and the structures of these constructs are described in Figures 1B, 2B, 4B and 5B. The constructs shown in FIG. 2E were generated as follows: (1) Dnmt-dCas9+scFv-Krab, generated by fusing Dnmt3A-Dnmt3L-dCas9-10×GCN4 (SEQ ID NOs: 151 and 179), T2A (SEQ ID NOs: 99 and 103), and scFv-Krab (SEQ ID NOs: 152 and 180); (2) dCas9+scFv-Dnmt-Krab, generated by fusing dCas9-10×GCN4 (SEQ ID NOs: 153 and 181), T2A (SEQ ID NOs: 99 and 103), and scFv-Dnmt3A-Dnmt3L-Krab (SEQ ID NOs: 154 and 182); (3) dCas9+scFv-Dnmt+scFv-Krab, generated by fusing dCas9-10×GCN4 (SEQ ID NOs: 154 and 182). NOs: 153 and 181), T2A (SEQ ID NOs: 99 and 103), scFv-Dnmt3A-Dnmt3L (SEQ ID NOs: 200 and 201), and scFv-Krab (SEQ ID NOs: 202 and 203).

[0441] The repression of CD151 and / or CD81 by constructs using different targeting sgRNAs (Table 4) was measured by FACS. The results are shown in Figures 1C, 2C-2E, 4C-4F, and 5C-5D. Editors with different effectors or conformations vary greatly in repressing gene expression, which strongly suggests that various modifications must be made when optimizing epigenetic editors.

[0442] Example 2: EPICAS constructs for VEGFA knockdown Three forms of EPICAS (EPICAS-V1, EPICAS-V2 and EPICAS-V3) specific for VEGFA were generated. The structures of these constructs are shown in Figure 6A. EPICAS-V1 contains the KRAB domain, while V2 and V3 contain the ZIM3-KRAB domain, and the orientation of DNMT3L and DNMT3A in V2 is opposite (3A-3L, instead of 3L-3A in V1 and V3).

[0443] The editing efficiency of VEGFA using two different constructs targeting human VEGFA sgRNA (Table 4) was measured by qPCR. The results are shown in Figure 6B. The reduction in mRNA expression caused by sgRNA1 was comparable between the constructs.

[0444] Example 3: Constructs for in vivo epigenetic modification of mouse PCSK9 To test the editing efficiency in vivo, four constructs were generated: (1) DNMT3A-DNMT3L-dCas9-KRAB (SEQ ID NOs: 138 and 166); (2) DNMT3A-DNMT3L-dCas9-EZH2 (SEQ ID NOs: 139 and 167); (3) DNMT3A-DNMT3L-dCas9-G9A (SEQ ID NOs: 140 and 168); (4) DNMT3A-DNMT3L-dCas9-HDAC3 (SEQ ID NOs: 144 and 172); (5) dCas9N-7-Dnmt3A-Dnmt3L-dCas9C-7-Krab (this construct was constructed by fusing dCas9N-7 (SEQ ID NO: 14), Dnmt3A-Dnmt3L (SEQ ID NO: 71), dCas9C-7 (SEQ ID NO: 72) and dCas9N-7-Dnmt3A-Dnmt3L (SEQ ID NO: 73). NO:15) and Krab (SEQ ID NO:51)).

[0445] The DNA sequence corresponding to each form was transcribed in vitro to obtain mRNA, which was then mixed with two gRNAs targeting PCSK9 (SEQ ID NO: 198-199) at a ratio of 2:1:1 to prepare LNP (molar ratio of LNP elements: MC3: cholesterol: DSPC: DMG-PEG2000 = 50:38.5:10:1.5), which was injected into wild-type C57 mice by tail vein injection. The injection dose was 4.5 mg (RNA mass) / kg body weight / mouse. Blood samples were collected from mice on the 7th, 14th and 21st days of injection, and the expression of PCSK9 protein in the blood was determined by Elisa, comparing mice not injected with LNP with mice injected with mRNA+control gRNA (sequence GAAGAGCCTGAGGCTCTTCT).

[0446] The results showed that the protein expression of PCSK9 in the serum of mice in the experimental group was significantly lower than that in the control group at all three time points, with a decrease of more than 50%.

Claims

1. Construct of Formula I: 5’-(A m1 -B m2 ) n1 -CasN-(A m3 -B m4 ) n2 -CasC-T p -E-3’(I), in: One of A and B is a polynucleotide encoding DNMT3A or a portion thereof; the other of A and B is a polynucleotide encoding DNMT3L or a portion thereof; CasN is a polynucleotide encoding the N-terminal portion of dCas9; CasC is a polynucleotide encoding the C-terminal portion of dCas9; E is 5'-(A m5 -B m6 ) n3 -K r -D q -3' or 5'-K r -D q -(A m5 -B m6 ) n3 -3'; K is a polynucleotide encoding KRAB or a portion thereof; D is a polynucleotide encoding a gene expression regulator; T comprises a polynucleotide encoding (i) an epitope capable of binding to an antibody or antigen-binding fragment thereof or (ii) a polypeptide sequence capable of binding to a nucleic acid structural element; m1, m2, m3, m4, m5 and m6 are each independently an integer selected from 0 to 3; n1, n2 and n3 are each independently an integer selected from 0 to 2; p is an integer selected from 0 to 20; q is an integer selected from 0 to 5; r is an integer selected from 0 to 5; as well as When p is 0, at least one of m1, m2, m3 and m4 is not 0, at least one of n1 and n2 is not 0, and at least one of q and r is not 0.

2. The construct according to claim 1, which has formula II: 5'-CasN-(A m3 -B m4 ) n2 -CasC-K r -D q -3'(II), in: n2 is an integer selected from 1 and 2; r is an integer selected from 1 to 5; q is an integer selected from 0 to 5; and At least one of m3 and m4 is not 0.

3. The construct according to claim 2, which has the formula IIa: 5′-CasN-(AB)-CasC-K r -D q -3'(IIa)。 4. The construct according to claim 1, which has formula III: 5′-(A m1 -B m2 ) n1 -CasN-(A m3 -B m4 ) n2 -CasC-T p -E-3′(III), wherein p is an integer selected from 1 to 20.

5. The construct according to claim 4, which has the formula IIIa: 5'-CasN-CasC-T p -3'(IIIa).

6. The construct according to claim 4, which has the formula IIIb: 5'-(A m1 -B m2 )-CasN-CasC-T p -E-3'(IIIb), At least one of m1 and m2 is not 0.

7. The construct according to claim 6, which has the formula IIIb-1: 5'-(AB)-CasN-CasC-T p -K r -D q -3'(IIIb-1), in: r is an integer selected from 1 to 5; and q is an integer selected from 0-5.

8. The construct according to claim 4, which has the formula IIIc: 5′-CasN-CasC-T p -E-3′(IIIc), in: n3 is an integer selected from 1 and 2; r is an integer selected from 1 to 5; as well as q is an integer selected from 0 to 5; and At least one of m5 and m6 is not 0.

9. The construct according to claim 8, which has the formula IIIc-1: 5′-CasN-CasC-T p -(TO m5 -B m6 ) n3 -K r -D q -3'(IIIc-1)。 10. The construct according to claim 8, which has the formula IIIc-2: 5′-CasN-CasC-T p -K r -D q -(TO m5 -B m6 ) n3 -3'(IIIc-2)。 11. The construct according to claim 1, which has formula IV: 5'-(AB)-CasN-CasC-K r -D q -3', in: r is an integer selected from 0 to 5; q is an integer selected from 0 to 5; and At least one of q and r is not 0.

12. The construct according to any one of claims 1 to 11, wherein T comprises (a) a polynucleotide encoding an epitope capable of binding to an antibody or an antigen-binding fragment thereof, and further comprises (b) a polynucleotide encoding a self-cleaving peptide at the 3' end of the polynucleotide in (a). 13 . The construct according to claim 12 , wherein the 3′ end of the nucleotide encoding the self-cleaving peptide further comprises a polynucleotide encoding (c) an antibody or an antigen-binding fragment thereof capable of binding to the epitope.

14. The construct according to any one of claims 1 to 11, wherein the T comprises (a) a polynucleotide encoding a polypeptide sequence capable of binding to a nucleotide sequence element, and further comprises a polynucleotide encoding a self-cleaving peptide at the 3' end of the polynucleotide in (a).

15. The construct according to any one of claims 1 to 14, wherein the self-cleaving peptide is selected from the group consisting of T2A, P2A, E2A and F2A self-cleaving peptides.

16. The construct of claim 15, wherein the self-cleaving peptide is T2A.

17. The construct according to any one of claims 1-16, wherein the DNMT3A comprises the amino acid sequence of SEQ ID NO:

69.

18. The construct according to any one of claims 1-17, wherein the polynucleotide encoding DNMT3A comprises the nucleic acid sequence of SEQ ID NO:

83.

19. The construct of any one of claims 1-18, wherein the DNMT3L comprises Homo sapiens DNMT3L, Mus musculus DNMT3L, Murus castellani DNMT3L, Murus sikkim DNMT3L, Rattus norvegicus DNMT3L, Rattus norvegicus DNMT3L, Rattus nerii DNMT3L, Rattus juncea DNMT3L, Rattus juncea DNMT3L, or Rattus leucopus DNMT3L.

20. The construct of any one of claims 1-19, wherein the DNMT3L comprises the amino acid sequence of any one of SEQ ID NOs: 74-82.

21. The construct according to any one of claims 1-20, wherein the polynucleotide encoding DNMT3L comprises the nucleic acid sequence of any one of SEQ ID NOs: 84-92.

22. The construct of any one of claims 1-21, wherein the KRAB comprises the amino acid sequence of SEQ ID NO: 51, 53, or 230-241.

23. The construct of any one of claims 1-22, wherein the polynucleotide encoding KRAB comprises the nucleic acid sequence of SEQ ID NO: 52, 54, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226 or 228.

24. The construct of any one of claims 1-23, wherein the gene expression regulator comprises Kruppel-associated repression cassette (KRAB), enhancer of zete homolog 2 (EZH2), G9A, lysine-specific histone demethylase 1A (LSD1), heterochromatin protein 1 (HP1), friend of GATA protein 1 (FOG1), histone deacetylase (HDAC3) and / or DOT1L.

25. The method of any one of claims 1-24, wherein the gene expression regulator comprises the amino acid sequence of SEQ ID NO: 51, 53, 55, 57, 59, 61, 63, 65 or 67.

26. The method according to any one of claims 1-25, wherein the polynucleotide encoding the gene expression regulator comprises the nucleic acid sequence of SEQ ID NO: 52, 54, 56, 58, 60, 62, 64, 66 or 68.

27. The construct of any one of claims 1-26, wherein the dCas9 comprises Staphylococcus aureus dCas9, Streptococcus pyogenes dCas9, Campylobacter jejuni dCas9, Corynebacterium diphtheriae dCas9, Eubacterium convexogastricum dCas9, Streptococcus pasteurianum dCas9, Lactobacillus fargesii dCas9, Chaetomium sphaeroides dCas9, Azospirillum (e.g., strain B510) dCas9, Gluconobacter diazoacetobacter dCas9, Neisseria cinerea dCas9, Roseburia intestinalis dCas9, Parvibacterium scoparium dCas9, Brine nitrate-lysing bacteria (e.g., strain DSM 16511) dCas9, Campylobacter gullus (e.g., strain CF89-12) dCas9, Streptococcus thermophilus (e.g., strain LMD-9) dCas9.

28. The construct of any one of claims 1-27, wherein the dCas9 comprises the amino acid sequence of any one of SEQ ID NOs: 106-122.

29. The construct of any one of claims 1-28, wherein the dCas9 comprises a Staphylococcus pyogenes dCas9.

30. The construct of any one of claims 1-29, wherein the dCas9 comprises the amino acid sequence of SEQ ID NO:

1.

31. The construct of any one of claims 1-30, wherein the N-terminal portion of dCas9 comprises the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 24.

32. The construct of any one of claims 1-31, wherein the C-terminal portion of dCas9 comprises the amino acid sequence of SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, or 25.

33. The construct of any one of claims 1-32, wherein the polynucleotide encoding the dCas9 comprises the nucleic acid sequence of SEQ ID NO:

26.

34. The construct of any one of claims 1-33, wherein the polynucleotide encoding the N-terminal portion of the dCas9 comprises the amino acid sequence of SEQ ID NO: 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47 or 49.

35. The construct of any one of claims 1-34, wherein the polynucleotide encoding the C-terminal portion of the dCas9 comprises the amino acid sequence of SEQ ID NO: 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48 or 50.

36. The construct according to any one of claims 1-35, wherein the epitope capable of binding to an antibody or antigen binding fragment thereof is selected from the group consisting of GCN4, T2A, 10×GCN4 and 10×GFP-11.

37. The construct of claim 36, wherein the GCN4 comprises the amino acid sequence of SEQ ID NO:

97.

38. The construct of claim 37, wherein the polynucleotide encoding the GCN4 comprises the nucleic acid sequence of SEQ ID NO:

101.

39. The construct of any one of claims 36-38, wherein the antibody or antigen-binding fragment is a single domain antibody, scFv, Fab, VH, VHH or an antibody mimetic.

40. The construct of claim 39, wherein the antigen binding fragment is a scFv.

41. The construct according to any one of claims 1 to 40, wherein the polypeptide sequence capable of binding to a nucleic acid structural element is selected from the group consisting of MS2 bacteriophage coat protein (MCP), PP7 and PCP.

42. construct according to claim 41, wherein the polypeptide sequence capable of binding to a nucleic acid structural element is MCP.

43. The construct of claim 42, wherein the MCP comprises the amino acid sequence of SEQ ID NO:

100.

44. according to the construct described in any one of claim 42-43, wherein the polynucleotide encoding described MCP comprises the nucleic acid sequence of SEQID NO:

105.

45. according to each described construct among the claim 41-44, wherein said nucleic acid structural element is RNA hairpin motif.

46. ​​The construct of claim 45, wherein the RNA hairpin motif is selected from the group consisting of MS2 and PP7.

47. according to the construct described in any one of claim 45-46, wherein said RNA hairpin motif is MS2 RNA hairpin motif.

48. The construct of claim 47, wherein the MS2 RNA hairpin motif comprises the nucleic acid sequence of SEQ ID NO:

104.

49. A construct according to any one of claims 1-48, comprising a nucleic acid sequence of any one of SEQ ID NOs: 162-189.

50. A polypeptide expressed by the construct of any one of claims 1-49.

51. A vector comprising the construct of any one of claims 1-49.

52. The vector of claim 51, further comprising a polynucleotide encoding a single guide RNA (sgRNA).

53. The vector according to any one of claims 51-52, wherein the polynucleotide encoding the sgRNA further comprises 2-20 copies of the nucleic acid structural element.

54. A cell comprising the construct of any one of claims 1-49.

55. A cell comprising the polypeptide of claim 50.

56. A cell comprising the vector of any one of claims 51-53.

57. The cell of any one of claims 54 to 56, further comprising at least one sgRNA.

58. The cell of claim 57, wherein the at least one sgRNA further comprises 2-20 copies of the nucleic acid structural element.

59. A composition comprising the construct of any one of claims 1-49.

60. A composition comprising the polypeptide of claim 50.

61. A composition comprising the vector of any one of claims 51-53.

62. The composition of any one of claims 59-61, further comprising at least one sgRNA.

63. The composition of claim 62, wherein the sgRNA further comprises 2-20 copies of the nucleic acid structural element.

64. The composition of any one of claims 59-63, further comprising a pharmaceutically acceptable carrier.

65. The use of a construct as described in any one of claims 1-48 or a polypeptide expressed by the construct in the preparation of a reagent for altering the expression of a gene product in a cell population and minimizing off-target modifications, the alteration being by a step comprising introducing into the cell population: i) the construct or a polypeptide expressed by the construct; and ii) at least one sgRNA, Wherein KRAB and / or gene expression regulator provides modification of at least one nucleotide near the gene and / or within the gene regulatory element, thereby changing the expression of the gene product.

66. The use according to claim 65, in: (a) Include 5'-(A m1 -B m2 ) n1 -CasN-(A m3 -B m4 ) n2 -CasC-T p -3' part, 5'-(A m1 -B m2 ) n1 -CasN-(A m3 -B m4 ) n2 -CasC-T p -3' part, 5'-(A m1 -B m2 )-CasN-CasC-T p -3' part, 5'-(AB)-CasN-CasC-T of Formula IIIb-1 p -3' part, 5'-CasN-CasC-T of Formula IIIc p -3' part, 5'-CasN-CasC-T of Formula IIIc-1 p -3' part or 5'-CasN-CasC-T of Formula IIIc-2 p - The polypeptide of i) and ii) the sgRNA of the 3' portion are recruited to the genomic locus, and (b) Inclusion of multiple copies The 5'-E-3' portion of formula I, The 5'-E-3' portion of formula III, The 5'-E-3' portion of formula IIIb, 5'-K of Formula IIIb-1 r -D q -3' part, The 5'-E-3' portion of formula IIIc, 5'-(A m5 -B m6 ) n3 -K r -D q -3' part or 5'-K of Formula IIIc-2 r -D q -(A m5 -B m6 ) n3 -3' portion i) is recruited to the genomic locus through the binding of the antibody or antigen-binding fragment thereof to the epitope, thereby recruiting the polypeptide expressed by the construct to the genomic locus and changing the expression of the gene product in the cell population.

67. The use according to claim 66, wherein the alteration is further carried out by introducing into the cell: iii) 5'-(A m5 -B m6 ) n3 -K r -D q -3' or 5'-K r -D q -(A m5 -B m6 ) n3 -3' of a second construct or a polypeptide expressed by the second construct, in, 5'-CasN-CasC-T comprising Formula IIIa p -3' portion i) the polypeptide and the sgRNA are recruited to the genomic locus, Wherein, multiple copies of the polypeptide of iii) are recruited to the genomic locus through the binding of the antibody or its antigen-binding fragment to the epitope, thereby recruiting the polypeptide expressed by the construct of i) and the construct of iii) to the genomic locus and changing the expression of the gene product in the cell population.

68. The use according to claim 65, in: (a) Include 5'-(A m1 -B m2 ) n1 -CasN-(A m3 -B m4 ) n2 -CasC-T p -3' part, 5'-(A m1 -B m2 ) n1 -CasN-(A m3 -B m4 ) n2 -CasC-T p -3' part, 5'-(A m1 -B m2 )-CasN-CasC-T p -3' part, 5'-(AB)-CasN-CasC-T of Formula IIIb-1 p -3' part, 5'-CasN-CasC-T of Formula IIIc p -3' part, 5'-CasN-CasC-T of Formula IIIc-1 p -3' part, or 5'-CasN-CasC-T of Formula IIIc-2 p - the polypeptide of i) and the gRNA of ii) the 3' portion are recruited to the genomic locus, and (b) Multiple copies of the inclusion The 5'-E-3' portion of formula I, The 5'-E-3' portion of formula III, The 5'-E-3' portion of formula IIIb, 5'-K of Formula IIIb-1 r -D q -3' part, The 5'-E-3' portion of formula IIIc, 5'-(A m5 -B m6 ) n3 -K r -D q -3' part or 5'-K of Formula IIIc-2 r -D q -(A m5 -B m6 ) n3 -3' portion i) is recruited to the genomic locus through the binding of the polypeptide sequence capable of binding to the nucleic acid structural element to the nucleic acid structural element, thereby recruiting the polypeptide expressed by the construct to the genomic locus and changing the expression of the gene product in the cell population.

69. The use according to claim 68, wherein the alteration is further carried out by introducing into the cell: iii) 5'-(A m5 -B m6 ) n3 -K r -D q -3' or 5'-K r -D q -(A m5 -B m6 ) n3 -3' of a second construct or a polypeptide expressed by the second construct, in, 5'-CasN-CasC-T comprising Formula IIIa p -3' portion i) the polypeptide and the sgRNA are recruited to the genomic locus, Wherein, multiple copies of the polypeptide of iii) are recruited to the genomic locus through the binding of the polypeptide sequence capable of binding to the nucleic acid structural element to the nucleic acid structural element, thereby recruiting the polypeptide expressed by the construct to the genomic locus and changing the expression of the gene product in the cell population.

70. Use of the construct of any one of claims 1-48 or one or more polypeptides expressed by the construct in the preparation of a medicament for reducing or eliminating the expression of a gene product in a subject in vivo, the reduction or elimination being by a step comprising introducing into the cells of the subject: i) the construct or one or more polypeptides expressed by the construct; and ii) at least one sgRNA, Wherein KRAB and / or a gene expression regulator provides for modification of at least one nucleotide near a gene and / or within a gene regulatory element, thereby altering the expression of the gene product in the subject.

71. The use of a construct as described in any one of claims 1 to 49 or one or more polypeptides expressed by the construct in the preparation of a drug for treating or alleviating the symptoms of a gene product-related disorder in a subject, wherein the treatment or alleviating step comprises introducing into the subject's cells: i) the construct or one or more polypeptides expressed by the construct; and ii) at least one sgRNA, Wherein KRAB and / or gene expression regulators provide modification of at least one nucleotide near a gene and / or within a gene regulatory element, thereby altering the expression of the gene product and treating or alleviating the symptoms of a disorder associated with the gene product in the subject.

72. The use according to any one of claims 65-69, wherein the expression of the gene product in the plurality of modified cells is reduced by 50-100% compared to a population of wild-type cells.

73. The use of any one of claims 65-69, wherein the ratio of on-target modification of the gene product to off-target modification of the gene product is about 10:

1.

74. The use according to any one of claims 65-73, wherein the modification of at least one nucleotide is DNA methylation or histone modification.

75. Use according to claim 74, wherein the modification of at least one nucleotide is DNA methylation.

76. The use according to any one of claims 65-75, wherein the regulatory element of the gene is a core promoter, a proximal promoter, a distal enhancer, a silencer, an insulator element, a boundary element or a locus control region.

77. The use according to any one of claims 65-76, wherein the modification of at least one nucleotide near the gene and / or within the gene regulatory element is located within about 100 bp, about 200 bp, about 300 bp, about 400 bp, about 500 bp, about 600 bp, about 700 bp, about 800 bp, about 900 bp, about 1000 bp, about 1100 bp, about 1200 bp, about 1300 bp, about 1400 bp or about 1500 bp upstream of the transcription start site of the gene.

78. The use according to any one of claims 65-76, wherein the modification of at least one nucleotide near the gene and / or within the gene regulatory element is located within about 100bp, about 200bp, about 300bp, about 400bp, about 500bp, about 600bp, about 700bp, about 800bp, about 900bp, about 1000bp, about 1100bp, about 1200bp, about 1300bp, about 1400bp or about 1500bp downstream of the transcription start site of the gene.

79. The use according to any one of claims 65-78, wherein the construct is deoxyribonucleic acid (DNA).

80. The use according to any one of claims 65-78, wherein the construct is messenger ribonucleic acid (mRNA).

81. The use according to any one of claims 65-80, wherein the construct is formulated in a liposome or lipid nanoparticle.

82. The use according to any one of claims 65-80, wherein the construct and the sgRNA are formulated in liposomes or lipid nanoparticles.

83. The use of claim 82, wherein the construct and the sgRNA are formulated in the same liposome or lipid nanoparticle.

84. The use of claim 82, wherein the construct and the sgRNA are formulated in different liposomes or lipid nanoparticles.

85. The use according to any one of claims 81-84, wherein the liposomes or lipid nanoparticles comprise ionizable lipids (20%-70%, molar ratio), pegylated lipids (0%-30%, molar ratio), supporting lipids (30%-50%, molar ratio) and cholesterol (10%-50%, molar ratio).

86. The use according to claim 85, wherein the ionizable lipid is selected from the group consisting of pH responsive ionizable lipids, thermal responsive ionizable lipids and light responsive ionizable lipids.

87. The use according to any one of claims 65-80, wherein the construct is formulated in an AAV vector.

88. The use according to any one of claims 65-80, wherein the construct and the sgRNA are formulated in an AAV vector.

89. The use according to claim 88, wherein the construct and the sgRNA are formulated in the same AAV vector.

90. The use according to claim 88, wherein the construct and the sgRNA are formulated in different AAV vectors.

91. The use according to any one of claims 65-90, wherein the agent or drug delivers the construct or one or more polypeptides expressed by the construct to the cell by local injection, systemic infusion, or a combination thereof.

92. The use according to any one of claims 65-91, wherein the gene product is selected from the group consisting of a VEGFA gene product, a PCSK9 gene product, an ANGPTL3 gene product, a PTBP1 gene product, a TTR gene product, an Ube3a-ATS gene product, a Ptp1b gene product, an APOC3 gene product, an hsd17b13 gene product, a bcl11a gene product and a TGF-β gene product.

93. The use according to any one of claims 70-92, wherein the subject is a human.

94. The use according to any one of claims 67-92, wherein the medicament is for treating or preventing a disease or condition selected from the group consisting of familial hypercholesterolemia (FH), non-alcoholic steatohepatitis (NASH), Parkinson's disease, liver fibrosis (HF), age-related maculopathy (AMD), Angelman syndrome (AS), type II diabetes, β-thalassemia and hepatocellular carcinoma.

Citation Information

Patent Citations

  • Engineering of systems, methods and optimized guide compositions for sequence manipulation

    EP2771468B1

  • Engineering of systems, methods and optimized guide compositions for sequence manipulation

    EP2784162B1

  • Group iii nitride semiconductor laser device

    US20130051418A1

  • System and method for analyzing a refrigerant sample

    US20130074611A1

  • Device for slicing a food product and device with a robot

    US20130074667A1

Cited By

  • Epigenetic editing tool targeting hepatitis b virus gene

    WO2026124637A1